WO2020088667A1 - 基于流感病毒m2蛋白的细胞穿透肽 - Google Patents
基于流感病毒m2蛋白的细胞穿透肽 Download PDFInfo
- Publication number
- WO2020088667A1 WO2020088667A1 PCT/CN2019/115107 CN2019115107W WO2020088667A1 WO 2020088667 A1 WO2020088667 A1 WO 2020088667A1 CN 2019115107 W CN2019115107 W CN 2019115107W WO 2020088667 A1 WO2020088667 A1 WO 2020088667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- cells
- polypeptide
- cell
- cancer
- Prior art date
Links
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title claims abstract description 73
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title claims abstract description 73
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 title claims description 33
- 102000004169 proteins and genes Human genes 0.000 title claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 103
- 238000000034 method Methods 0.000 claims abstract description 49
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 40
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 40
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 292
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 249
- 229920001184 polypeptide Polymers 0.000 claims description 234
- 210000004027 cell Anatomy 0.000 claims description 233
- 150000001413 amino acids Chemical group 0.000 claims description 185
- 235000001014 amino acid Nutrition 0.000 claims description 151
- 229940024606 amino acid Drugs 0.000 claims description 139
- -1 Anguining Chemical compound 0.000 claims description 137
- 238000006467 substitution reaction Methods 0.000 claims description 54
- 229910052740 iodine Inorganic materials 0.000 claims description 51
- 125000000539 amino acid group Chemical group 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 150000007523 nucleic acids Chemical class 0.000 claims description 46
- 238000012217 deletion Methods 0.000 claims description 45
- 230000037430 deletion Effects 0.000 claims description 45
- 229910052731 fluorine Inorganic materials 0.000 claims description 45
- 238000003780 insertion Methods 0.000 claims description 44
- 230000037431 insertion Effects 0.000 claims description 44
- 230000003612 virological effect Effects 0.000 claims description 42
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 41
- 238000011534 incubation Methods 0.000 claims description 39
- 239000002537 cosmetic Substances 0.000 claims description 37
- 239000011734 sodium Substances 0.000 claims description 35
- 229910052708 sodium Inorganic materials 0.000 claims description 35
- 108020004414 DNA Proteins 0.000 claims description 33
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000002209 hydrophobic effect Effects 0.000 claims description 32
- 235000018102 proteins Nutrition 0.000 claims description 31
- 241000700605 Viruses Species 0.000 claims description 30
- 230000006870 function Effects 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 30
- 229910052700 potassium Inorganic materials 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 26
- 108020004459 Small interfering RNA Proteins 0.000 claims description 25
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 25
- 210000002919 epithelial cell Anatomy 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 229940083542 sodium Drugs 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000002679 microRNA Substances 0.000 claims description 19
- 239000004055 small Interfering RNA Substances 0.000 claims description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 229940088598 enzyme Drugs 0.000 claims description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 16
- 108010054624 red fluorescent protein Proteins 0.000 claims description 16
- 229910052727 yttrium Inorganic materials 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 15
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 14
- 239000004090 neuroprotective agent Substances 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 14
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 14
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 13
- 206010039491 Sarcoma Diseases 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 13
- 229940088710 antibiotic agent Drugs 0.000 claims description 13
- 229940041181 antineoplastic drug Drugs 0.000 claims description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims description 13
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 13
- 239000002619 cytotoxin Substances 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 12
- 108091006047 fluorescent proteins Proteins 0.000 claims description 12
- 102000034287 fluorescent proteins Human genes 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 230000002438 mitochondrial effect Effects 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 12
- 230000035897 transcription Effects 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 12
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 230000009385 viral infection Effects 0.000 claims description 11
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 10
- 108700011259 MicroRNAs Proteins 0.000 claims description 10
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 206010002022 amyloidosis Diseases 0.000 claims description 10
- 230000007812 deficiency Effects 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- 108020003224 Small Nucleolar RNA Proteins 0.000 claims description 9
- 102000042773 Small Nucleolar RNA Human genes 0.000 claims description 9
- 208000015114 central nervous system disease Diseases 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 239000005090 green fluorescent protein Substances 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 108091070501 miRNA Proteins 0.000 claims description 9
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 8
- 208000013824 Acidemia Diseases 0.000 claims description 8
- 208000010444 Acidosis Diseases 0.000 claims description 8
- 108010024976 Asparaginase Proteins 0.000 claims description 8
- 229930186147 Cephalosporin Natural products 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 8
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 8
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 8
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 8
- 108091060271 Small temporal RNA Proteins 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 210000004507 artificial chromosome Anatomy 0.000 claims description 8
- 229940124587 cephalosporin Drugs 0.000 claims description 8
- 150000001780 cephalosporins Chemical class 0.000 claims description 8
- 108010021843 fluorescent protein 583 Proteins 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 229960005280 isotretinoin Drugs 0.000 claims description 8
- 206010038038 rectal cancer Diseases 0.000 claims description 8
- 201000001275 rectum cancer Diseases 0.000 claims description 8
- 229910052594 sapphire Inorganic materials 0.000 claims description 8
- 239000010980 sapphire Substances 0.000 claims description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 229960004961 mechlorethamine Drugs 0.000 claims description 7
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 7
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 210000002345 respiratory system Anatomy 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 241001515965 unidentified phage Species 0.000 claims description 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 6
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 6
- 102000006992 Interferon-alpha Human genes 0.000 claims description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 6
- 108010000817 Leuprolide Proteins 0.000 claims description 6
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 6
- 206010048215 Xanthomatosis Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000003796 beauty Effects 0.000 claims description 6
- 229960003669 carbenicillin Drugs 0.000 claims description 6
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 6
- 229960005243 carmustine Drugs 0.000 claims description 6
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 claims description 6
- 229960003408 cefazolin sodium Drugs 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 201000010064 diabetes insipidus Diseases 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 208000025750 heavy chain disease Diseases 0.000 claims description 6
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 6
- 229960004338 leuprorelin Drugs 0.000 claims description 6
- 230000008774 maternal effect Effects 0.000 claims description 6
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 6
- 229960004857 mitomycin Drugs 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- 210000004927 skin cell Anatomy 0.000 claims description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 claims description 6
- 229960003087 tioguanine Drugs 0.000 claims description 6
- 229910052720 vanadium Inorganic materials 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 5
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 5
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 5
- 108010087806 Carnosine Proteins 0.000 claims description 5
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 5
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 5
- 201000007201 aphasia Diseases 0.000 claims description 5
- 229940044199 carnosine Drugs 0.000 claims description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 201000005962 mycosis fungoides Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 5
- 229960005224 roxithromycin Drugs 0.000 claims description 5
- 230000009759 skin aging Effects 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 206010043207 temporal arteritis Diseases 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 5
- 230000002087 whitening effect Effects 0.000 claims description 5
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 4
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 4
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 4
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 claims description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 102000015790 Asparaginase Human genes 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 108091005950 Azurite Proteins 0.000 claims description 4
- 108010001478 Bacitracin Proteins 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 108030001720 Bontoxilysin Proteins 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 claims description 4
- 108091005944 Cerulean Proteins 0.000 claims description 4
- 241000579895 Chlorostilbon Species 0.000 claims description 4
- 108091005960 Citrine Proteins 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 108091005943 CyPet Proteins 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- OGZSUORSSIIDJK-UHFFFAOYSA-N FC1=C(F)C(F)=C(F)C(F)=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 OGZSUORSSIIDJK-UHFFFAOYSA-N 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 102000003815 Interleukin-11 Human genes 0.000 claims description 4
- 108090000177 Interleukin-11 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 206010067852 Lipofibroma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 108010016076 Octreotide Proteins 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- 241000545067 Venus Species 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 claims description 4
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 4
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 229960003272 asparaginase Drugs 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229940053031 botulinum toxin Drugs 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 229960003719 cefdinir Drugs 0.000 claims description 4
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 4
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 claims description 4
- 229960002417 cefoperazone sodium Drugs 0.000 claims description 4
- 229960002727 cefotaxime sodium Drugs 0.000 claims description 4
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 4
- 229960005446 cefpiramide Drugs 0.000 claims description 4
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 claims description 4
- 229960000484 ceftazidime Drugs 0.000 claims description 4
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011035 citrine Substances 0.000 claims description 4
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 claims description 4
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 229960000605 dexrazoxane Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000010976 emerald Substances 0.000 claims description 4
- 229910052876 emerald Inorganic materials 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 4
- 210000001339 epidermal cell Anatomy 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims description 4
- 229960001751 fluoxymesterone Drugs 0.000 claims description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000308 fosfomycin Drugs 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 210000002768 hair cell Anatomy 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims description 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 229960000826 meclocycline Drugs 0.000 claims description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- 230000000442 meristematic effect Effects 0.000 claims description 4
- 210000000473 mesophyll cell Anatomy 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 229960004584 methylprednisolone Drugs 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 201000005737 orchitis Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 4
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 4
- 210000004694 pigment cell Anatomy 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002096 quantum dot Substances 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 208000007442 rickets Diseases 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 201000002314 small intestine cancer Diseases 0.000 claims description 4
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960002135 sulfadimidine Drugs 0.000 claims description 4
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229960002180 tetracycline Drugs 0.000 claims description 4
- 229960003433 thalidomide Drugs 0.000 claims description 4
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 4
- 229960003053 thiamphenicol Drugs 0.000 claims description 4
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 3
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims description 3
- VICZJOJMIRKAFN-UHFFFAOYSA-N 3,5,7,8,10,12,13,21-octaethyl-1,23-dihydroporphyrin-2-one Chemical compound CCN1C(C=C2N=C(C=C3C(=C(CC)C(N3)=C3CC)CC)C=C2)C(=O)C(CC)=C1C(CC)=C1C(CC)=C(CC)C3=N1 VICZJOJMIRKAFN-UHFFFAOYSA-N 0.000 claims description 3
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims description 3
- 229930195573 Amycin Natural products 0.000 claims description 3
- 208000036640 Asperger disease Diseases 0.000 claims description 3
- 201000006062 Asperger syndrome Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 3
- 201000004085 CLL/SLL Diseases 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 101710088194 Dehydrogenase Proteins 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 3
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims description 3
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 3
- 206010021131 Hypouricaemia Diseases 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 claims description 3
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 102000006386 Myelin Proteins Human genes 0.000 claims description 3
- 108010083674 Myelin Proteins Proteins 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 229930195708 Penicillin V Natural products 0.000 claims description 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 3
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims description 3
- 208000035415 Reinfection Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims description 3
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 claims description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 206010003230 arteritis Diseases 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 230000002146 bilateral effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 3
- 239000000298 carbocyanine Substances 0.000 claims description 3
- 201000003961 cecum cancer Diseases 0.000 claims description 3
- 229960004682 cefoperazone Drugs 0.000 claims description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 3
- 229960005495 cefotetan Drugs 0.000 claims description 3
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 3
- 229960002682 cefoxitin Drugs 0.000 claims description 3
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 3
- 229960005090 cefpodoxime Drugs 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 206010008129 cerebral palsy Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims description 3
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims description 3
- 229960002227 clindamycin Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010918 connective tissue cancer Diseases 0.000 claims description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 3
- 229950001513 coumamycin Drugs 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 claims description 3
- 230000008482 dysregulation Effects 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims description 3
- 229960004675 fusidic acid Drugs 0.000 claims description 3
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 3
- 230000002008 hemorrhagic effect Effects 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000005012 myelin Anatomy 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000210 nalidixic acid Drugs 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 210000001577 neostriatum Anatomy 0.000 claims description 3
- 230000002232 neuromuscular Effects 0.000 claims description 3
- SRQKTCXJCCHINN-NYYWCZLTSA-N nifuratel Chemical compound O=C1OC(CSC)CN1\N=C\C1=CC=C([N+]([O-])=O)O1 SRQKTCXJCCHINN-NYYWCZLTSA-N 0.000 claims description 3
- 229960002136 nifuratel Drugs 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 3
- 150000002923 oximes Chemical class 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 229940056360 penicillin g Drugs 0.000 claims description 3
- 229940056367 penicillin v Drugs 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 claims description 3
- 229940063179 platinol Drugs 0.000 claims description 3
- 208000037244 polycythemia vera Diseases 0.000 claims description 3
- 150000004032 porphyrins Chemical class 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 229960004306 sulfadiazine Drugs 0.000 claims description 3
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 239000010937 tungsten Substances 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 claims description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- WKZGKZQVLRQTCT-ABLWVSNPSA-N (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-formyloxy-5-oxopentanoic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)OC=O)C(O)=O)C=C1 WKZGKZQVLRQTCT-ABLWVSNPSA-N 0.000 claims description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 2
- ZHIKHAVOCHJPNC-SQAHNGQVSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol;undec-10-enoic acid Chemical compound OC(=O)CCCCCCCCC=C.N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N ZHIKHAVOCHJPNC-SQAHNGQVSA-N 0.000 claims description 2
- RZXTUCFALKTJJO-WQDIDPJDSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;hexadecanoic Chemical compound CCCCCCCCCCCCCCCC(O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO RZXTUCFALKTJJO-WQDIDPJDSA-N 0.000 claims description 2
- UDIIBEDMEYAVNG-CORWDWJASA-N (2s)-3-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-[(3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[(3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxypropanamide Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)C1O[C@@H]1[C@@H](O)[C@H](OC2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-CORWDWJASA-N 0.000 claims description 2
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 claims description 2
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 claims description 2
- MZRHTYDFTZJMLV-UHFFFAOYSA-N (3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)methanol Chemical compound C1=CC=C2N([O-])C(C)=C(CO)[N+](=O)C2=C1 MZRHTYDFTZJMLV-UHFFFAOYSA-N 0.000 claims description 2
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 claims description 2
- XTSSJGRRFMNXGO-YZPBMOCRSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;sulfu Chemical compound OS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XTSSJGRRFMNXGO-YZPBMOCRSA-N 0.000 claims description 2
- POMORUSPLDFVEK-PHXAWWDYSA-N (4r)-5-[[(2s,3s)-1-[[(2s)-6-amino-1-[[(2r)-5-amino-1-[[(2s,3s)-1-[[(2r)-1-[[(2s)-1-[[(2r)-1-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methy Chemical compound OC1=CC=CC=C1C(=O)OCOC(=O)C1=CC=CC=C1O.C1SC(C(N)C(C)CC)=NC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 POMORUSPLDFVEK-PHXAWWDYSA-N 0.000 claims description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 claims description 2
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 claims description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- OAPVUSSHCBRCOL-KBHRXELFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O OAPVUSSHCBRCOL-KBHRXELFSA-N 0.000 claims description 2
- LSBUIZREQYVRSY-CYJZLJNKSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 LSBUIZREQYVRSY-CYJZLJNKSA-N 0.000 claims description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 claims description 2
- DOIVPHUVGVJOMX-UHFFFAOYSA-N 1,10-phenanthroline;ruthenium Chemical compound [Ru].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 DOIVPHUVGVJOMX-UHFFFAOYSA-N 0.000 claims description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 2
- UVLNTEYLVSFUIH-UHFFFAOYSA-N 1-(1,2-thiazol-3-yl)ethanone Chemical compound CC(=O)C=1C=CSN=1 UVLNTEYLVSFUIH-UHFFFAOYSA-N 0.000 claims description 2
- PXMNMQRDXWABCY-UHFFFAOYSA-N 1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol Chemical compound C1=NC=NN1CC(O)(C(C)(C)C)CCC1=CC=C(Cl)C=C1 PXMNMQRDXWABCY-UHFFFAOYSA-N 0.000 claims description 2
- FQIMYHJEQGTNSA-UHFFFAOYSA-N 1-acetylsulfonylethanone;sodium Chemical compound [Na].CC(=O)S(=O)(=O)C(C)=O FQIMYHJEQGTNSA-UHFFFAOYSA-N 0.000 claims description 2
- QHLKJRAHRXUJLD-UHFFFAOYSA-N 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 QHLKJRAHRXUJLD-UHFFFAOYSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- YOSZEPWSVKKQOV-UHFFFAOYSA-N 12h-benzo[a]phenoxazine Chemical compound C1=CC=CC2=C3NC4=CC=CC=C4OC3=CC=C21 YOSZEPWSVKKQOV-UHFFFAOYSA-N 0.000 claims description 2
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 claims description 2
- KETXQNLMOUVTQB-UHFFFAOYSA-N 2,3,7,8,12,13,17,18-octaethylporphyrin;platinum Chemical compound [Pt].C=1C(C(=C2CC)CC)=NC2=CC(C(=C2CC)CC)=NC2=CC(C(=C2CC)CC)=NC2=CC2=NC=1C(CC)=C2CC KETXQNLMOUVTQB-UHFFFAOYSA-N 0.000 claims description 2
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 claims description 2
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 claims description 2
- NTRKBPHPPMYMKJ-VHXUMFCXSA-N 2-[(1s,2r,3r,7r,8s,9s,10r,12r,14e,16s)-9-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O NTRKBPHPPMYMKJ-VHXUMFCXSA-N 0.000 claims description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 2
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 claims description 2
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 claims description 2
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 claims description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 2
- KCVTVKMPZQSSNU-UHFFFAOYSA-N 2-pyridin-4-ylethanethioyl chloride Chemical compound ClC(=S)CC1=CC=NC=C1 KCVTVKMPZQSSNU-UHFFFAOYSA-N 0.000 claims description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 claims description 2
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 claims description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 2
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 claims description 2
- NRSJYUSYBNFGAK-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Br NRSJYUSYBNFGAK-UHFFFAOYSA-N 0.000 claims description 2
- IHXWECHPYNPJRR-UHFFFAOYSA-N 3-hydroxycyclobut-2-en-1-one Chemical compound OC1=CC(=O)C1 IHXWECHPYNPJRR-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 claims description 2
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 claims description 2
- SKZWFYFFTOHWQP-UHFFFAOYSA-L 4,7-diphenyl-1,10-phenanthroline;ruthenium(2+);dichloride Chemical compound Cl[Ru]Cl.C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21.C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21.C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 SKZWFYFFTOHWQP-UHFFFAOYSA-L 0.000 claims description 2
- MKNQNPYGAQGARI-UHFFFAOYSA-N 4-(bromomethyl)phenol Chemical compound OC1=CC=C(CBr)C=C1 MKNQNPYGAQGARI-UHFFFAOYSA-N 0.000 claims description 2
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims description 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 claims description 2
- DNVVZWSVACQWJE-UHFFFAOYSA-N 4-amino-2-hydroxybenzoic acid phenyl ester Chemical compound OC1=CC(N)=CC=C1C(=O)OC1=CC=CC=C1 DNVVZWSVACQWJE-UHFFFAOYSA-N 0.000 claims description 2
- MTERSQYMYBGZTP-UHFFFAOYSA-N 4-amino-n-(5-methyl-2-phenylpyrazol-3-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 MTERSQYMYBGZTP-UHFFFAOYSA-N 0.000 claims description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 2
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 2
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 2
- KWBXQDNGHQLAMB-UHFFFAOYSA-N 4-sulfanyl-3h-1,3-thiazole-2-thione Chemical compound SC1=CSC(=S)N1 KWBXQDNGHQLAMB-UHFFFAOYSA-N 0.000 claims description 2
- HJTDPDQRTRMIGM-UHFFFAOYSA-N 5-bromo-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound BrC=1C(C(C=CC1)(C)O)C HJTDPDQRTRMIGM-UHFFFAOYSA-N 0.000 claims description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 claims description 2
- LQVMZVKOVPITOO-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbonochloridate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)Cl)=CC=C2 LQVMZVKOVPITOO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005660 Abamectin Substances 0.000 claims description 2
- OYMZTORLGBISLR-UHFFFAOYSA-N Acetomycin Natural products CC1C(OC(C)=O)OC(=O)C1(C)C(C)=O OYMZTORLGBISLR-UHFFFAOYSA-N 0.000 claims description 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 2
- 241000701242 Adenoviridae Species 0.000 claims description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 208000012791 Alpha-heavy chain disease Diseases 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- ZZLPMVKBERHMQN-CROFIWJMSA-N Amicycline Chemical compound C1C2=CC=C(N)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O ZZLPMVKBERHMQN-CROFIWJMSA-N 0.000 claims description 2
- FVVDKUPCWXUVNP-UHFFFAOYSA-M Aminosalicylate sodium anhydrous Chemical compound [Na+].NC1=CC=C(C([O-])=O)C(O)=C1 FVVDKUPCWXUVNP-UHFFFAOYSA-M 0.000 claims description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 claims description 2
- 229930183010 Amphotericin Natural products 0.000 claims description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 2
- 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 235000019783 Bacitracin Methylene Disalicylate Nutrition 0.000 claims description 2
- 208000029862 Barrett adenocarcinoma Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 206010004485 Berylliosis Diseases 0.000 claims description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 2
- 241000776207 Bornaviridae Species 0.000 claims description 2
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- REACMANCWHKJSM-DWBVFMGKSA-M Cefsulodin sodium Chemical compound [Na+].C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S([O-])(=O)=O)[C@H]2SC1 REACMANCWHKJSM-DWBVFMGKSA-M 0.000 claims description 2
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 2
- 206010007882 Cellulitis Diseases 0.000 claims description 2
- 206010008027 Cerebellar atrophy Diseases 0.000 claims description 2
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010008617 Cholecystitis chronic Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000008158 Chorioamnionitis Diseases 0.000 claims description 2
- 208000023355 Chronic beryllium disease Diseases 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 102100021906 Cyclin-O Human genes 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
- 108010013198 Daptomycin Proteins 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000257465 Echinoidea Species 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 108010074604 Epoetin Alfa Proteins 0.000 claims description 2
- 241000588698 Erwinia Species 0.000 claims description 2
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010016228 Fasciitis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241000710781 Flaviviridae Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 208000027472 Galactosemias Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 108010026389 Gramicidin Proteins 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 2
- 241000700739 Hepadnaviridae Species 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 229930191564 Monensin Natural products 0.000 claims description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 2
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims description 2
- 208000012799 Mu-heavy chain disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 206010028561 Myeloid metaplasia Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 2
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 claims description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 2
- HMKMKLAEOLHRDT-UHFFFAOYSA-N N1C(C=C2C3=C4C=CC=CC4=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 Chemical class N1C(C=C2C3=C4C=CC=CC4=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 HMKMKLAEOLHRDT-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 2
- 206010051606 Necrotising colitis Diseases 0.000 claims description 2
- 206010028885 Necrotising fasciitis Diseases 0.000 claims description 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 2
- 206010060860 Neurological symptom Diseases 0.000 claims description 2
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- RKTNPKZEPLCLSF-GNERTXCBSA-N OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 RKTNPKZEPLCLSF-GNERTXCBSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 2
- 208000025610 Paget disease of the vulva Diseases 0.000 claims description 2
- 208000016222 Pancreatic disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000701945 Parvoviridae Species 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 239000004186 Penicillin G benzathine Substances 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 2
- 201000011252 Phenylketonuria Diseases 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 241001631648 Polyomaviridae Species 0.000 claims description 2
- 241000700625 Poxviridae Species 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 201000007981 Reye syndrome Diseases 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- 241000711897 Rinderpest morbillivirus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
- MBDKCBPSCQUHQT-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)C=2C(OC1=CC(=CC=C1C2)N(CC)CC)=O.[In+3] Chemical compound S1C(=NC2=C1C=CC=C2)C=2C(OC1=CC(=CC=C1C2)N(CC)CC)=O.[In+3] MBDKCBPSCQUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000007893 Salpingitis Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 2
- 229930192786 Sisomicin Natural products 0.000 claims description 2
- 101710142969 Somatoliberin Proteins 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 239000004187 Spiramycin Substances 0.000 claims description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 2
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 claims description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 239000005839 Tebuconazole Substances 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 150000001217 Terbium Chemical class 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 239000004188 Virginiamycin Substances 0.000 claims description 2
- 108010080702 Virginiamycin Proteins 0.000 claims description 2
- 206010048214 Xanthoma Diseases 0.000 claims description 2
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 2
- PPORNUWQIKUROY-AINMIYBESA-N [(2r,3s,4r,5r,6r)-2-[(2r,3s,4r,5s,6s)-2-[(3s)-3-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-4-[[(3r,4s,5s)-6-[[(2s)-1-[2-[(4r)-4-[4-[(4-amino-4-iminobutyl)carbamoyl]-1,3-thiazol-2-yl] Chemical compound O([C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC(C)[C@H](NC(=O)C=1C(=C(N)N=C(N=1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)C)C(=O)N[C@H](CCO)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCC(N)=N)C(C)(C)O)[C@H]1O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]1O PPORNUWQIKUROY-AINMIYBESA-N 0.000 claims description 2
- OYMZTORLGBISLR-RHFNHBFPSA-N acetomycin Chemical compound C[C@@H]1[C@H](OC(C)=O)OC(=O)[C@]1(C)C(C)=O OYMZTORLGBISLR-RHFNHBFPSA-N 0.000 claims description 2
- 125000005595 acetylacetonate group Chemical group 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 229930183665 actinomycin Natural products 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 229940064305 adrucil Drugs 0.000 claims description 2
- 229940060236 ala-cort Drugs 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 claims description 2
- 229950010221 alexidine Drugs 0.000 claims description 2
- 229960001445 alitretinoin Drugs 0.000 claims description 2
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000025751 alpha chain disease Diseases 0.000 claims description 2
- 229950008157 amicycline Drugs 0.000 claims description 2
- 229960001097 amifostine Drugs 0.000 claims description 2
- 229960001656 amikacin sulfate Drugs 0.000 claims description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003437 aminoglutethimide Drugs 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229940009444 amphotericin Drugs 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 2
- 229960001931 ampicillin sodium Drugs 0.000 claims description 2
- 229960001694 anagrelide Drugs 0.000 claims description 2
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 2
- 108010082685 antiarrhythmic peptide Proteins 0.000 claims description 2
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims description 2
- 229950006334 apramycin Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 2
- 210000003050 axon Anatomy 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960003623 azlocillin Drugs 0.000 claims description 2
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 claims description 2
- 229960003200 azlocillin sodium Drugs 0.000 claims description 2
- 239000000987 azo dye Substances 0.000 claims description 2
- 229960003071 bacitracin Drugs 0.000 claims description 2
- 229930184125 bacitracin Natural products 0.000 claims description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 2
- 229940032022 bacitracin methylene disalicylate Drugs 0.000 claims description 2
- 108010054309 bacitracin methylenedisalicylic acid Proteins 0.000 claims description 2
- 229960005364 bacitracin zinc Drugs 0.000 claims description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims description 2
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 2
- 229960003169 biapenem Drugs 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 229940108502 bicnu Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 108010006025 bovine growth hormone Proteins 0.000 claims description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 2
- 201000000135 breast papillary carcinoma Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229940112133 busulfex Drugs 0.000 claims description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 claims description 2
- VANYVCHXDYVKSI-MXWBXKMOSA-L calcium;(6ar,10s,10ar,11s,11ar,12s)-8-carbamoyl-10-(dimethylamino)-4,6a,7,11,12-pentahydroxy-12-methyl-6,9-dioxo-10,10a,11,11a-tetrahydrotetracen-5-olate Chemical compound [Ca+2].C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C([O-])C2=C1O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C([O-])C2=C1O VANYVCHXDYVKSI-MXWBXKMOSA-L 0.000 claims description 2
- 229940112129 campath Drugs 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229940001981 carac Drugs 0.000 claims description 2
- 229960000427 carbadox Drugs 0.000 claims description 2
- 229960005255 carbenicillin disodium Drugs 0.000 claims description 2
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 claims description 2
- 229940097647 casodex Drugs 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960004841 cefadroxil Drugs 0.000 claims description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- 229960000927 cefepime hydrochloride Drugs 0.000 claims description 2
- 229960003791 cefmenoxime Drugs 0.000 claims description 2
- MPTNDTIREFCQLK-UNVJPQNDSA-N cefmenoxime hydrochloride Chemical compound [H+].[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C MPTNDTIREFCQLK-UNVJPQNDSA-N 0.000 claims description 2
- 229960003585 cefmetazole Drugs 0.000 claims description 2
- 229960002676 cefmetazole sodium Drugs 0.000 claims description 2
- 229960004489 cefonicid Drugs 0.000 claims description 2
- 229960000915 cefonicid monosodium Drugs 0.000 claims description 2
- NAXFZVGOZUWLEP-RFXDPDBWSA-L cefonicid sodium Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS([O-])(=O)=O NAXFZVGOZUWLEP-RFXDPDBWSA-L 0.000 claims description 2
- BWRRTAXZCKVRON-DGPOFWGLSA-N cefotiam dihydrochloride Chemical compound Cl.Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 BWRRTAXZCKVRON-DGPOFWGLSA-N 0.000 claims description 2
- 229960004700 cefotiam hydrochloride Drugs 0.000 claims description 2
- 229960003016 cefoxitin sodium Drugs 0.000 claims description 2
- 229960002838 cefpirome sulfate Drugs 0.000 claims description 2
- 229960002580 cefprozil Drugs 0.000 claims description 2
- 229960002588 cefradine Drugs 0.000 claims description 2
- 229960001281 cefsulodin sodium Drugs 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229960002620 cefuroxime axetil Drugs 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 229940084959 cephalexin hydrochloride Drugs 0.000 claims description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 2
- 206010008323 cervicitis Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- XMEVHPAGJVLHIG-DXDJYCPMSA-N chembl1950577 Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-DXDJYCPMSA-N 0.000 claims description 2
- GJPGCACMCURAKH-YQCFNCLSSA-L chembl2364574 Chemical compound [Ca+2].O=C1C2=C([O-])C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O.O=C1C2=C([O-])C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O GJPGCACMCURAKH-YQCFNCLSSA-L 0.000 claims description 2
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 claims description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 2
- 229960001805 chloramphenicol palmitate Drugs 0.000 claims description 2
- PXKHGMGELZGJQE-ILBGXUMGSA-N chloramphenicol palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 PXKHGMGELZGJQE-ILBGXUMGSA-N 0.000 claims description 2
- 229960002579 chloramphenicol sodium succinate Drugs 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- WWAABJGNHFGXSJ-UHFFFAOYSA-N chlorophenol red Chemical compound C1=C(Cl)C(O)=CC=C1C1(C=2C=C(Cl)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 WWAABJGNHFGXSJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005443 chloroxylenol Drugs 0.000 claims description 2
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- CPCIOUMUZMHAAR-UHFFFAOYSA-N chromen-2-one;sodium Chemical compound [Na].C1=CC=C2OC(=O)C=CC2=C1 CPCIOUMUZMHAAR-UHFFFAOYSA-N 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 claims description 2
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960002436 cladribine Drugs 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960001200 clindamycin hydrochloride Drugs 0.000 claims description 2
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 2
- 229960004287 clofazimine Drugs 0.000 claims description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 claims description 2
- 229930003836 cresol Natural products 0.000 claims description 2
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 claims description 2
- 150000003983 crown ethers Chemical class 0.000 claims description 2
- JLYVRXJEQTZZBE-UHFFFAOYSA-N ctk1c6083 Chemical compound NP(N)(N)=S JLYVRXJEQTZZBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960003077 cycloserine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 201000004400 dacryoadenitis Diseases 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960000860 dapsone Drugs 0.000 claims description 2
- 229960005484 daptomycin Drugs 0.000 claims description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 2
- 229960003109 daunorubicin hydrochloride Drugs 0.000 claims description 2
- 229940107841 daunoxome Drugs 0.000 claims description 2
- 229940026692 decadron Drugs 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 229960005104 demeclocycline hydrochloride Drugs 0.000 claims description 2
- 108010017271 denileukin diftitox Proteins 0.000 claims description 2
- 229940070968 depocyt Drugs 0.000 claims description 2
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 claims description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- 229960004060 dicloxacillin sodium Drugs 0.000 claims description 2
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- JAZCSWFKVAHBLR-UHFFFAOYSA-N dihydrogen phosphate;phenylazanium Chemical compound OP(O)(O)=O.NC1=CC=CC=C1 JAZCSWFKVAHBLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229940115080 doxil Drugs 0.000 claims description 2
- 229960003788 doxycycline calcium Drugs 0.000 claims description 2
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims description 2
- 229940075117 droxia Drugs 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 claims description 2
- 229940099302 efudex Drugs 0.000 claims description 2
- 201000002246 embryonal cancer Diseases 0.000 claims description 2
- 229940000733 emcyt Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002549 enoxacin Drugs 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 229960002457 epicillin Drugs 0.000 claims description 2
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 201000010063 epididymitis Diseases 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229940082789 erbitux Drugs 0.000 claims description 2
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 claims description 2
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 claims description 2
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 claims description 2
- 229960004213 erythromycin lactobionate Drugs 0.000 claims description 2
- 229950001028 erythromycin propionate Drugs 0.000 claims description 2
- 229960004142 erythromycin stearate Drugs 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 2
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002001 ethionamide Drugs 0.000 claims description 2
- 229940098617 ethyol Drugs 0.000 claims description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 2
- 229960000752 etoposide phosphate Drugs 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 208000004313 familial eosinophilia Diseases 0.000 claims description 2
- 229950006194 fenamisal Drugs 0.000 claims description 2
- 206010016629 fibroma Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003306 fleroxacin Drugs 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960000702 flumequine Drugs 0.000 claims description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims description 2
- 229940064300 fluoroplex Drugs 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- VXAOKODLROCQJS-UHFFFAOYSA-N furan;hydrochloride Chemical compound Cl.C=1C=COC=1 VXAOKODLROCQJS-UHFFFAOYSA-N 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 229940020967 gemzar Drugs 0.000 claims description 2
- 201000003115 germ cell cancer Diseases 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 229940080856 gleevec Drugs 0.000 claims description 2
- 229960004905 gramicidin Drugs 0.000 claims description 2
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 229940003183 hexalen Drugs 0.000 claims description 2
- 229940096120 hydrea Drugs 0.000 claims description 2
- 229950000785 hydrocortisone phosphate Drugs 0.000 claims description 2
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 claims description 2
- VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 claims description 2
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 claims description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 229940090411 ifex Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 208000009326 ileitis Diseases 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229940074383 interleukin-11 Drugs 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
- 239000002555 ionophore Substances 0.000 claims description 2
- 230000000236 ionophoric effect Effects 0.000 claims description 2
- 229940084651 iressa Drugs 0.000 claims description 2
- 229910052741 iridium Inorganic materials 0.000 claims description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 201000002529 islet cell tumor Diseases 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims description 2
- 229960002064 kanamycin sulfate Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000021601 lentivirus infection Diseases 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 229940087875 leukine Drugs 0.000 claims description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 201000003265 lymphadenitis Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 230000005291 magnetic effect Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229940087732 matulane Drugs 0.000 claims description 2
- 229940087412 maxidex Drugs 0.000 claims description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims description 2
- 229940090004 megace Drugs 0.000 claims description 2
- 229960001786 megestrol Drugs 0.000 claims description 2
- 229960004296 megestrol acetate Drugs 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 229950005684 mequidox Drugs 0.000 claims description 2
- 229960002260 meropenem Drugs 0.000 claims description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 2
- 229960004635 mesna Drugs 0.000 claims description 2
- 229940101533 mesnex Drugs 0.000 claims description 2
- 229940042016 methacycline Drugs 0.000 claims description 2
- 229940019826 methicillin sodium Drugs 0.000 claims description 2
- MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 claims description 2
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 claims description 2
- 229960003058 methotrexate sodium Drugs 0.000 claims description 2
- BPMVRAQIQQEBLN-OBPBNMOMSA-N methyl n-[(e)-(1-hydroxy-4-oxidoquinoxalin-4-ium-2-ylidene)methyl]iminocarbamate Chemical compound C1=CC=C2N(O)C(=C/N=NC(=O)OC)/C=[N+]([O-])C2=C1 BPMVRAQIQQEBLN-OBPBNMOMSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 229960001994 mezlocillin sodium Drugs 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 229960002421 minocycline hydrochloride Drugs 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229960005358 monensin Drugs 0.000 claims description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 208000026114 mu chain disease Diseases 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 201000002077 muscle cancer Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229940090009 myleran Drugs 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- PKUBDVAOXLEWBF-UHFFFAOYSA-N n-[1-(4-acetylphenyl)-1,3-dihydroxypropan-2-yl]-2,2-dichloroacetamide Chemical compound CC(=O)C1=CC=C(C(O)C(CO)NC(=O)C(Cl)Cl)C=C1 PKUBDVAOXLEWBF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002159 nanocrystal Substances 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 201000007970 necrotizing fasciitis Diseases 0.000 claims description 2
- 229940053050 neomycin sulfate Drugs 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 229960004832 netilmicin sulfate Drugs 0.000 claims description 2
- 229940071846 neulasta Drugs 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 claims description 2
- 229940099637 nilandron Drugs 0.000 claims description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005130 niridazole Drugs 0.000 claims description 2
- IHRSXGONVFFQQF-SDXDJHTJSA-N nitrazine Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=CC=C2C(=O)\C1=N/NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O IHRSXGONVFFQQF-SDXDJHTJSA-N 0.000 claims description 2
- 229960000564 nitrofurantoin Drugs 0.000 claims description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004781 novobiocin sodium Drugs 0.000 claims description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- HCIIFBHDBOCSAF-UHFFFAOYSA-N octaethylporphyrin Chemical compound N1C(C=C2C(=C(CC)C(C=C3C(=C(CC)C(=C4)N3)CC)=N2)CC)=C(CC)C(CC)=C1C=C1C(CC)=C(CC)C4=N1 HCIIFBHDBOCSAF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- 229960001494 octreotide acetate Drugs 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 229960002378 oftasceine Drugs 0.000 claims description 2
- 229940100027 ontak Drugs 0.000 claims description 2
- 208000005963 oophoritis Diseases 0.000 claims description 2
- 229940003515 orapred Drugs 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 2
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 claims description 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- 229960003994 oxacillin sodium Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 229940116315 oxalic acid Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 150000004893 oxazines Chemical class 0.000 claims description 2
- 229960004548 oxytetracycline calcium Drugs 0.000 claims description 2
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
- 229940046231 pamidronate Drugs 0.000 claims description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims description 2
- 229940096763 panretin Drugs 0.000 claims description 2
- 229940014662 pantothenate Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 229940097097 pediapred Drugs 0.000 claims description 2
- 229960004236 pefloxacin Drugs 0.000 claims description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001808 pefloxacin mesylate Drugs 0.000 claims description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 2
- 108010044644 pegfilgrastim Proteins 0.000 claims description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims description 2
- 229940106366 pegintron Drugs 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 229940056365 penicillin g benzathine Drugs 0.000 claims description 2
- 229940024772 penicillin v benzathine Drugs 0.000 claims description 2
- 229940090663 penicillin v potassium Drugs 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- GVZXLJKMZPWKFX-UHFFFAOYSA-N perylene-1,2-diimine Chemical compound C1=CC(C2=C3C(=CC(C2=N)=N)C=CC=C32)=C3C2=CC=CC3=C1 GVZXLJKMZPWKFX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 claims description 2
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 2
- BBTOYUUSUQNIIY-ANPZCEIESA-N phenoxymethylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 BBTOYUUSUQNIIY-ANPZCEIESA-N 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 239000003504 photosensitizing agent Substances 0.000 claims description 2
- 208000020943 pineal parenchymal cell neoplasm Diseases 0.000 claims description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 2
- 229960005264 piperacillin sodium Drugs 0.000 claims description 2
- 208000008423 pleurisy Diseases 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- 229940096111 prelone Drugs 0.000 claims description 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 229940029359 procrit Drugs 0.000 claims description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 229960005206 pyrazinamide Drugs 0.000 claims description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005442 quinupristin Drugs 0.000 claims description 2
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 claims description 2
- 108700028429 quinupristin Proteins 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229940043267 rhodamine b Drugs 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 2
- 229960003040 rifaximin Drugs 0.000 claims description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 2
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003889 rosoxacin Drugs 0.000 claims description 2
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003052 roxarsone Drugs 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- VWNQJLIVSOOFBX-UHFFFAOYSA-L ruthenium(2+);dichloride;hexahydrate Chemical compound O.O.O.O.O.O.Cl[Ru]Cl VWNQJLIVSOOFBX-UHFFFAOYSA-L 0.000 claims description 2
- 239000004576 sand Substances 0.000 claims description 2
- 201000003774 sarcomatosis Diseases 0.000 claims description 2
- 108010038379 sargramostim Proteins 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 210000004706 scrotum Anatomy 0.000 claims description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 2
- 229940043175 silybin Drugs 0.000 claims description 2
- 235000014899 silybin Nutrition 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 229960005456 sisomicin Drugs 0.000 claims description 2
- 229960001435 sisomicin sulfate Drugs 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 229940046927 sodium aminosalicylate Drugs 0.000 claims description 2
- XOIQMTLWECTKJL-FBZUZRIGSA-M sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C([O-])=O)O2 XOIQMTLWECTKJL-FBZUZRIGSA-M 0.000 claims description 2
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 claims description 2
- JLDCNMJPBBKAHH-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 JLDCNMJPBBKAHH-UHFFFAOYSA-N 0.000 claims description 2
- WZTUULPOBSTZKR-CFOLLTDRSA-M sodium;(6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS([O-])(=O)=O WZTUULPOBSTZKR-CFOLLTDRSA-M 0.000 claims description 2
- UDBORWKCIDLNIG-UHFFFAOYSA-N sodium;1h-inden-1-ide Chemical compound [Na+].C1=CC=C2[CH-]C=CC2=C1 UDBORWKCIDLNIG-UHFFFAOYSA-N 0.000 claims description 2
- UVDWKWQHKOALJL-ZTHLIMQFSA-M sodium;dihydrogen phosphate;2-[(1s,2r,3r,7r,8s,9s,10r,12r,14e,16s)-9-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde Chemical compound [Na+].OP(O)([O-])=O.O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O UVDWKWQHKOALJL-ZTHLIMQFSA-M 0.000 claims description 2
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 claims description 2
- OWMHBKYAOYHOQK-UHFFFAOYSA-N sodium;methanidylbenzene Chemical compound [Na+].[CH2-]C1=CC=CC=C1 OWMHBKYAOYHOQK-UHFFFAOYSA-N 0.000 claims description 2
- 229940088542 solu-cortef Drugs 0.000 claims description 2
- 229940087854 solu-medrol Drugs 0.000 claims description 2
- 229960004954 sparfloxacin Drugs 0.000 claims description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- 229960000887 spectinomycin hydrochloride Drugs 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 235000019372 spiramycin Nutrition 0.000 claims description 2
- 229960001294 spiramycin Drugs 0.000 claims description 2
- 229930191512 spiramycin Natural products 0.000 claims description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- 229960002673 sulfacetamide Drugs 0.000 claims description 2
- 229960001182 sulfadiazine sodium Drugs 0.000 claims description 2
- 229960004673 sulfadoxine Drugs 0.000 claims description 2
- 229950003013 sulfapyrazole Drugs 0.000 claims description 2
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001544 sulfathiazole Drugs 0.000 claims description 2
- UILMMYFRNCCPLK-UHFFFAOYSA-N sulfuric acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound OS(O)(=O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 UILMMYFRNCCPLK-UHFFFAOYSA-N 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 201000008753 synovium neoplasm Diseases 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 229940061353 temodar Drugs 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 2
- 229940110675 theracys Drugs 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- 229960004477 tobramycin sulfate Drugs 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 229940035307 toposar Drugs 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 229940111528 trexall Drugs 0.000 claims description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001082 trimethoprim Drugs 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002712 trimethoprim sulfate Drugs 0.000 claims description 2
- 229940086984 trisenox Drugs 0.000 claims description 2
- 229910052722 tritium Inorganic materials 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- 208000000143 urethritis Diseases 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- 229960001572 vancomycin hydrochloride Drugs 0.000 claims description 2
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 claims description 2
- 229940099039 velcade Drugs 0.000 claims description 2
- 229940061389 viadur Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- 229960004982 vinblastine sulfate Drugs 0.000 claims description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 229960002166 vinorelbine tartrate Drugs 0.000 claims description 2
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 claims description 2
- 229960003842 virginiamycin Drugs 0.000 claims description 2
- 235000019373 virginiamycin Nutrition 0.000 claims description 2
- 208000028010 vulval Paget disease Diseases 0.000 claims description 2
- 208000002003 vulvitis Diseases 0.000 claims description 2
- 208000010484 vulvovaginitis Diseases 0.000 claims description 2
- 239000001018 xanthene dye Substances 0.000 claims description 2
- 229940053867 xeloda Drugs 0.000 claims description 2
- 229940053890 zanosar Drugs 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 229940043810 zinc pyrithione Drugs 0.000 claims description 2
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 claims description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 6
- 239000002924 silencing RNA Substances 0.000 claims 6
- 108020004688 Small Nuclear RNA Proteins 0.000 claims 5
- 208000016097 disease of metabolism Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- MJBPUQUGJNAPAZ-AWEZNQCLSA-N butin Chemical compound C1([C@@H]2CC(=O)C3=CC=C(C=C3O2)O)=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-AWEZNQCLSA-N 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- PPJJEMJYGGEVPV-JKPGXYSKSA-N (1r,4ar,12as)-3-acetyl-1-amino-4,4a,6,7-tetrahydroxy-8,11-dimethyl-12,12a-dihydro-1h-tetracene-2,5-dione;hydrochloride Chemical compound Cl.C1=C(C)C(O)=C2C(O)=C(C([C@]3(O)C(O)=C(C([C@H](N)[C@@H]3C3)=O)C(=O)C)=O)C3=C(C)C2=C1 PPJJEMJYGGEVPV-JKPGXYSKSA-N 0.000 claims 1
- VCXSWLXWTJZWGQ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)[C@@H](N)CC(O)=O VCXSWLXWTJZWGQ-DKWTVANSSA-N 0.000 claims 1
- CHEANNSDVJOIBS-MHZLTWQESA-N (3s)-3-cyclopropyl-3-[3-[[3-(5,5-dimethylcyclopenten-1-yl)-4-(2-fluoro-5-methoxyphenyl)phenyl]methoxy]phenyl]propanoic acid Chemical compound COC1=CC=C(F)C(C=2C(=CC(COC=3C=C(C=CC=3)[C@@H](CC(O)=O)C3CC3)=CC=2)C=2C(CCC=2)(C)C)=C1 CHEANNSDVJOIBS-MHZLTWQESA-N 0.000 claims 1
- GOSPYHYMXMXYDB-RNWHKREASA-N (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one acetic acid Chemical compound CC(O)=O.COc1ccc2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5Oc1c2[C@]45CCN3C GOSPYHYMXMXYDB-RNWHKREASA-N 0.000 claims 1
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 claims 1
- ICIDIYCNVITODC-UVPAEMEASA-N (4s,4as,5ar,12ar)-2-carbamoyl-4-(dimethylazaniumyl)-10,11,12a-trihydroxy-7-nitro-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracen-1-olate Chemical compound C1C2=C([N+]([O-])=O)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O ICIDIYCNVITODC-UVPAEMEASA-N 0.000 claims 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims 1
- QWBBPBRQALCEIZ-UHFFFAOYSA-N 2,3-dimethylphenol Chemical compound CC1=CC=CC(O)=C1C QWBBPBRQALCEIZ-UHFFFAOYSA-N 0.000 claims 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 241001533362 Astroviridae Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 claims 1
- OTNRKVJTTSPVLD-UHFFFAOYSA-N C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.C(C)C2=C(C=1C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C2N1)CC)CC)N4)CC)CC)N3)CC)CC)CC Chemical compound C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.C(C)C2=C(C=1C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C2N1)CC)CC)N4)CC)CC)N3)CC)CC)CC OTNRKVJTTSPVLD-UHFFFAOYSA-N 0.000 claims 1
- 206010007275 Carcinoid tumour Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- 239000004099 Chlortetracycline Substances 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 1
- 102100030497 Cytochrome c Human genes 0.000 claims 1
- 108010075031 Cytochromes c Proteins 0.000 claims 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims 1
- 241001269524 Dura Species 0.000 claims 1
- 241000735495 Erica <angiosperm> Species 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 108010029961 Filgrastim Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000027294 Fusi Species 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 claims 1
- 206010073365 Intraductal papillary mucinous carcinoma of pancreas Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000035177 MELAS Diseases 0.000 claims 1
- 208000035172 MERRF Diseases 0.000 claims 1
- UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 239000004105 Penicillin G potassium Substances 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 241001112091 Pseudoviridae Species 0.000 claims 1
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 229960000473 altretamine Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 201000011188 breast medullary carcinoma Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- BWENFVHXWNVVGN-HANWARPLSA-N chembl2107409 Chemical compound N(/[C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)=C\C1=CC=CO1 BWENFVHXWNVVGN-HANWARPLSA-N 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 1
- 229960002155 chlorothiazide Drugs 0.000 claims 1
- 229960004475 chlortetracycline Drugs 0.000 claims 1
- 235000019365 chlortetracycline Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 229940094488 cytarabine liposome Drugs 0.000 claims 1
- 229960002398 demeclocycline Drugs 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 claims 1
- 229940042317 doxorubicin liposome Drugs 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 229960001842 estramustine Drugs 0.000 claims 1
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 claims 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 claims 1
- 229960004177 filgrastim Drugs 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- NGLNCTNUNFMLBM-UHFFFAOYSA-N hexadecanoic acid;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCC(O)=O NGLNCTNUNFMLBM-UHFFFAOYSA-N 0.000 claims 1
- ILZDRYGMISWQJJ-UHFFFAOYSA-H hexasodium 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ILZDRYGMISWQJJ-UHFFFAOYSA-H 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- DXKRGNXUIRKXNR-UHFFFAOYSA-N ibafloxacin Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(C)C(F)=C3 DXKRGNXUIRKXNR-UHFFFAOYSA-N 0.000 claims 1
- 229950007954 ibafloxacin Drugs 0.000 claims 1
- MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 claims 1
- 229960004849 isoconazole Drugs 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229930192532 kitamycin Natural products 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 206010025382 macrocytosis Diseases 0.000 claims 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 1
- 210000001087 myotubule Anatomy 0.000 claims 1
- 229960001775 nafcillin sodium Drugs 0.000 claims 1
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 201000001705 nipple carcinoma Diseases 0.000 claims 1
- 229950003587 nitrocycline Drugs 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 210000001711 oxyntic cell Anatomy 0.000 claims 1
- 229960003540 oxyquinoline Drugs 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- 201000004754 pancreatic intraductal papillary-mucinous neoplasm Diseases 0.000 claims 1
- 235000019368 penicillin G potassium Nutrition 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920003216 poly(methylphenylsiloxane) Polymers 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 229940093916 potassium phosphate Drugs 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 229940117820 purinethol Drugs 0.000 claims 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 claims 1
- 229960002026 pyrithione Drugs 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- ROKRAUFZFDQWLE-UHFFFAOYSA-M sodium;1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylate Chemical compound [Na+].C1=C(C)N=C2N(CC)C=C(C([O-])=O)C(=O)C2=C1 ROKRAUFZFDQWLE-UHFFFAOYSA-M 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims 1
- 229960000551 sulfacetamide sodium Drugs 0.000 claims 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 claims 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 claims 1
- 229960001326 sultamicillin Drugs 0.000 claims 1
- 201000008759 sweat gland cancer Diseases 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 108091008023 transcriptional regulators Proteins 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 208000012991 uterine carcinoma Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 230000001131 transforming effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 79
- 238000001514 detection method Methods 0.000 description 54
- 238000000684 flow cytometry Methods 0.000 description 46
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
- 230000007547 defect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 208000009905 Neurofibromatoses Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 2
- 208000013300 Multiple mitochondrial DNA deletion syndrome Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 201000005264 laryngeal carcinoma Diseases 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- RZLRMVZBGPHYJA-XXJPCBNGSA-N (1s,2e,5s,8s,9s,10e,14r,15r,16s)-5-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-8-[(2s,3r,4s,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,9,14-trimethyl-13,17-dioxabicyclo[14.1.0]heptadeca-2,10-diene-4,12-dione Chemical compound O[C@@H]1[C@@H](OC)C[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)/C=C/C(=O)O[C@H](C)[C@@H](CO[C@H]2[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O2)OC)[C@@H]2O[C@H]2/C=C/C(=O)[C@@](C)(O)CC1 RZLRMVZBGPHYJA-XXJPCBNGSA-N 0.000 description 1
- FHNKBSDJERHDHZ-UHFFFAOYSA-N (2,4-dimethylphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=C(C)C=C1C FHNKBSDJERHDHZ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- DDVJEYDLTXRYAJ-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1CNC(C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F DDVJEYDLTXRYAJ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- ZKWWRCVSLWBZMJ-KGYSUWQBSA-N 2-chloro-n-(2-chloroethyl)-n-[(e)-[(e)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]ethanamine Chemical compound [O-][N+](=O)C1=CC=C(\C=C\C=N\N(CCCl)CCCl)O1 ZKWWRCVSLWBZMJ-KGYSUWQBSA-N 0.000 description 1
- WKRBKYFIJPGYQC-UHFFFAOYSA-N 3-methylglutaconic acid Chemical compound OC(=O)CC(C)=CC(O)=O WKRBKYFIJPGYQC-UHFFFAOYSA-N 0.000 description 1
- DWPHNSNJHSXKPT-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline;ruthenium(2+) Chemical compound [Ru+2].C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DWPHNSNJHSXKPT-UHFFFAOYSA-N 0.000 description 1
- MGUKYHHAGPFJMC-UHFFFAOYSA-N 4-[3-(4-hydroxy-2,5-dimethylphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-2,5-dimethylphenol Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C)C=2)C)=C1C MGUKYHHAGPFJMC-UHFFFAOYSA-N 0.000 description 1
- LHGMHYDJNXEEFG-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]iminocyclohexa-2,5-dien-1-one Chemical compound C1=CC(N(C)C)=CC=C1N=C1C=CC(=O)C=C1 LHGMHYDJNXEEFG-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- SUNPCXPCGUAHMJ-UHFFFAOYSA-N CN1C(=NC2=C1C=CC=C2)C=2C(OC1=CC(=CC=C1C2)N(CC)CC)=O.[Ir+3] Chemical compound CN1C(=NC2=C1C=CC=C2)C=2C(OC1=CC(=CC=C1C2)N(CC)CC)=O.[Ir+3] SUNPCXPCGUAHMJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- DQAQEPOCRJOFIZ-UHFFFAOYSA-N ClC1=CC=CC=C1.[I] Chemical compound ClC1=CC=CC=C1.[I] DQAQEPOCRJOFIZ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001247414 Couma Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- RZLRMVZBGPHYJA-UHFFFAOYSA-N Cynanformoside B Natural products OC1C(OC)CC(C)OC1OC1C(C)C=CC(=O)OC(C)C(COC2C(C(OC)C(O)C(C)O2)OC)C2OC2C=CC(=O)C(C)(O)CC1 RZLRMVZBGPHYJA-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 244000039154 Erica Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QZJIMDIBFFHQDW-LMLSDSMGSA-N Fosfomycin tromethamine Chemical compound C[C@@H]1O[C@@H]1P(O)([O-])=O.OCC([NH3+])(CO)CO QZJIMDIBFFHQDW-LMLSDSMGSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000405147 Hermes Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- HQJNLDDXAFPBCM-UHFFFAOYSA-N Kidamycin Natural products CCC1OC(CC(NC)C1O)c2cc(C3CC(NC)C(O)C(CC)O3)c4C(=O)c5cc(CC)c6C(=O)C=C(Oc6c5C(=O)c4c2O)C(=CC)C HQJNLDDXAFPBCM-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- VXVAFQMBYKUOIZ-UHFFFAOYSA-N Neutramycin Natural products COC(=O)C=CC#CC#CCO VXVAFQMBYKUOIZ-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- ZUHRLTIPDRLJHR-UHFFFAOYSA-N Rosamicin Natural products CCC1OC(=O)CC(O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC=O)CC(C)C(=O)C=CC3OC3C1C ZUHRLTIPDRLJHR-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- JTJAMAJKINOBDT-FIJHNNTRSA-N [(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(1s,2r,3r,7r,8s,9s,10r,12r,14e,16s)-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-6-methyloxan-3-yl] propanoate Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1OC(=O)CC JTJAMAJKINOBDT-FIJHNNTRSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024554 amdinocillin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- GQUMQTDURIYYIA-MRFRVZCGSA-N chembl2106006 Chemical compound OS(O)(=O)=O.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O GQUMQTDURIYYIA-MRFRVZCGSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- MFTJRTUKCOVIMD-KUWIHEQQSA-N kidamycin Chemical compound OC1=C2C(=O)C3=C4OC(C(\C)=C/C)=CC(=O)C4=C(C)C=C3C(=O)C2=C([C@@H]2O[C@H](C)[C@@H](O)[C@H](C2)N(C)C)C=C1[C@H]1C[C@](C)(N(C)C)[C@H](O)[C@@H](C)O1 MFTJRTUKCOVIMD-KUWIHEQQSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000024305 myofibroblastoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229950003438 neutramycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000020205 notochordal tumor Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056362 penicillin g procaine Drugs 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- ULBKMFLWMIGVOJ-JOPMDFRVSA-M potassium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2s)-2-phenoxybutanoyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].O([C@@H](CC)C(=O)N[C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C1=CC=CC=C1 ULBKMFLWMIGVOJ-JOPMDFRVSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000007048 respiratory system cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- IUPCWCLVECYZRV-JZMZINANSA-N rosaramicin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IUPCWCLVECYZRV-JZMZINANSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- 201000007321 sebaceous carcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BVGLWBKHBMAPKY-QBGWIPKPSA-M sodium;(2r)-3-[[(2s,5r,6r)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl]amino]-3-oxo-2-thiophen-3-ylpropanoate;hydrate Chemical compound O.[Na+].C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)C=CSC=1 BVGLWBKHBMAPKY-QBGWIPKPSA-M 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PQMSFAORUFMASU-UHFFFAOYSA-M sulfacetamide sodium anhydrous Chemical compound [Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 PQMSFAORUFMASU-UHFFFAOYSA-M 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- SXNQAQBMEWMYAU-UHFFFAOYSA-N sulfo butanoate Chemical compound CCCC(=O)OS(O)(=O)=O SXNQAQBMEWMYAU-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960004840 temafloxacin hydrochloride Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention belongs to the field of protein engineering and relates to a cell penetrating peptide.
- the present invention provides cell-penetrating peptides based on influenza virus M2 protein, methods for their preparation and modification, and related uses.
- the present invention also provides conjugates, fusion proteins and compositions containing these cell penetrating peptides, as well as methods for using cell penetrating peptides to penetrate cells, introduce molecules into cells, and treat diseases.
- Cell penetrating peptides are a class of peptides that can "penetrate” cells.
- the source, sequence length, and amino acid composition of cell-penetrating peptides vary, but they all have the function of translocating the plasma membrane and transporting biologically active molecules such as proteins, peptides, DNA, RNA, and small molecule drugs into cells. Since it was first reported in 1988 that the trans-activator of HIV-1 virus (TAT) can be efficiently internalized by cells, some other cell-penetrating peptides have been discovered in the art, including Penetratin, DPV1047 , MPG and Pep-1 etc.
- TAT HIV-1 virus
- Influenza virus M2 (Matrix-2) protein is a proton-selective ion channel protein present in the viral envelope of influenza A virus. This channel exists as a homotetramer (consisting of 4 identical M2 units). In influenza A viruses, proton conduction of the M2 protein is essential for viral replication because it can form highly selective, pH-adjusted proton conduction channels.
- the M2 protein unit consists of three domains consisting of 97 amino acid residues, namely: (i) extracellular N-terminal domain (amino acid residues 1-24); (ii) span Membrane segment (amino acid residues 25-43); and (iii) intracellular C-terminal domain (amino acid residues 44-97).
- the transmembrane section forms pores of the ion channel.
- the first 17 residues (amino acid residues 45-62) of the cytoplasmic tail of the M2 protein form a highly conserved amphiphilic helix, which plays a role in virus budding and assembly.
- amino acid residues 70-77 in the cytoplasmic tail are important for binding M1 protein and generating infectious virus particles.
- the inventors have unexpectedly found that polypeptides and fragments derived from influenza virus M2 protein have the function of cell penetrating peptides, and their penetration efficiency is much higher than that of existing cell penetrating peptides in the art, and can be lower The concentration goes into many types of cells. Further research found that the cell-penetrating peptide function of M2 protein is mainly concentrated in its amino acid sequence 44-67. The present inventors obtained the cell penetrating peptide with even higher penetration efficiency by modifying the polypeptide fragment of the influenza virus M2 protein, thus completing the present invention.
- the invention relates to a polypeptide having an amino acid sequence selected from:
- a sequence comprising at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the sequence of amino acids 44-67 of the influenza virus M2 protein or a fragment thereof Amino acid sequence,
- fragment is at least 8 amino acids in length, and wherein the polypeptide has the function of cell penetrating peptide.
- cell penetrating peptide (“CPP") is generally used to indicate the ability to transport different types of cargo molecules across cell membranes and thereby promote a variety of molecular cargoes (from nanoscale particles to small chemical molecules, large molecules, and large DNA) Fragment) short peptides taken up by cells.
- “Cargo” molecules bind to cell penetrating peptides through chemical linkage by covalent bonds or through non-covalent interactions.
- Cell penetrating peptides usually have an amino acid composition that includes relatively high abundances of positively charged amino acids such as lysine or arginine, or they have an alternating pattern of polar / charged amino acids and non-polar, hydrophobic amino acids sequence.
- CPP translocation differs in three main mechanisms of entry: direct penetration into the membrane, entry regulated by endocytosis, and translocation through the formation of temporary structures.
- CPP transduction is an area where research is ongoing. It has been found that cell penetrating peptides have a large number of applications in medicine as drug delivery agents in the treatment of different diseases (including cancer) and viral inhibitors, as well as contrast agents for cell labeling and imaging.
- Cargo molecule refers herein to a molecule linked to a cell penetrating peptide by covalent or non-covalent binding, the presence of which allows its internalization to be promoted or enabled.
- “cargo molecules” include peptides, proteins, polysaccharides, lipids, their compositions including lipoproteins and glycoproteins, nucleic acids (eg DNA, siRNA, shRNA, antisense oligonucleotides, trap DNA, plasmids) ), Small molecule drugs (e.g. cyclosporin A, paclitaxel, doxorubicin, methotrexate, 5-aminolevulinic acid), imaging agents (e.g.
- the cargo molecule when the cargo molecule is a peptide, polypeptide or protein, it may include one or more peptides, polypeptides or proteins linked together.
- the cargo molecule when the cargo molecule is a nucleic acid, the nucleic acid may include one or more nucleic acids, each of which encodes one or more peptides or polypeptides.
- the cargo molecule can also be a combination of proteins, lipids and / or polysaccharides, including lipoproteins and glycoproteins.
- the nucleic acid may be a natural or artificial, single-stranded or double-stranded DNA molecule or RNA molecule.
- the nucleic acid molecules can be one or more nucleic acids of the same type (eg, having the same nucleotide sequence) or different types of nucleic acids.
- Nucleic acid molecules include but are not limited to one or more of the following: DNA, complementary DNA (cDNA), decoy DNA (decoy DNA), RNA, small interfering RNA (siRNA), micro RNA (miRNA), small hairpin RNA ( shRNA), hourly sequence RNA (stRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), pentose nucleic acid (PNA), antisense oligomers, plasmids and other modified nucleic acids.
- DNA complementary DNA
- cDNA complementary DNA
- decoy DNA decoy DNA
- RNA small interfering RNA
- miRNA micro RNA
- shRNA small hairpin RNA
- stRNA hourly sequence RNA
- snoRNA small nucleolar RNA
- snRNA small nuclear RNA
- PNA pentose nucleic acid
- antisense oligomers plasmids and other modified nucleic acids.
- protein and “polypeptide” are used interchangeably herein and generally refer to a polymer of amino acid residues connected by peptide bonds, and do not limit the minimum length of the product. Therefore, the above term includes peptides, oligopeptides, polypeptides, dimers (heterologous and homologous), multimers (heterologous and homologous) and so on.
- Protein and “polypeptide” encompass full-length proteins and fragments thereof. The term also includes post-expression modifications of polypeptides, such as glycosylation, acetylation, phosphorylation and the like.
- the polypeptide includes the amino acid sequence at positions 44-67 of the M2 protein of influenza virus.
- the polypeptide may include an additional amino acid sequence at the N-terminus and / or C-terminus of amino acids 44-67 of the M2 protein.
- the polypeptide may include the native sequence at amino acids 44-67 and both ends of the M2 protein.
- the polypeptide may include an N-terminal extended sequence of amino acids 44-67 of the M2 protein, for example, M43 protein positions 43-67, 42-67, 41-67, 40-67, Sequences of amino acids at positions 39-67, 38-67, 37-67, 36-67, 35-67, 34-67, etc.
- the polypeptide may include a C-terminal extended sequence of amino acids 44-67 of the M2 protein.
- the polypeptide may include positions 43-68, 42-69, 41-70, 40-71, 39-72, 38-73, 37-74 of the M2 protein The sequence of amino acids at positions 36, 75-35, 35-76, 34-77, etc.
- the polypeptide may include a native sequence extending in both directions from the N-terminus and the C-terminus of amino acids 44-67 of the M2 protein.
- polypeptide may also include unnatural sequences, such as heterologous sequences, at the N-terminal and / or C-terminal of amino acids 44-67 of the M2 protein.
- the heterologous sequence may be selected from various tags, fluorescent proteins, functional parts, and amino acid sequences derived from other proteins or polypeptides, etc., as long as the heterologous sequence does not affect the cell-penetrating peptide function of the polypeptide.
- the polypeptide comprises a fragment of the above sequence, and the fragment has a cell penetrating peptide function.
- the present invention has identified multiple functional fragments of the 44-67 amino acid sequence of the influenza virus M2 protein.
- the fragment may be at least 8 amino acids, at least 9 amino acids, at least 10 amino acids, at least 11 amino acids, at least 12 amino acids, at least 13 amino acids, at least 14 amino acids, at least 15 amino acids Amino acids, at least 16 amino acids, at least 17 amino acids, at least 18 amino acids, at least 19 amino acids, at least 20 amino acids, at least 21 amino acids, at least 22 amino acids, or at least 23 amino acids.
- There is no specific limitation on the choice of amino acid fragment as long as the fragment has a cell-penetrating peptide function.
- the fragment includes amino acids 44-48 or amino acids 45-48 of the M2 protein.
- the polypeptide fragments with amino acids 44-48 or 45-48 of M2 protein have strong cell penetrating peptide function.
- the polypeptide fragment may not include amino acids 44-48 or 45-48 of the M2 protein.
- the fragment includes or consists of amino acids 44-65, 44-61, 45-62, or 44-56 of the M2 protein.
- the fragment may also include a sequence that extends and / or truncates one or more amino acid residues at the N-terminus and / or C-terminus of the above sequence.
- the polypeptide includes an amino acid sequence modified with one or more amino acid residues in the amino acid sequence at positions 44-67 of the influenza virus M2 protein or a fragment thereof.
- the modification of the amino acid residue includes substitution, insertion, deletion and / or addition of the amino acid residue.
- the amino acid modification is an amino acid substitution.
- the number of amino acid residues can be determined based on the length of the polypeptide and / or its amino acid composition. For example, when the length of the polypeptide is about 25 amino acids, the number of amino acid substitutions, insertions, and deletions may be 1-12, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12. When the length of the polypeptide is about 20 amino acids, the number of amino acid substitutions, insertions, and deletions may be 1-10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. When the length of the polypeptide is about 15 amino acids, the number of amino acid substitutions, insertions, and deletions may be 1-7, such as 1, 2, 3, 4, 5, 6, or 7.
- amino acid substitution is a conservative amino acid substitution.
- Constant amino acid substitutions refers to substitutions between amino acid residues with similar charge properties or side chain groups, which generally do not affect the normal function of a protein or polypeptide.
- the insertion is of a hydrophobic amino acid or a positively charged amino acid.
- the deletion is a deletion of hydrophilic amino acids.
- the amino acid substitutions are substituted with hydrophobic amino acids or positively charged amino acids.
- the hydrophobic amino acid is preferably C, A, F, I, L, M, P, V, W, M or Y, more preferably I.
- the positively charged amino acid is preferably K, R or H, more preferably K or R.
- the hydrophobic amino acid or positively charged amino acid is selected from I, F, and R residues.
- the hydrophilic amino acid is preferably D, E, Q, S or T.
- the polypeptide may also include an amino acid sequence having at least 60% sequence identity with the amino acid sequence at positions 44-67 of the M2 protein or a fragment thereof, as long as the polypeptide has a cell penetrating peptide function.
- the polypeptide may include an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 80%, at least 85%, at least 90%, the amino acid sequence of the M2 protein at positions 44-67 or a fragment thereof Or an amino acid sequence with at least 95% sequence identity, as long as the polypeptide has cell-penetrating peptide function.
- the percentage of sequence identity between two sequences can be determined by, for example, using a mathematical algorithm.
- sequence comparison i.e., alignment
- the program can be appropriately executed by the computer. Examples of such programs include, but are not limited to, the CLUSTAL, ALIGN program (Version 2.0) of the PC / Gene program, and GAP, BESTFIT, BLAST, FASTA, and TFASTA of the Wisconsin genetics software package. Alignment using these procedures can be implemented, for example, by using initial parameters.
- influenza virus may be any type of influenza virus.
- influenza virus may be H1N1, H5N1, H5N6, or H7N9 type influenza virus, but is not limited thereto. It is known in the art that the amino acid sequence of the M2 protein is conserved among influenza viruses of different types.
- the M2 protein of the invention may be derived from the following influenza virus strains: A / Caledonia / 20/1999 (H1N1), A / HongKong / 97/98 (H5N1) and A / chicken / Jilin / 9 / 2004 (H5N1), but not limited to this.
- the present invention relates to a method for engineering cell-penetrating peptides based on influenza virus M2 protein and variant sequences obtained.
- the present invention has strong cell penetrating peptide functions for JiLin-2004 (H5N1) -M2-44-56, JiLin-2004 (H5N1) -M2-45-62 and JiLin-2004 (H5N1) -M2- The 44-65 polypeptides were modified, and variant polypeptide sequences with similar or even stronger cell-penetrating peptide functions were obtained.
- the invention relates to a polypeptide having the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19- The amino acid sequence of X20-X21-X22-X23-X24; wherein X1 is D, R, L, I or absent; X2 is R, I or S; X3 is L, I, F, A, R or K; X4 Is F, R or I; X5 is F, R or I; X6 is K, R or I; X7 is C, I or R; X8 is A, I, F, K or R; X9 is Y, I, F , K or R; X10 is R or S; X11 is R, S or does not exist; X12 is L, I, F, R or K or does not exist; X13 is K, R, T
- the polypeptide has an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the amino acid sequence; or
- the polypeptide has an amino acid sequence in which one or more amino acid residues have been deleted, inserted, or substituted in the amino acid sequence.
- the invention relates to a polypeptide having an amino acid sequence selected from:
- c. comprising an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity with DRLFFKCIYRRLK,
- polypeptide has the function of cell penetrating peptide.
- DRLFFKCIYRRLK corresponds to the amino acid sequence of positions 44-56 of the Jilin-2004 (H5N1) influenza virus M2 protein (JiLin-2004 (H5N1) -M2-44-56), which has a strong cell-penetrating peptide function. Accordingly, the cell penetrating peptide of the present invention may include this sequence or a functional variant sequence thereof.
- the substitution, deletion, or insertion of one or more amino acid residues is a substitution, deletion, or insertion of 1-5 amino acid residues, such as 1, 2, 3, 4, or 5 amino acid substitutions, Missing or inserted.
- at least one, at least two, at least three, at least four, or all five of the substitutions may be substituted with hydrophobic amino acids or positively charged amino acids, such as selected from I, F, and R Residues.
- the insertion is of a hydrophobic amino acid or a positively charged amino acid.
- the deletion is a deletion of hydrophilic amino acids.
- the polypeptide has the amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13; wherein X1 is D or R; X2 is R; X3 Is L, I, or F; X4 is F; X5 is F; X6 is K or R; X7 is C or R; X8 is I or F; X9 is Y, I or F; X10 is R; X11 is R; X12 is L, I or F; and X13 is K or R; or the polypeptide has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or An amino acid sequence with 100% sequence identity; or an amino acid sequence in which one or more amino acid residues have been deleted, inserted, or substituted.
- the polypeptide has an amino acid sequence selected from the group consisting of RRLFFKCIYRRLK, RRLFFRCIYRRLK, RRLFFRRIYRRLK, RRLFFRRIYRRLR, DRIFFKCIYRRLK, DRIFFKCIIRRLK, DRIFFKCIIRRIK, DRFFFKCIYRRLK, DRFFFKRFYRRK
- the invention relates to a polypeptide having an amino acid sequence selected from:
- a. contains the amino acid sequence of RLFFKCIYRRLKYGLKRG;
- c. contains an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with RLFFKCIYRRLKYGLKRG, wherein the polypeptide has the function of cell penetrating peptide .
- RLFFKCIYRRLKYGLKRG corresponds to the amino acid sequence at positions 45-62 of the M2 protein of JiLin-2004 (H5N1) influenza virus (JiLin-2004 (H5N1) -M2-45-62), which has a strong cell-penetrating peptide function. Accordingly, the cell penetrating peptide of the present invention may include this sequence or a functional variant sequence thereof.
- the substitution, deletion, or insertion of the one or more amino acid residues is a substitution, deletion, or insertion of 1-6 amino acid residues, such as 1, 2, 3, 4, 5 or 6 amino acid substitutions , Missing or inserted.
- at least one, at least two, at least three, at least four, at least five, or all six of the substitutions may be substituted with hydrophobic amino acids or positively charged amino acids, for example selected from I, F and R residues.
- the insertion is of a hydrophobic amino acid or a positively charged amino acid.
- the deletion is a deletion of hydrophilic amino acids.
- the polypeptide has the amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18; wherein X1 Is R or S; X2 is A, L or F; X3 is F or I; X4 is F or I; X5 is R or K; X6 is I, C or R; X7 is A, I or F; X8 is K , Y or F; X9 is R or S; X10 is R or S; X11 is A, L or F; X12 is K, R or T; X13 is Y, F or K; X14 is G, R or K; X15 Is L, F or A; X16 is K, R or T; X17 is R or T; and X18 is G, R or K or the polypeptide has at least 60%, at
- the present invention relates to the unit point mutant polypeptide sequence of JiLin-2004 (H5N1) -M2-45-62 polypeptide.
- the polypeptide having an amino acid sequence selected from the group: SLFFKCIYRRLKYGLKRG, RAFFKCIYRRLKYGLKRG, RLIFKCIYRRLKYGLKRG, RLFIKCIYRRLKYGLKRG, RLFFKIIYRRLKYGLKRG, RLFFKCAYRRLKYGLKRG, RLFFKCIKRRLKYGLKRG, RLFFKCIYSRLKYGLKRG, RLFFKCIYRSLKYGLKRG, SLFFKCIYRRLKYGLKRG, RLFFKCIYRRAKYGLKRG, RLFFKCIYRRLTYGLKRG, RLFFKCIYRRLKKGLKRG, RLFFKCIYRRLKYKLKRG, RLFFKCIYRRLKKGLKRG, RLFFKCIYRRLKYK
- the invention relates to a polypeptide having an amino acid sequence selected from:
- a. contains the amino acid sequence of DRLFFKCIYRRLKYGLKRGPST;
- c. comprising an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity with DRLFFKCIYRRLKYGLKRGPST,
- polypeptide has the function of cell penetrating peptide.
- DRLFFKCIYRRLKYGLKRGPST corresponds to the amino acid sequence at positions 44-65 of the M2 protein of JiLin-2004 (H5N1) influenza virus (JiLin-2004 (H5N1) -M2-44-65), which has a strong cell-penetrating peptide function. Accordingly, the cell penetrating peptide of the present invention may include this sequence or a functional variant sequence thereof.
- the substitution, deletion, or insertion of the one or more amino acid residues is a substitution, deletion, or insertion of 1-10 amino acid residues, such as 1, 2, 3, 4, 5, 6, 7 , 8, 9 or 10 amino acid substitutions, deletions or insertions.
- at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or all ten of the substitutions can be Substitutions are hydrophobic amino acids or positively charged amino acids, for example selected from I, F and R residues.
- the insertion is of a hydrophobic amino acid or a positively charged amino acid.
- the deletion is a deletion of hydrophilic amino acids.
- the polypeptide has X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-
- the amino acid sequence of X22 where X1 is D or R; X2 is R; X3 is L or F; X4 is F; X5 is F; X6 is K or R; X7 is C or R; X8 is I or F; X9 is Y or F; X10 is R; X11 is R; X12 is L or F; X13 is K or R; X14 is Y or F; X15 is G or R; X16 is L; X17 is K or R; X18 is R; X19 is G, or R or K; X20 is P; X21 is S or K; and X22 is T or V; or the polypeptide has
- the invention relates to a polypeptide having an amino acid sequence selected from:
- a. contains the amino acid sequence of DRLFFKCIYRRLKYGLKR;
- c. comprising an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity with DRLFFKCIYRRLKYGLKR,
- polypeptide has the function of cell penetrating peptide.
- the substitution, deletion or insertion of the one or more amino acid residues is 1-10 or 1-6, such as the substitution, deletion or insertion of 5, 4, 3 or 2 amino acid residues .
- At least one of the substitutions is a hydrophobic amino acid or a positively charged amino acid.
- the insertion is of a hydrophobic amino acid or a positively charged amino acid.
- the deletion is a deletion of hydrophilic amino acids.
- the polypeptide has the amino acid sequence of the formula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18; wherein X1 Is D, R, L or I; X2 is R or I; X3 is L, R or K; X4 is F or R; X5 is F or R; X6 is K or I; X7 is C, R or I; X8 Is I, K or R; X9 is Y, K or R; X10 is R; X11 is R; X12 is L, R or K; X13 is K; X14 is Y or R; X15 is G; X16 is L or R X17 is K or I; and X18 is R or I; or the polypeptide has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%,
- the invention also relates to conjugates and fusion proteins, which comprise the polypeptide of the invention.
- the conjugate comprises the present invention and a moiety conjugated to the polypeptide
- the moiety may not be particularly limited, and may be a therapeutic moiety, a detectable moiety, or a cosmetic moiety, It is selected from proteins, peptides, nucleic acids, antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioisotopes, fluorescent markers, luminescent substances, chromogenic substances and enzymes.
- the selection of the protein, peptide, nucleic acid, antibiotic, anti-inflammatory drug, anti-tumor drug, neuroprotective agent, chemotherapeutic agent, cytotoxin, radioisotope, fluorescent marker, luminescent substance, chromogenic substance, and enzyme is not particularly limited as long as It does not affect the cell-penetrating peptide function of the polypeptide of the present invention.
- the therapeutic moiety is selected from: 13-cis-retinoic acid, 2-amino-6-mercaptopurine, 2-CdA, 2-chlorodeoxyadenosine, 5-fluorouracil, 6-thioguanine, 6 -Mercaptopurine, isotretinoin (Accutane), actinomycin D, doxorubicin, Adrucil, Anguining, Ala-Cort, aldesleukin, alemtuzumab, alitretinoin, Alkaban- AQ, Aklan, all-trans retinoic acid, interferon alpha, hexamethonamine, methotrexate, amifostine, lumit, anagrelide, andro, anastrozole, cytarabine, Enron Espoo, Adalco, Raininide, Arnold, Arsenic Trioxide, Asparaginase, ATRA, Avastin, BCG, BCNU, Bevacizum
- the detectable moiety is selected from the group consisting of: UV-Vis label, near infrared label, luminescent group, phosphorescent group, magnetic spin resonance label, photosensitizer, photocleavable moiety, chelating center, heavy atom, Radioisotopes, spin resonance labels with isotope detection, paramagnetic moieties, chromophores, luminophores such as metal porphyrins; benzoporphyrins; azabenzoporphyrins; naphthoporphyrins, phthalocyanines; polycyclic Aromatic hydrocarbons, such as perylene, perylene diimine, pyrene; azo dyes; xanthene dyes; boron dipyrromethene, aza-boron dipyrromethene, cyanine dyes, metal-ligand complexes such as Pyridine, bipyridyl, phenanthroline, coumarin, and acetylace
- the cosmetic moiety may be a cosmetic polypeptide, such as palmitoylpentapeptide 4, palmitoyl tetrapeptide 7, carnosine, acetyl hexapeptide 8, aFGF, bFGF or EGF, botulinum toxin, elastin, Hyaluronic acid.
- the polypeptide of the invention is conjugated to one of the moieties. In other embodiments, the polypeptide of the present invention is conjugated to a variety of such moieties.
- the polypeptide of the present invention is combined with one of the moieties in a non-covalent form. In other embodiments, the polypeptides of the present invention are combined with a variety of these non-covalent forms.
- the method of conjugating the polypeptide of the present invention to the part is not particularly limited, and conjugation can be performed by, for example, physical adsorption or chemical linkage.
- the polypeptide of the present invention and the moiety may be conjugated in a non-covalent or covalent manner.
- the fusion protein comprises a polypeptide of the present invention and a portion fused to the polypeptide, the portion may be selected from an antigen, an antibody or antigen-binding portion thereof, ligand, receptor, cytokine , Transcription regulators, fluorescent proteins and enzymes.
- the portion fused to the polypeptide is a therapeutic portion, such as human growth hormone, bovine growth hormone, porcine growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, granulocyte-colony stimulating factor, granulocyte macrophage -Colony-stimulating factor, macrophage-colony stimulating factor, erythropoietin, bone morphogenetic protein, interferon, insulin, atrial peptide hormone-III, monoclonal antibody, tumor necrosis factor, macrophage activating factor, interleukin, Tumor degrading factor, insulin-like growth factor, epidermal growth factor, tissue plasminogen activator and urokinase.
- a therapeutic portion such as human growth hormone, bovine growth hormone, porcine growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, granulocyte-colony stimulating factor, granulocyte macrophage -Colony-stimulating factor, macrophage-colony stimulating factor, erythrop
- the portion fused to the polypeptide is a detectable portion, such as green fluorescent protein, eg, GFP, GFP-2, tagGFP, turboGFP, eGFP, Emerald, Azami Green, monomer Azami Green, CopGFP, AceGFP, ZsGreenl ), Yellow fluorescent protein (for example, YFP, eYFP, Citrine, Venus, YPet, PhiYFP, ZsYellowl), blue fluorescent protein (for example, eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire), cyan fluorescent protein (E.g., eCFP, Cerulean, CyPet, AmCyanl, Midoriishi-Cyan), red fluorescent protein (e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRe
- the part fused to the polypeptide is a cosmetic part, including cosmetic polypeptides, such as palmitoylpentapeptide 4, palmitoyl tetrapeptide 7, carnosine, acetylhexapeptide 8, aFGF, bFGF or EGF, botulinum Bacillus toxin, elastin, hyaluronic acid.
- cosmetic polypeptides such as palmitoylpentapeptide 4, palmitoyl tetrapeptide 7, carnosine, acetylhexapeptide 8, aFGF, bFGF or EGF, botulinum Bacillus toxin, elastin, hyaluronic acid.
- the selection of the antigen, antibody or antigen-binding portion thereof, ligand, receptor, cytokine, transcription regulator, fluorescent protein and enzyme is not particularly limited as long as it does not affect the cell-penetrating peptide function of the polypeptide of the present invention.
- the polypeptide and the portion are directly fused. In other embodiments, the polypeptide and the portion are fused by a linker, for example, by a flexible linker.
- the polypeptide may be fused to the portion at its N-terminus. In other embodiments, the polypeptide may be fused to the portion at its C-terminus. In still other embodiments, the polypeptide may be fused to multiple of the portions at its N-terminus and C-terminus.
- the invention relates to a method of allowing a polypeptide to penetrate a cell, which includes the step of incubating the polypeptide, conjugate or fusion protein of the invention with the cell.
- the cell is a cell line (eg, an immortalized cell line), such as an animal or plant cell line, or a microbial cell, such as a bacterial cell or fungal cell, or a primary cell isolated from a subject or Plant cells in culture.
- a cell line eg, an immortalized cell line
- an animal or plant cell line such as an animal or plant cell line
- a microbial cell such as a bacterial cell or fungal cell, or a primary cell isolated from a subject or Plant cells in culture.
- the cell is selected from tumor cells, fibroblasts, epithelial cells, endothelial cells, immune cells, skin cells, and nerve cells; or selected from meristematic cells, stone cells, parenchyma cells, germ cells, Root hair cells, ductal cells, sieve tube cells, mesophyll cells and guard cells, epidermal cells and pigment cells.
- the epithelial cells are selected from digestive tract epithelial cells and respiratory tract epithelial cells.
- the type of the tumor cell is not limited, and can be derived from various types of cancer, for example: basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and CNS cancer; breast cancer; peritoneal cancer; cervical cancer; bile duct cancer; Chorionic carcinoma; colon and rectal cancer; connective tissue cancer; digestive system cancer; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer; glioblastoma; liver cancer; liver cancer; Laryngeal cancer; leukemia; liver cancer; lung cancer; lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer Retinoblastoma; rhabdomyosarcoma; rectal cancer; respiratory system cancer; salivary adenocarcinoma; sarcoma; skin
- the cell is selected from A549 cells, HCT-116 cells, MKN-45 cells, 293T cells, HUVEC cells, ESF-1 cells, HeLa cells, and MRC-5 cells, and is not limited thereto.
- the polypeptide, conjugate or fusion protein can be incubated with the cell for 5 minutes to 24 hours, such as 10 minutes to 12 hours, 30 minutes to 6 hours or 1 hour to 3 hours.
- the concentration of the polypeptide, conjugate or fusion protein may be 0.01 ⁇ M to 100 ⁇ M, such as 0.03 ⁇ M to 30 ⁇ M, 0.1 ⁇ M to 10 ⁇ M or 1 ⁇ M to 3 ⁇ M.
- the invention in another aspect, relates to a method of introducing a molecule into a cell, the method comprising the step of incubating the molecule with a mixture of the polypeptide, conjugate or fusion protein of the invention and the cell.
- the molecule is selected from proteins, nucleic acids, peptides, lipids, metabolites, drugs, and small molecule compounds.
- the molecule is selected from antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioactive isotopes, fluorescent labels, luminophores, chromogenic substances, antigens, cytokines, Transcription regulators and enzymes.
- the molecule is a small RNA (small RNA), for example selected from siRNA and microRNA.
- small RNA small RNA
- the cell is a cell line (eg, an immortalized cell line) or a primary cell isolated from a subject.
- the cells are selected from tumor cells, fibroblasts, epithelial cells, endothelial cells, immune cells, skin cells, and nerve cells.
- the epithelial cells are selected from digestive tract epithelial cells and respiratory tract epithelial cells.
- the cell is selected from A549 cells, HCT-116 cells, MKN-45 cells, 293T cells, HUVEC cells, ESF-1 cells, HeLa cells, and MRC-5 cells.
- the invention relates to the use of the polypeptides, conjugates and fusion proteins of the invention for introducing molecules into cells.
- the molecule is selected from proteins, nucleic acids, peptides, lipids, metabolites, drugs, and small molecule compounds.
- the molecule is selected from antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioactive isotopes, fluorescent labels, luminophores, chromogenic substances, antigens, cytokines, Transcription regulators and enzymes.
- the molecule is a small RNA, for example selected from siRNA and microRNA.
- the cell is a cell line or a primary cell isolated from a subject.
- the cells are selected from tumor cells, fibroblasts, epithelial cells, endothelial cells, immune cells, skin cells, and nerve cells.
- the epithelial cells are selected from digestive tract epithelial cells and respiratory tract epithelial cells.
- the cell is selected from A549 cells, HCT-116 cells, MKN-45 cells, 293T cells, HUVEC cells, ESF-1 cells, HeLa cells, and MRC-5 cells.
- the present invention relates to a method for treating a disease, diagnosing a disease, tracing, preferably intracellular tracing, or cosmetically, the method comprising administering a polypeptide, conjugate or fusion of the present invention to a subject in need protein.
- the present invention relates to a method for treating a disease, diagnosing a disease, tracing, preferably intracellular tracing or cosmetic, the method comprising administering to a subject in need thereof a polypeptide, conjugate or Fusion proteins and ingredients selected from the group consisting of antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioisotopes, fluorescent markers, luminescent substances, chromogenic substances, antigens, cytokines, transcription Regulatory factors, enzymes and nucleic acids, including small RNA.
- the nucleic acid may be a natural or artificial DNA or RNA molecule, which is single-stranded or double-stranded.
- the nucleic acid molecule may be one or more nucleic acids of the same type (eg, having the same nucleotide sequence) or different types of nucleic acids.
- the nucleic acid molecule includes one or more of DNA, cDNA, decoy DNA, RNA, siRNA, miRNA, shRNA, stRNA, snoRNA, snRNA, PNA, antisense oligomer, plasmid, and other modified nucleic acids, but is not limited thereto.
- the small RNA is selected from siRNA and microRNA.
- the disease may be selected from cancer, viral infection, central nervous system disease, inflammatory disease, autoimmunity Diseases, mitochondrial-related diseases and metabolic diseases.
- the invention relates to the use of the polypeptides, conjugates or fusion proteins of the invention in the treatment of diseases or in cosmetic applications.
- the disease is selected from cancer, viral infections, central nervous system diseases, inflammatory diseases, autoimmune diseases, mitochondrial-related diseases, and metabolic diseases.
- the invention relates to the use of a polypeptide, conjugate or fusion protein of the invention in the preparation of a pharmaceutical composition for the treatment of disease, diagnosis of disease, tracing, preferably intracellular tracing or cosmetic use.
- the pharmaceutical composition further comprises ingredients selected from the group consisting of antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioisotopes, fluorescent markers, luminescent substances, Chromogenic substances, antigens, cytokines, transcription regulators, enzymes and small RNA.
- the small RNA is selected from siRNA and microRNA.
- the disease may be selected from cancer, viral infections, central nervous system diseases, inflammatory diseases, autoimmune diseases, mitochondrial-related diseases, and metabolic diseases.
- the present invention relates to a nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide or fusion protein of the present invention.
- the invention relates to a vector, which comprises the nucleic acid molecule of the invention.
- beauty treatment includes elimination of delaying skin aging, whitening, and anti-wrinkle.
- cosmetic substances such as cosmetic polypeptides, such as palmitoylpentapeptide 4, palmitoylpentapeptide 7, carnosine, acetylhexapeptide 8, aFGF, bFGF or EGF , Botulinum toxin, elastin, hyaluronic acid, etc. are connected to the penetrating peptide of the present invention in a covalent or non-covalent manner for delivery into cells, thereby exerting efficacy.
- vector refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
- a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
- the vector can be introduced into the host cell by methods such as transformation, transduction, or transfection, and then the genetic material elements carried by it can be expressed in the host cell.
- Vectors are recognized by those skilled in the art, including but not limited to: (1) plasmids; (2) phagemids; (3) Kos plasmids; (4) artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial Chromosome (BAC) or P1-derived artificial chromosome (PAC); (5) bacteriophage such as lambda bacteriophage or M13 bacteriophage and (6) animal viruses such as retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, spores Herpes virus (such as simple herpes simplex virus), pox virus, baculovirus.
- a vector can contain multiple elements that control expression, including but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes; in addition, the vector can also contain replication initiation sites.
- the invention relates to a composition comprising the polypeptide, conjugate or fusion protein of the invention.
- the composition further comprises an ingredient selected from the group consisting of antibiotics, anti-inflammatory drugs, anti-tumor drugs, neuroprotective agents, chemotherapeutic agents, cytotoxins, radioisotopes, fluorescent markers, luminescent substances, Color substances, antigens, cytokines, transcription regulators, enzymes, and small RNA.
- the small RNA is selected from siRNA and microRNA.
- the composition is a pharmaceutical composition and further comprises one or more pharmaceutically acceptable carriers.
- pharmaceutically acceptable carrier refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, medium, encapsulating material, manufacturing aid (such as lubricants, magnesium talc, calcium or zinc stearate or stearic acid) or solvent encapsulating materials, which are involved in maintaining the stability, solubility or activity of the LAP binder.
- a pharmaceutically acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent, medium, encapsulating material, manufacturing aid (such as lubricants, magnesium talc, calcium or zinc stearate or stearic acid) or solvent encapsulating materials, which are involved in maintaining the stability, solubility or activity of the LAP binder.
- manufacturing aid Such as lubricants, magnesium talc, calcium or zinc stearate or stearic acid
- solvent encapsulating materials which are involved in maintaining the stability, solubility or activity
- materials that can serve as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as Sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) excipient Agents such as cocoa butter and suppository wax; (8) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (9) glycols such as propylene glycol; (10) polyols, Such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (11) esters such as ethyl oleate and ethyl laurate; (12) agar; (13) buffers such as magnesium hydroxide and hydrogen Alumina; (14) alg
- cancer refers to malignant neoplasms (Stedman ’s Medical Dictionary, 25th .; Hensyled .; Williams & Wilkins: Philadelphia, 1990).
- exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal cancer; rectal cancer; angiosarcoma (eg, lymphatic sarcoma, lymphatic endothelial sarcoma, angiosarcoma); cecum cancer; benign monoclonal gammopathy; bile cancer (Eg, cholangiocarcinoma); bladder cancer; breast cancer (eg, adenocarcinoma of the breast, papillary carcinoma of the breast, breast cancer, medullary carcinoma of the breast); brain cancer (eg, meningioma, glioblastoma) Tumors, gliomas (eg, astrocytoma, oligodendroglioma), medul
- viral infections include, but are not limited to, viral diseases of the poxviridae family, viral diseases of the herpesviridae family, viral diseases of the adenoviridae family, viral diseases of the papillomavirus family and polyomaviridae family, viral diseases of the parvoviridae family Diseases, viral diseases of Hepadnaviridae, viral diseases of Retroviridae, viral diseases of Reoviridae, viral diseases of Bornaviridae, viral diseases of Rhabdoviridae, viruses of Filaviridae sexual diseases, viral diseases of the Paramyxoviridae family, viral diseases of the Orthomyxoviridae family, viral diseases of the Buniaviridae family, viral diseases of the Coviviridae family, viral diseases of the small RNAviridae family, viral diseases of the Caliciviridae family Diseases, Astroviruses, Viral Diseases, Coronaviruses, Viral Diseases, Togaviridae, Viral Disease
- viral infections are infections caused by the following viruses: Hepatitis A, B, C virus, influenza virus, varicella virus, herpes simplex virus type I (HSV-I), herpes simplex virus type II (HSV-II), Rinderpest virus, respiratory syncytial virus, cytomegalovirus, sea urchin virus, arbovirus, hantavirus, mumps virus, measles virus, rubella virus, type I human immunodeficiency virus (HIV-1), type II human immunity Defective virus (HIV-2), any Candidavirus (eg dengue virus), alphavirus, flavivirus, coronavirus, rabies virus, green monkey virus, Ebola virus, parainfluenza Virus, Orthomyxovirus, Sand Virus, Type I Human T-cell Leukemia Virus, Type II Human T-cell Leukemia Virus, Simian Immunodeficiency Virus, Lentivirus, Epstein-Barr Virus, Human Herpes Virus, Mimi Her
- central nervous system diseases include, but are not limited to, neurodegenerative diseases, stroke, epilepsy, brain trauma, shock, HIV dementia, glaucoma, multiple sclerosis, and the like. Stroke is divided into hemorrhagic and ischemic stroke. Neurodegenerative diseases include Alzheimer's disease, cerebellar atrophy, multiple sclerosis, primary lateral sclerosis, spinal muscular atrophy, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease, bovine spongiform Encephalopathy, ataxia telangiectasia, amyotrophic lateral sclerosis.
- inflammatory disease refers to a disease caused by, caused by, or causing inflammation.
- inflammatory disease also refers to an unregulated inflammatory response that leads to an excessive response of macrophages, granulocytes and / or T-lymphocytes, which leads to normal tissue damage and / or cell death.
- Inflammatory diseases can be acute or chronic inflammatory conditions and can be caused by infection or non-infection.
- Inflammatory diseases include, but are not limited to, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, rheumatic polymyalgia (PMR), gouty arthritis, degenerative arthritis, tendonitis , Bursitis, psoriasis, cystic fibrosis, osteoarthritis, rheumatoid arthritis, inflammatory arthritis, Shogren syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), Ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (eg, type I), myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Goodpasture's disease , Mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pernicious
- autoimmune disease refers to a disease that arises from an inappropriate immune response in a subject against substances and tissues normally present in the body. In other words, the immune system mistakes a part of the body as a pathogen and attacks its own cells. This may be limited to certain tissues (for example, in autoimmune thyroiditis) or specific tissues including different sites (for example, Good Pasteur disease, which may affect the basement membranes of both lungs and kidneys).
- the treatment of autoimmune diseases usually uses immunosuppressive agents, for example, drugs that reduce the immune response.
- Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture syndrome, necrotizing vasculitis, lymphadenitis, nodular periarteritis, systemic lupus erythematosus, rheumatoid disease, arthritis, Psoriatic arthritis, systemic lupus erythematosus, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, antiphospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (Eg, Wegener's granulomatosis, microscopic polyangiitis), uveitis, Shogren syndrome, Crohn's disease, Wright syndrome, ankylosing spondylitis, Lyme arthritis, Guran- Barre syndrome, Hashimoto's thyroiditis, and cardiomyopathy.
- glomerulonephritis Goodpasture
- metabolic diseases include, but are not limited to, phenylketonuria, xanthoma, amyloidosis, xanthomatosis, xanthomatosis, lipomatous fibroma, lipofibroma, lipofibroma, hyperlipidemia Disease, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, hyperlipidemia, amyloidosis, amyloidosis, amyloidosis, galactosemia, obesity, hyperlipidemia, bone Asthenia, rickets, osteomalacia and rickets, osteoporosis, diabetes as used herein, "mitochondrial-related diseases” include Huntington's disease, amyotrophic lateral sclerosis, mitochondrial brain muscle disease with lactate And stroke-like syndrome (MELAS); myoclonic epilepsy with red ragged muscle fibrosis (MERRF); neuromuscular relaxation, dysregulation, retinitis pigmentosa / maternal genetic Leishmanias
- mitochondrial-related diseases include, but are not limited to, Huntington's disease, amyotrophic lateral sclerosis, mitochondrial brain muscle disease with lactic acidemia and stroke-like syndrome MELAS; myoclonic epilepsy with red ragged fibrosis , MERRF; neuromuscular relaxation, dysregulation, retinitis pigmentosa / maternal inherited Ley symptoms NARP / MILS; Leber's optic neuropathy LHON; Kearns-Sayre syndrome KSS; Pearson's bone marrow pancreatopathy PMPS; chronic progressive extraocular muscles Paralytic CPEO; Reye's syndrome; Alperz's syndrome; multiple mitochondrial DNA deletion syndromes; mitochondrial DNA depletion syndrome; complex I deficiency; complex II succinate dehydrogenase SDH deficiency; complex III deficiency; cytochrome c Oxidase COX, complex IV deficiency; complex V deficiency; adenine nucleotide transporter
- Figure 1 Laser confocal technology detects the cell entry of different peptides labeled with rhodamine.
- Figure 2 Flow cytometry to detect the entry of cells with different concentrations of FITC-labeled polypeptide.
- Figure 3 Flow cytometry detection of FITC-labeled polypeptide entry in A549 cells. Peptide concentration: 1 ⁇ M.
- Figure 4 Flow cytometry detection of FITC-labeled polypeptide entry in A549 cells. Peptide concentration: 3 ⁇ M.
- Figure 5 Flow cytometry detection of the entry of FITC-labeled polypeptide A549 cells. Peptide concentration: 10 ⁇ M.
- Figure 6 Flow cytometry detection of different concentrations of FITC-labeled polypeptide entering A549 cells.
- Figure 7 Flow cytometry detection of FITC-labeled polypeptide cell entry. Left, HeLa cells; peptide concentration: 10 ⁇ M. Right, MRC5 cells, peptide concentration: 3 ⁇ M.
- Figure 8 Flow cytometry detection of FITC-labeled entry of A549 cells with different polypeptide fragments.
- Figure 9 Flow cytometry detection of entry of FI549-labeled A549 cells with different polypeptide fragments. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 10 Flow cytometry detection of FITC-labeled A549 cell entry with different polypeptide fragments. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 11 Flow cytometry detection of FITC-labeled A549 cell entry with different polypeptide fragments. Peptide concentration: 1 ⁇ M. Incubation time: 3 hours.
- Figure 12 Flow cytometry detection of entry of FI549-labeled A549 cells with different polypeptide fragments. Peptide concentration: 1 ⁇ M. Incubation time: 3 hours.
- Figure 13 Flow cytometry detection of entry of 293T cells with different polypeptide fragments labeled with FITC. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 14 Flow cytometry detection of FITC-labeled polypeptide entry in 293T cells. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 15 Flow cytometry detection of entry of HUVEC cells with different polypeptide fragments labeled with FITC. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 16 Flow cytometry detection of FITC-labeled TAT and M2 (44-65) polypeptide HUVEC cell entry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 17 Flow cytometry detection of entry of FITC-labeled different polypeptide fragments in HCT-116 cells. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 18 Flow cytometry detection of FITC labeled TAT, M2 (44-65) and M2 (45-62) polypeptide entry into HCT-116 cells. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 19 Flow cytometry detection of FITC-labeled MNK-45 cell entry with different polypeptide fragments. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 20 Flow cytometry detection of FITC-labeled TAT, M2 (44-65) and M2 (45-62) polypeptide MKN-45 cell entry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 21 Flow cytometry detection of entry of U937 cells with different polypeptide fragments labeled with FITC. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 22 Flow cytometry detection of FI937-labeled TAT, M2 (44-65) and M2 (45-62) polypeptide U937 cell entry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 23 Flow cytometry detection of FITC-labeled TAT, M2 (44-65) and M2 (44-61) polypeptide MRC5 cell entry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 24 Flow cytometry detection of FITC-labeled TAT and M2 (44-65) polypeptide ESF-1 cell entry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 25 Laser confocal experiments detect the entry of ESF-1 cells with different polypeptide fragments labeled by FITC. Peptide concentration: 3 ⁇ M. Incubation time: 1 hour.
- Figure 26 Flow cytometry to detect the entry of polypeptide A549 cells at different incubation times. Peptide concentration: 1 ⁇ M. The incubation time is left: 5 minutes; middle: 10 minutes; right: 30 minutes.
- Figure 27 Flow cytometry to detect the entry of polypeptide A549 cells at different incubation times. Peptide concentration: 1 ⁇ M.
- Figure 28 Flow cytometry detection comparing different cell penetrating peptides with the entry of A549 cells of the present invention's Jilin-2004 (H5N1) -M2-45-62 polypeptide. Peptide concentration: 1 ⁇ M.
- Figure 29 Flow cytometry detection comparing A549 cells with different cell penetrating peptides and the Jilin-2004 (H5N1) -M2-44-61 polypeptide of the invention. Peptide concentration: 1 ⁇ M.
- Figure 30 Flow cytometry detection comparing different cell penetrating peptides with the entry of A549 cells of the present invention's Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 1 ⁇ M.
- Figure 31 Flow cytometry detection comparing different cell penetrating peptides with the entry of A549 cells of the Jilin-2004 (H5N1) -M2-45-62 polypeptide of the present invention. Peptide concentration: 3 ⁇ M.
- Figure 32 Flow cytometry detection comparing different cell penetrating peptides with the entry of A549 cells of the Jilin-2004 (H5N1) -M2-44-61 polypeptide of the present invention. Peptide concentration: 3 ⁇ M.
- Figure 33 Flow cytometry detection comparing different cell penetrating peptides with the entry of A549 cells of the present invention's Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 3 ⁇ M.
- Figure 34 Flow cytometry detection of the entry of A549 cells mutated sequence of Jilin-2004 (H5N1) -M2-44-56 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 35 Flow cytometry detection of the entry of A549 cells mutated sequence of Jilin-2004 (H5N1) -M2-45-62 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 36 Laser confocal technology detects the entry of A549 cells with Jilin-2004 (H5N1) -M2-45-62 polypeptide and its mutant sequence.
- Figure 37 Flow cytometry detection of A549 cell entry with Jilin-2004 (H5N1) -M2-45-62 polypeptide unit point mutation sequence. Peptide concentration: 1 ⁇ M. Incubation time: 3 hours.
- Figure 38 Laser confocal technology detects the entry of A549 cells of Jilin-2004 (H5N1) -M2-45-62 polypeptide and its unit point mutation sequence.
- Figure 39 Flow cytometry detection of the entry of A549 cells mutated sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 40 Flow cytometry detection of the entry of A549 cells mutated sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 3 ⁇ M. Incubation time: 1 hour.
- Figure 41 Flow cytometry detection of 293T cell entry for the mutant sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 42 Flow cytometry detection of MRC5 cell entry for the mutant sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 43 U937 cell entry for the detection of the mutant sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide by flow cytometry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 44 HCT-116 cell entry for the detection of the mutant sequence of Jilin-2004 (H5N1) -M2-44-65 polypeptide by flow cytometry. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 45 Flow cytometry detection of different cell penetrating peptides entering cells carrying small RNA.
- Figure 46 Laser confocal technology detects the entry of Jilin-2004 (H5N1) -M2-45-62 polypeptide carrying small RNA.
- Figure 47 Laser confocal technology detects the entry of Jilin-2004 (H5N1) -M2-44-56 polypeptide carrying small RNA.
- Figure 48 Laser confocal detection of Jilin-2004 (H5N1) -M2-44-61, Jilin-2004 (H5N1) -M2-44-65 and Jilin-2004 (H5N1) -M2-44-65mut8 polypeptides carrying small RNA Cell entry.
- Figure 49 Dual-fluorescence reporter gene detection The function of different cell penetrating peptides carrying PGY-sRNA-6 into cells.
- Figure 50 Cell entry of Jilin-2004 (H5N1) -M2-44-56 carrying ⁇ -galactosidase.
- Figure 51 Laser confocal technique detects the entry of A549 cells into a mixture of EGFP and cell penetrating peptides. Incubation time: 1 hour.
- Figure 52 Flow cytometry detection of different concentrations of EGFP-M2 (71-85) and EGFP-M2 (45-62) fusion protein A549 cell entry. Incubation time: 1 hour.
- Figure 53 Flow cytometry detection of entry of A549 cells with different EGFP fusion proteins. Protein concentration: 10nM. Incubation time: 1 hour.
- Figure 54 Flow cytometry detection of entry of A549 cells with different EGFP fusion proteins. Protein concentration: 30nM. Incubation time: 1 hour.
- Figure 55 Flow cytometry detection of A549 cell entry with different EGFP fusion proteins. Protein concentration: 100nM. Incubation time: 1 hour.
- Figure 56 Laser confocal technology detects the entry of A549 cells with different EGFP fusion proteins. Protein concentration: 30nM. Incubation time: 1 hour.
- Figure 57 Laser confocal technique detects the entry of A549 cells with different EGFP fusion proteins. Protein concentration: 100nM. Incubation time: 1 hour.
- Figure 58 Laser confocal technique detects the entry of A549 cells with different EGFP fusion proteins. Protein concentration: 300nM. Incubation time: 1 hour.
- Figure 59 Flow cytometry detection of the entry of A549 cells mutated sequence of Jilin-2004 (H5N1) -M2-44-61 polypeptide. Peptide concentration: 1 ⁇ M. Incubation time: 1 hour.
- Figure 60 Ultra-high resolution microscopy detected the entry of cells carrying small RNAs of Jilin-2004 (H5N1) -M2-44-61 and Jilin-2004 (H5N1) -M2-44-65 polypeptides.
- Figure 61 Fluorescence quantitative PCR detection of different fragments of influenza virus M2 polypeptides carrying small RNA into cells.
- Figure 62 Real-time quantitative qPCR detection of the entry of Jilin-2004 (H5N1) -M2-45-62 polypeptide and its point mutation sequence carrying small RNA in A549 cells.
- Figure 63 Fluorescence quantitative PCR detection of the entry of Jilin-2004 (H5N1) -M2-45-62 polypeptide and its mutant sequences carrying A549 cells with small RNA.
- Figure 64 Fluorescence quantitative PCR detection of the entry of Jilin-2004 (H5N1) -M2-44-61 polypeptide and its mutant sequence carrying A549 cells with small RNA
- Figure 65 Fluorescence quantitative PCR to detect the entry of Jilin-2004 (H5N1) -M2-44-65 polypeptide and its mutant sequence carrying A549 cells with small RNA.
- Figure 66 Dual fluorescent reporter gene detection The function of different cell penetrating peptides carrying HJT-sRNA-m7 into cells.
- Figure 67 Enzyme-linked immunosorbent assay to detect the expression of IL-1 ⁇ after LPS stimulation of different cell-penetrating peptides carrying small RNA.
- Figure 68 Enzyme-linked immunosorbent assay to detect the expression of TNF- ⁇ after different cell penetrating peptides carrying small RNA LPS stimulated cells.
- Figure 69 Western blot detection of different cell penetrating peptides carrying HJT-sRNA-m7 into cells to detect anti-fibrotic function.
- Figure 70 Laser confocal detection of the expression of Jilin-2004 (H5N1) -M2-44-61 and Jilin-2004 (H5N1) -M2-45-62 polypeptides carrying GFP plasmid into cells.
- Figure 71 Laser confocal technique detects the fusion protein of EGFP and cell penetrating peptide into different organs of mice.
- Figure 72 Fluorescence quantitative PCR detection of Jilin-2004 (H5N1) -M2-44-61 polypeptide carrying PGY-sRNA-23 into mouse organs.
- Figure 73 Fluorescence quantitative PCR detection of Jilin-2004 (H5N1) -M2-44-61 polypeptide carrying PGY-sRNA-26 into mouse organs.
- Figure 74 The enzyme-linked immunosorbent assay detects the anti-inflammatory function of PGY-sRNA-6 carried by Jilin-2004 (H5N1) -M2-44-61 polypeptide.
- Figure 75 Fluorescence quantitative PCR detection of Jilin-2004 (H5N1) -M2-44-61 carrying miR-1246antagomir into mouse lung tissue.
- Figure 76 Enzyme-linked immunosorbent assay to detect the expression of TNF- ⁇ in the alveolar lavage fluid after Jilin-2004 (H5N1) -M2-44-61 carrying miR-1246antagomir in LPS-induced acute lung injury mice
- Figure 77 Enzyme-linked immunosorbent assay to detect the expression of IL-6 in the alveolar lavage fluid carrying small molecule silybin in Jilin-2004 (H5N1) -M2-44-61 in LPS-induced acute lung injury mice.
- Figure 78 PET-28a-EGFP vector plasmid map.
- Figure 79 Vector map of pEAK13.
- NS1-GFP plasmid was constructed in our laboratory (pEAK13 vector), NS1 is the NS1 protein of influenza virus A / HongKong / 97/98 (H5N1) (expressed in the nucleus. NS1-GFP is N-terminal NS1, directly fused with GFP protein ).
- GFP is at the N-terminus and the polypeptide is directly fused and expressed at the C-terminus (PET-28a-EGFP vector).
- the corresponding medium is selected as the diluent for different types of cells, and the polypeptide working solution is configured.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 12-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- the 30 ⁇ M polypeptide was mixed with 300 nM FAM-labeled small RNA. After addition, the cells were placed in a 37 ° C., 5% CO 2 incubator and protected from light for a corresponding period of time.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 12-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- the working solution of fusion protein with different concentrations is prepared with the medium, and after addition, the cells are placed in a 5% CO 2 incubator at 37 ° C. and protected from light for a corresponding time.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 48-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- the cell culture medium was replaced with different concentrations of polypeptide working solutions prepared with the culture medium, and after addition, the cells were placed in a 37 ° C, 5% CO 2 incubator, protected from light and incubated for a corresponding time.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 48-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 48-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 12-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- Real-time quantitative qPCR detects the entry of small RNA carried by the polypeptide.
- A549 cells After digesting A549 cells with 0.05% trypsin, divide them into the wells of a 12-well plate, and control the plating density so that the cells grow to about 80% to 85% after 24 hours. The cells were cultured in a 5% CO 2 incubator at 37 ° C.
- C57 BL / 6 male mice are 6-8 weeks old, weigh about 20 grams, 4 mice in each group, and make a mark.
- mice After 1 hour of intraperitoneal injection, sacrifice mice and take organs, including 8 organs or tissues including brain, heart, liver, spleen, lung, kidney, stomach, small intestine, and thymus. And immediately placed in liquid nitrogen to save.
- RNA reverse transcription special primers all target sRNA and internal reference U6 reverse transcription primers should be included.
- each reaction system should contain the following components:
- relative gene expression value 2 (-(Ct target gene-Ct internal reference)) calculate the relative expression level of the target gene.
- Double fluorescent reporter gene system to detect the function of peptides carrying small RNA entry
- THP-1 cells are divided into 12-well plates, and the cells are cultured in a 5% CO 2 incubator at 37 ° C.
- wash the plate take out the coated ELISA plate, discard the CaptureAntibody solution and pat the residual liquid on the filter paper, then add 300 ⁇ L of the prepared wash solution (PBS + 0.1% tween 20) to wash, each Stay for 1min for the second time (using an ELISA plate shaker), each time the liquid must be poured out and the residual liquid should be patted dry on the filter paper (the same below), washed 4 times;
- Blocking After washing, add 300 ⁇ L of blocking solution (PBS + 1% BSA) and incubate at room temperature for 1 hour;
- Sample addition add the prepared standard to the left and right rows of the ELISA plate, add samples to other wells, and incubate at room temperature for 2h;
- Substrate addition Wash the washing solution 4 times, add 100 ⁇ L TMB Substrate Solution, try to operate in the dark, and then immediately put it in the drawer in the dark for about 10-20 minutes. After the color turns blue, add 100 ⁇ L of the stop solution to stop the reaction. From blue to yellow;
- Absorbance measurement is carried out within 30min, 450nm detection wavelength, 570nm reference wavelength.
- C57 BL / 6 male mice are 6-8 weeks old, weigh about 20 grams, 4 mice in each group, and make a mark.
- the amount of ultrapure water added (0.22 ⁇ m filter membrane filtration) was calculated based on the mass of the synthesized peptide and the relative molecular mass to dissolve the peptide.
- calculate the amount of ultrapure water needed to dissolve the small RNA based on the number of moles of the small RNA. Let stand, mix well, and then dissolve the peptide and small RNA for the next experiment.
- poly (I: C) was dissolved in PBS to prepare a stock solution with a concentration of 10 mg / mL. According to the dosage of 500ug poly (I: C) per mouse, each tube was filled with 50uL. Acute lung injury model was made by tracheal instillation method. The mice were sacrificed after 6h and the alveolar lavage fluid was collected for testing.
- wash the plate take out the coated ELISA plate, discard the CaptureAntibody solution and pat the residual liquid on the filter paper, then add 300 ⁇ L of the prepared wash solution (PBS + 0.1% tween 20) to wash, each Stay for 1min for the second time (using an ELISA plate shaker), each time the liquid must be poured out and the residual liquid should be patted dry on the filter paper (the same below), washed 4 times;
- Blocking After washing, add 300 ⁇ L of blocking solution (PBS + 1% BSA) and incubate at room temperature for 1 hour;
- Sample addition add the prepared standard to the left and right rows of the ELISA plate, add samples to other wells, and incubate at room temperature for 2h;
- Substrate addition Wash the washing solution 4 times, add 100 ⁇ L TMB Substrate Solution, try to operate in the dark, and then immediately put it in the drawer for about 10-20 minutes. After the color turns blue, add 100 ⁇ L of stop solution to stop the reaction. The color changes from blue to yellow;
- Absorbance measurement is carried out within 30min, 450nm detection wavelength, 570nm reference wavelength.
- MRC-5 cells were divided into 12-well plates, and the cells were placed at 37 ° C and cultured in a 5% CO 2 incubator.
- Protein electrophoresis add electrophoresis buffer, the initial voltage of electrophoresis is 80V; when bromophenol blue dye reaches the separation gel, increase the voltage to 120V to continue electrophoresis until bromophenol blue dye reaches the bottom of the separation gel or all the gel is eluted;
- Blocking put in 3% BSA blocking solution after the film transfer and block at room temperature for 1h;
- Fibronectin antibody (sigma F7387)
- C57 BL / 6 male mice are 6-8 weeks old, weigh about 20 grams, 4 mice in each group, and make a mark.
- Each mouse is injected intraperitoneally with 360 ⁇ L of PBS or PBS containing 1 mg of fusion protein.
- mice After 1 hour, sacrifice the mouse, take the mouse organs (liver, spleen, kidney and brain), embed in paraffin, and perform paraffin section.
- the container holding the buffer solution must also be equipped with a lid. At the beginning, the slide rack may lower the temperature of the repair solution, but it will rise to 95-100 ° C within a few minutes.
- the primary antibody is diluted with TBS containing 1% BSA and added to the slide.
- Enzyme-linked immunosorbent assay to detect the function of peptides carrying small molecule drugs silybin and small RNA into mice organs.
- C57 BL / 6 male mice are 6-8 weeks old, weigh about 20 grams, 4 mice in each group, and make a mark. Calculate the amount of ultrapure water added (0.22 ⁇ m filter membrane filtration) according to the quality of the synthesized peptide and the relative molecular mass, dissolve the peptide, and DMSO to dissolve the small molecule drug. Let stand, mix well, and then dissolve the peptide and small RNA for the next experiment.
- C57 BL / 6 male mice are 6-8 weeks old, weigh about 20 grams, 4 mice in each group, and make a mark. Calculate the amount of ultrapure water added (0.22 ⁇ m filter membrane filtration) according to the quality of the synthesized peptide and the relative molecular mass, dissolve the peptide, and DMSO to dissolve the small molecule drug. Let stand, mix well, and then dissolve the peptide and small RNA for the next experiment.
- Example 2 Cell entry of polypeptide sequence derived from influenza virus M2 protein
- H1N1 M2 protein of Caledonia / 20/1999
- H5N1 A / HongKong / 97/98
- Table 1 the peptide sequences listed in Table 1 were synthesized, in which TAT HIV was used as a positive control cell Permeable peptide.
- the peptide was labeled at the N-terminus with a rhodamine tag.
- Rhodamine labeled Caledonia / 20/1999 H1N1) -M2-NM-AH (45-62) and A / HongKong / 97/98 (H5N1) -M2-NM-AH (45-62) polypeptide and positive control TAT
- the peptide can enter A549 cells at a concentration of 30 ⁇ M.
- Rhodamine-labeled Caledonia / 20/1999 H1N1) -M2-NM-AH (60-82) and A / HongKong / 97/98 (H5N1) -M2-NM-AH (60-82) polypeptides at the concentration of At 30 ⁇ M, no signal was detected in A549 cells, ie, no entry into the cells.
- the above results indicate that the influenza virus M2 protein has the function of cell-penetrating peptide, and its cell-penetrating peptide function is related to the fragment of amino acids 45-62.
- the M2 protein sequence based on A / chicken / Jilin / 9/2004 (H5N1) (which is the same as A / HongKong / 97/98 used in Example 2 (H5N1) -M2 is highly conserved)
- the polypeptide sequences shown in Table 2 were synthesized. According to the structure of M2 protein, its sequence consisting of 97 amino acids was synthesized in segments. In order to facilitate the cell entry of the detected polypeptide, FITC was used to label the polypeptide at the N-terminus.
- Jilin-2004 (H5N1) -M2-45-62 polypeptide was tested for cell entry function at different concentrations (100 ⁇ M, 30 ⁇ M, 10 ⁇ M, 3 ⁇ M, and 1 ⁇ M). The results are shown in FIG. 2. From this result, it can be seen that Jilin-2004 (H5N1) -M2-45-62 polypeptide can achieve obvious A549 cell entry at all concentrations tested, and its entry effect is much stronger than FITC-labeled TAT polypeptide (positive control).
- Jilin-2004 H5N1 -M2-45-62 and Jilin-2004 (H5N1) -M2-44- were tested using HeLa cells and MRC5 cells 61.
- the results are shown in Figure 7. The above results are consistent with the results obtained using A549 cells, indicating that the cell-penetrating peptide function of M2-related polypeptides is not limited to specific cells, but has certain universality.
- Example 3 the cell-penetrating peptide characteristic of M2 protein is mainly concentrated in fragments 44-67. Therefore, the N-terminal and C-terminal sequentially truncated fragments of the above fragments were further synthesized (Table 3).
- the preferred polypeptide fragments are identified by testing the cell entry function of the polypeptide fragments shown in Table 3.
- Figure 8 shows data for polypeptides that are sequentially truncated from the N-terminus. This result shows that with the sequential removal of the 44th amino acid to the 48th amino acid at the N-terminus, the cell entry effect of the polypeptide gradually weakens, and the cell entry effect is better when the 44th amino acid is present.
- Fig. 9 and Fig. 10 show the results of flow cytometry detection of the peptides sequentially truncated from the C-terminus (amino acid 67), in which the concentration of the polypeptide used was 1 ⁇ M and the incubation time was 1 hour.
- This result indicates that Jilin-2004 (H5N1) -M2-44-65 and Jilin-2004 (H5N1) -M2-44-61 polypeptides have even better entry effects than other polypeptides.
- Figures 11 and 12 show the results of cell entry after 3 hours of incubation, which is consistent with the results in Figures 9 and 10, indicating that Jilin-2004 (H5N1) -M2-44-65 and Jilin-2004 (H5N1) -M2 -44-61 polypeptide has even better entry effect. It has also been shown that the JiLin-2004 (H5N1) -M2-45-62 polypeptide also has a good cell penetrating peptide effect.
- Figures 13 and 14 show the results of using 293T cells;
- Figures 15 and 16 show the results of using HUVEC cells;
- Figures 17 and 18 show the results of using HCT-116 cells;
- Figures 19 and 20 show the use of The results of MKN-45 cells;
- Figures 21 and 22 show the results of using U937 cells;
- Figure 23 show the results of using MRC5 cells;
- Figure 24 and Figure 25 show the results of using ESF-1 cells.
- Jilin-2004 (H5N1) -M2-44-61 polypeptide was selected, and the effect of the incubation time between the polypeptide and the cell on the cell entry of the polypeptide was studied using A549 cells. Blank A549 cells, NC and TAT were used as blank control, negative control and positive control respectively. First, the cell entry at three time points of 5 min, 10 min, and 30 min was detected, and the results are shown in FIG. 26. This result shows that when using 1 ⁇ M Jilin-2004 (H5N1) -M2-44-61 polypeptide, the cell entry can be detected by incubating with A549 cells for 5 minutes, and the cell entry amount increases with the incubation time Also increased.
- the incubation time was further extended to 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours, and the cell entry effect of the polypeptide was tested.
- the 1 ⁇ M NC negative control polypeptide when used, no polypeptide entered at all time points.
- a positive control TAT polypeptide of 1 M When used, it started to enter the cell at 5 minutes, and the entry effect was obvious at the 1 hour time point.
- the 1 ⁇ M Jilin-2004 (H5N1) -M2-44-61 polypeptide it started to enter the cell at 5 minutes, and already had a strong entry effect at 30 minutes. The effect of entry at a time is not much different.
- Example 6 Comparison of cell entry effects of cell-penetrating peptides based on M2 protein and existing cell-penetrating peptides
- the 17 cell-penetrating peptides reported by FITC were synthesized (see Table 4).
- JiLin-2004 (H5N1) -M2-45-62 and JiLin-2004 (H5N1) -M2-44 based on influenza virus M2 protein were compared under the conditions of 1 ⁇ M polypeptide concentration and 1 hour incubation time -61 and the cell entry effect of JiLin-2004 (H5N1) -M2-44-65 polypeptide and the above 17 cell penetrating peptides, as shown in FIG. 28, FIG. 29 and FIG.
- JiLin-2004 (H5N1) -M2-44-56, JiLin-2004 (H5N1) -M2-45-62 and JiLin-2004 (H5N1) -M2-44-65 polypeptides with obvious cell entry effect were modified. Mutate one or more amino acid residues in the polypeptide sequence, and examine the effect of amino acid mutations on its cell-penetrating peptide function. Table 5 shows the polypeptide sequences of JiLin-2004 (H5N1) -M2-44-56 and its mutations.
- Example 8-1 Modification of JiLin-2004 (H5N1) -M2-45-62 polypeptide
- unit point mutation polypeptide sequence based on JiLin-2004 (H5N1) -M2-45-62 polypeptide shown in Table 7 was synthesized, and its cell penetrating peptide function was tested.
- the cell penetrating peptide function of JiLin-2004 (H5N1) -M2-45-62 and its unit point mutant was detected by imaging using laser confocal technology. The results are shown in Figure 38. Both JiLin-2004 (H5N1) -M2-45-62 and its 18 unit point mutant polypeptide sequences have cell-penetrating peptide functions. And the cell-penetrating peptide function of mutants mut45, mut48, mut50, mut51 and mut61 is stronger than that of parent JiLin-2004 (H5N1) -M2-45-62 polypeptide.
- Example 8-2 Modification of JiLin-2004 (H5N1) -M2-44-61 polypeptide
- the JiLin-2004 (H5N1) -M2-44-61 polypeptide and its 15 mutants all have the function of cell-penetrating peptides, and all are stronger than positive Control TAT.
- the cell-penetrating peptide function of mutants mut13 and mut14 is stronger than that of the parent JiLin-2004 (H5N1) -M2-44-61 polypeptide.
- JiLin-2004 (H5N1) -M2-44-65 polypeptide and its 28 mutants all have the function of cell penetrating peptides, and all are stronger than positive Control TAT.
- the cell-penetrating peptide function of mutants mut8, mut25 and mut26 is stronger than that of the parent JiLin-2004 (H5N1) -M2-44-65 polypeptide.
- Figure 41 shows the test results using 293T cells.
- JiLin-2004 (H5N1) -M2-44-65 polypeptide and its 28 kinds of mutants all have the function of cell penetrating peptide, and are stronger than the positive control TAT.
- the cell-penetrating peptides of mutants mut8, mut9, mut12, mut17, mut25, mut26 and mut27 are stronger than the parent JiLin-2004 (H5N1) -M2-44-65 polypeptide.
- Figure 42 shows the results of detection using MRC5 cells.
- JiLin-2004 (H5N1) -M2-44-65 polypeptide and its 28 kinds of mutants all have the function of cell penetrating peptide, and are stronger than the positive control TAT.
- the cell-penetrating peptides of mutants mut8, mut9, mut12, and mut25 are stronger than the parent JiLin-2004 (H5N1) -M2-44-65 polypeptide.
- Example 10 Cell penetrating peptides carry small RNA into cells
- JiLin-2004 (H5N1) -M2-44-61, JiLin-2004 (H5N1) -M2-44-65 polypeptide and its mutant mut8 (JiLin-2004 (H5N1) -M2-44-65mut8) were detected The ability of small RNA.
- the polypeptide and 200 nM Cy3 labeled small RNA were mixed and incubated with A549 cells, as shown in the results in Figure 48, the polypeptide was able to carry small RNA into the cell within 1 hour, and its effect was stronger than the transfection reagent RNAiMax .
- JiLin-2004 (H5N1) -M2-44-65mut8 mutant polypeptide to carry small RNA into cells is even stronger.
- 10 ⁇ M peptide and 200 nM Cy3 labeled small RNA were mixed and incubated with A549 cells, as shown in Figure 60, JiLin-2004 (H5N1) -M2-44-61 and JiLin-2004 (H5N1)- M2-44-65 polypeptide can carry Cy3 labeled small RNA into A549 cells, and the effect is significantly stronger than the transfection reagent RNAiMax and also stronger than TAT.
- the confocal laser experiment was used to detect the entry of polypeptide-carrying small RNA.
- FIG. 62 shows that JiLin-2004 (H5N1) -M2-45-62 and its unit point-mutated polypeptide sequences all have the ability to carry small RNA into cells, and wild-type JiLin-2004 (H5N1) -M2-45-62, JiLin -2004 (H5N1) -M2-45-62mut45, JiLin-2004 (H5N1) -M2-45-62mut46, JiLin-2004 (H5N1) -M2-45-62mut47, JiLin-2004 (H5N1) -M2- 45-62 mut48, JiLin-2004 (H5N1) -M2-45-62 mut49, JiLin-2004 (H5N1) -M2-45-62 mut51, JiLin-2004 (H5N1) -M2-45-62 mut52, JiLin-2004 (H5N1) -M2-45-62mut53, JiLin-2004 (H5N1) -M2-45-62mut55,
- Figure 63 shows that JiLin-2004 (H5N1) -M2-45-62 and its mutant polypeptide sequences all have the ability to carry small RNA into cells, and wild type JiLin-2004 (H5N1) -M2-45-62, JiLin-2004 (H5N1) -M2-45-62 mut1, JiLin-2004 (H5N1) -M2-45-62 mut5, JiLin-2004 (H5N1) -M2-45-62 mut8 and JiLin-2004 (H5N1) -M2-45- 62
- the ability of mut23 to carry small RNA into cells is stronger than the RNAiMax group of transfection reagents.
- Figure 64 shows that all of JiLin-2004 (H5N1) -M2-44-61 and its mutant polypeptide sequences have the ability to carry small RNA into cells, and wild type JiLin-2004 (H5N1) -M2-44-61, JiLin-2004 (H5N1) -M2-44-61 mut1, JiLin-2004 (H5N1) -M2-44-61 mut4, JiLin-2004 (H5N1) -M2-44-61 mut6, JiLin-2004 (H5N1) -M2-44- 61mut8, JiLin-2004 (H5N1) -M2-44-61mut10, JiLin-2004 (H5N1) -M2-44-61mut12, JiLin-2004 (H5N1) -M2-44-61mut14, JiLin-2004 (H5N1 ) -M2-44-61 mut16 and JiLin-2004 (H5N1) -M2-44-61 mut17 are both capable of carrying small RNA into cells than the transfection reagent RNA
- Figure 65 shows that all of JiLin-2004 (H5N1) -M2-44-65 and its mutant polypeptide sequences have the ability to carry small RNA into cells, and wild type JiLin-2004 (H5N1) -M2-44-65, JiLin-2004 (H5N1) -M2-44-65 mut1, JiLin-2004 (H5N1) -M2-44-65 mut2, JiLin-2004 (H5N1) -M2-44-65 mut5, JiLin-2004 (H5N1) -M2-44- 65mut6, JiLin-2004 (H5N1) -M2-44-65mut7, JiLin-2004 (H5N1) -M2-44-65mut11, JiLin-2004 (H5N1) -M2-44-65mut15, JiLin-2004 (H5N1 ) -M2-44-65mut17, JiLin-2004 (H5N1) -M2-44-65mut23, JiLin-2004 (H5N1) -M2-44-65mut26 and JiL
- influenza virus-derived peptides with cell-penetrating peptide function can carry small RNA into cells, and the carrying capacity is stronger than that of control cell-penetrating peptide TAT.
- the ability of most cell-penetrating peptides to carry small RNA into cells is significantly stronger than currently recognized transfection reagent RNAimax.
- Example 11-1 Cell penetrating peptides carry small RNA into and exert their functions
- Example 9 it was further verified whether the cell-penetrating peptide of the present invention can carry the small RNA into the cell after carrying the small RNA to achieve the normal function of the small RNA.
- Previous experiments have demonstrated that PGY-dsRNA-6 can target the 3'-UTR region that binds to the RELA gene and achieve the function of inhibiting its expression. Experiments were conducted using JiLin-2004 (H5N1) -M2-45-62, JiLin-2004 (H5N1) -M2-44-61 and JiLin-2004 (H5N1) -M2-44-56 and 293T cells.
- HJT-sRNA-m7 can target the 3'-UTR region of the COLLAGEN3A1 gene and achieve the function of inhibiting its expression.
- Experiments were performed in HEK293T cells using JiLin-2004 (H5N1) -M2-44-61. The cell penetrating peptide at a concentration of 30 ⁇ M was mixed with 300 nM of HJT-sRNA-m7 and incubated with the cells, and the luciferase reporter gene in the cells was detected.
- PGY-dsRNA-6 can target the 3'-UTR region that binds to the RELA gene to exert its anti-inflammatory function.
- Figures 67 and 68 show that in the model of LPS-induced THP-1 inflammation, JiLin-2004 (H5N1) -M2- PGY-sRNA-6 carried by 44-61 effectively reduced the expression of IL-1 ⁇ and TNF- ⁇ in the supernatant of THP-1 cells. Therefore, JiLin-2004 (H5N1) -M2-44-61 can carry small RNA into cells and play its small RNA function.
- HJT-sRNA-m7 can target the 3'-UTR region of the COLLAGEN3A1 gene to play its fibrotic function.
- Figure 69 shows that TGF-beta1 induced MRC-5 cell fibrosis model, JiLin-2004 (H5N1) -M2
- the HJT-sRNA-m7 carried by -44-61 effectively reduced the expression of Fibronectin in MRC-5 cells. It is proved once again that JiLin-2004 (H5N1) -M2-44-61 can carry small RNA into cells and play its small RNA function.
- Example 11-2 The cell penetrating peptide carries the plasmid and enters its expression function
- the present invention confirms that the cell penetrating peptides JiLin-2004 (H5N1) -M2-44-61 and JiLin-2004 (H5N1) -M2-45-62 derived from influenza virus M2 can carry small RNA into cells and exert their small RNA The function of itself.
- a plasmid carrying a GFP protein that can be expressed in the nucleus FIG. 70 shows that both JiLin-2004 (H5N1) -M2-44-61 and JiLin-2004 (H5N1) -M2-45-62 can use the NS1-GFP plasmid. Carried into HEK293 cells and expressed GFP protein in the nucleus. The control TAT group showed almost no expression of GFP fluorescent protein.
- Example 12 Cell penetrating peptides carry proteins into cells
- the EGFP protein was used for further verification.
- FIG. 51 when 3 ⁇ M of JiLin-2004 (H5N1) -M2-44-56 polypeptide was mixed with 1 ⁇ M of GFP protein and incubated with A549 cells for 1 hour, JiLin-2004 (H5N1) -M2-44 was observed -56 polypeptide carries GFP protein into cells, and its effect is stronger than the positive control TAT.
- Example 13 The fusion protein of cell penetrating peptide and EGFP has the function of cell penetrating peptide
- FIG. 52 shows EGFP-JiLin-2004 (H5N1) -M2-45-62 fusion protein and EGFP-TAT and EGFP-JiLin-2004 (H5N1) -M2-71 using different concentrations (10nM, 30nM, 100nM and 300nM) -85 as a control experiment in which the fusion protein was incubated with A549 cells for 1 hour.
- Figure 53, Figure 54 and Figure 55 show the use of 10nM, 30nM and 100nM EGFP-JiLin-2004 (H5N1) -M2-45-62 and EGFP-JiLin-2004 (H5N1) -M2-44-61 fusion protein Experimental results, in which the fusion protein was incubated with A549 cells for 1 hour.
- EGFP-JiLin-2004 H5N1 -M2-45-62 and EGFP-JiLin-2004 (H5N1) -M2-44-61 fusion proteins can enter A549 cells at the above concentrations, while EGFP-TAT fusion protein was only observed at high concentration (100 nM).
- Fig. 56, Fig. 57 and Fig. 58 show the related laser confocal experiment results. Among them, Fig. 56 shows the result of using 10nM cell penetrating peptide, Fig. 57 shows the result of using 30nM cell penetrating peptide, and Fig.
- Example 14 Fusion protein of cell penetrating peptide and EGFP can directly enter mouse organs
- Example 13 demonstrates that EGFP-JiLin-2004 (H5N1) -M2-45-62 and EGFP-JiLin-2004 (H5N1) -M2-44-61 fusion proteins still have the function of penetrating peptides and can efficiently enter cells.
- Figure 71 shows that EGFP-JiLin-2004 (H5N1) -M2-44-61 can enter mouse brain, kidney, liver and spleen tissues 1 hour after intraperitoneal injection in mice, and its entry effect is stronger than that under the same experimental conditions.
- Example 15 Cell penetrating peptides can carry small RNA into mouse organs
- Example 10 the functions of the cell penetration peptide derived from influenza virus M2 protein and the control cell penetration peptide carrying small RNA into cells were detected by laser confocal detection and real-time quantitative qPCR method, and the ability to carry small RNA in cell experiments was selected
- the strongest JiLin-2004 (H5N1) -M2-44-61 was tested in mice.
- Figures 72 and 73 show that JiLin-2004 (H5N1) -M2-44-61 can effectively deliver small RNAs (PGY-sRNA-23 and PGY-sRNA-26) to mouse organs, in which the heart of the mouse , Liver, spleen, lung, kidney, stomach, small intestine, thymus and other eight organs or tissues have detected small RNA expression.
- the ability of JiLin-2004 (H5N1) -M2-44-61 to deliver small RNA on mice is significantly stronger than TAT.
- Example 16 Cell penetrating peptides can carry small RNA into mouse organs and function
- PGY-dsRNA-6 can target the 3'-UTR region of RELA gene to exert its anti-inflammatory function.
- JiLin-2004 (H5N1) PGY-sRNA-6 carried by M2-44-61 can effectively reduce the expression of IL-6 and TNF- ⁇ in the alveolar lavage fluid of mice, and reduce the acute lung injury in mice.
- the PGY-sRNA-6 carried by the cell-penetrating peptide control TAT can only slightly reduce the expression of IL-6 in the alveolar lavage fluid of mice, but has no effect on the expression of TNF- ⁇ .
- JiLin-2004 (H5N1) -M2-44-61 has a stronger ability to carry small RNA in mouse organs than TAT, and small RNA can better perform its functions.
- Example 17 Cell penetrating peptides can carry small RNAantagomir into mouse organs and function
- JiLin-2004 (H5N1) -M2-44-61 carrying miR1246antagomir has the best effect of preventing lung injury. Therefore, JiLin-2004 (H5N1) -M2-44-61 can help small RNA enter into mice better and play its role.
- Example 18 Cell penetrating peptides can carry small molecule drugs into mouse organs and function
- JiLin-2004 (H5N1) -M2-44-61 can carry the small molecule drug silybin into mouse organs and more Good to play its anti-acute lung injury function.
- JiLin-2004 (H5N1) -M2-44-61 itself has no effect of preventing lung injury, and the small molecule compound silybin has a tendency to prevent lung injury at this dose .
- JiLin-2004 (H5N1) -M2-44-61 carrying the small molecule drug silybin has the best effect to prevent lung damage. Therefore, JiLin-2004 (H5N1) -M2-44-61 can help small molecule compounds enter the mouse body better and play its role.
Abstract
提供了一种基于流感病毒M2蛋白的细胞穿透肽及其制备和改造方法,还提供了包含所述细胞穿透肽的缀合物、融合蛋白和组合物,所述细胞穿透肽可用于穿透细胞、向细胞中导入分子以及治疗疾病。
Description
本申请要求2018年11月2日提交的,发明名称为“基于流感病毒M2蛋白的细胞穿透肽”,PCT申请号PCT/CN2018/113755的专利申请的优先权,其内容通过引用并入本文。
本发明属于蛋白质工程领域,涉及一种细胞穿透肽。具体而言,本发明提供了基于流感病毒M2蛋白的细胞穿透肽、其制备和改造方法以及相关用途。本发明还提供了包含这些细胞穿透肽的缀合物、融合蛋白和组合物,以及使用细胞穿透肽穿透细胞、向细胞中导入分子以及治疗疾病的方法。
细胞穿透肽(cell penetrating peptides,CPP)是一类能够“穿透”细胞的多肽。细胞穿透肽的来源、序列长度和氨基酸组成各异,但都具有使质膜移位,并将生物活性分子例如蛋白质、肽、DNA、RNA和小分子药物等运输到细胞中的功能。自1988年首次报道了HIV-1病毒的转录反式激活蛋白(trans-activator of transcription,TAT)能够被细胞高效内化以来,本领域已经陆续发现了一些其它细胞穿透肽,包括Penetratin、DPV1047、MPG和Pep-1等。
许多治疗性分子例如抗生素、抗炎性药物、抗肿瘤药物和神经保护剂等由于细胞和组织障碍的存在而不能到达其特定靶标,特别是在靶标存在于细胞内的情况下,因此其治疗效果受到限制。由于细胞穿透肽能够穿透细胞,其可以用作媒介物将多种类型的治疗性分子运输到细胞中,使其到达靶标。目前已经有大量临床前研究评估了一些细胞穿透肽在疾病治疗中的价值,并在许多疾病模型包括癌症和心血管疾病中获得了有希望的结果。
尽管已经鉴定和评估了一些细胞穿透肽,然而,现有的细胞穿透肽存在各种问题,例如穿透细胞和将分子运输到细胞中的效率低,以及能够穿透的细胞类型有限等。因此,本领域对于新的细胞穿透肽存在需要,其具有高穿透效率,从而能够以低浓度将生物活性分子高效率递送到多种类型的细胞中。
流感病毒M2(Matrix-2)蛋白是一种存在于甲型流感病毒的病毒包膜中的质子选择性离子通道蛋白。该通道作为同源四聚体(由4个相同的M2单元组成)存在。在甲型流感病毒中,M2蛋白的质子传导对于病毒复制至关重要,因为它能够形成高选择性,pH调节的质子传导通道。
在甲型流感病毒中,M2蛋白单元由包含由97个氨基酸残基组成的三个结构域,分别为:(i)细胞外N末端结构域(氨基酸残基1-24);(ii)跨膜区段(氨基酸残基25-43);和(iii)细胞内C末端结构域(氨基酸残基44-97)。其中,跨膜区段形成离子通道的孔。M2蛋白的细胞质尾部的前17个残基(氨基酸残基45-62)形成高度保守的两亲性螺旋,其在病毒出芽和组装中起作用。此外,细胞质尾部的氨基酸残基70-77对于结合M1蛋白和产生感染性病毒颗粒是重要的。
发明内容
细胞穿透肽
本发明人出乎意料的发现,来源于流感病毒M2蛋白的多肽及其片段具有细胞穿透肽的功能,其穿透效率远高于本领域中的现有细胞穿透肽,并能较低浓度进入多种类型的细胞。进一步研究发现M2蛋白的细胞穿透肽功能主要集中在其氨基酸44-67这段序列。本发明人通过对流感病毒M2蛋白的多肽片段进行改造,获得了穿透效率甚至更高的细胞穿透肽,从而完成了本发明。
因此,在一个方面,本发明涉及一种多肽,其具有选自以下氨基酸序列:
a.包含流感病毒M2蛋白第44-67位氨基酸的序列或其片段的氨基酸序列;
b.包含在流感病毒M2蛋白第44-67位氨基酸的序列或其片段中进行了一个或多个氨基酸残基的修饰的氨基酸序列;和
c.包含与流感病毒M2蛋白第44-67位氨基酸的序列或其片段具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,
其中所述片段长度为至少8个氨基酸,且其中所述多肽具有细胞穿透肽的功能。
术语“细胞穿透肽”(“CPP”)一般用于表示能够跨细胞膜运输不同类 型的货物分子并由此促进多种分子货物(从纳米级颗粒到小的化学分子、大分子以及DNA的大片段)的细胞摄入的短肽。“货物”分子通过由共价键的化学连接或者通过非共价相互作用来与细胞穿透肽结合。细胞穿透肽通常具有包括相对高丰度的带正电的氨基酸例如赖氨酸或精氨酸的氨基酸组合物,或者其具有包括极性/带电氨基酸与非极性、疏水氨基酸的交替模式的序列。这两种结构分别被称作多聚阳离子的或两亲的。细胞穿透肽具有不同的大小、氨基酸序列和电荷,但所有CPP均具有共同点,即使细胞膜易位并促进多种分子货物传递到细胞的细胞质或细胞器的能力。目前,CPP易位的理论在三种主要的进入机制上不同:膜中直接穿透、内吞作用调节的进入,以及通过形成临时结构的易位。CPP转导是一个研究正在进行中的领域。已发现细胞穿透肽在医学中作为药物传递剂在治疗不同的疾病(包括癌症)和病毒抑制剂以及用于细胞标记和成像的对比剂中有大量应用。
“货物分子”在本文中是指通过共价或非共价结合与细胞穿透肽相连的分子,所述细胞穿透肽的存在使得其细胞内在化被促进或能够实现。在本发明中,“货物分子”包括肽、蛋白质、多糖、脂质、包括脂蛋白和糖蛋白的其组合物、核酸(例如DNA、siRNA、shRNA、反义寡核苷酸、陷阱DNA、质粒)、小分子药(例如环孢霉素A、紫杉醇、阿霉素、氨甲蝶呤、5-氨基乙酰丙酸)、成像剂(例如荧光团、量子点(QD)、示踪剂、金属螯合剂如钆(Gd
3+)小分子量螯合剂、超顺磁离子氧化物(SPIO))。应当理解的是,当货物分子是肽、多肽或蛋白质时,其可包括连接在一起的一个或多个肽、多肽或蛋白质。此外,当货物分子是核酸时,所述核酸可包括一个或多个核酸,其每一个编码一个或多个肽或多肽。货物分子还可以是蛋白质、脂质和/或多糖的组合物,包括脂蛋白和糖蛋白。核酸可为天然或人工的、单链或双链的DNA分子或RNA分子。核酸分子可为相同类型(例如,具有相同的核苷酸序列)的一或更多个核酸或不同类型的核酸。核酸分子包含但不限于以下的一或更多者:DNA、互补DNA(cDNA)、诱饵DNA(decoy DNA)、RNA、小干扰RNA(siRNA)、微小RNA(miRNA)、小发夹式RNA(shRNA)、小时序RNA(stRNA)、小核仁RNA(snoRNA)、小胞核RNA(snRNA)、戊糖核酸(pentose nucleic acid;PNA)、反义寡聚物、质粒和其它修饰核酸。
在本发明中,术语“蛋白质”和“多肽”在本文中可互换使用并且通常指通过肽键连接的氨基酸残基的聚合物,并且不限制产物的最小长度。因此, 上述术语包含肽、寡肽、多肽、二聚体(异源和同源),多聚体(异源和同源)等等。“蛋白质”和“多肽”涵盖了全长蛋白质及其片段。该术语还包括多肽的表达后修饰,如糖基化、乙酰化、磷酸化等。
在一些实施方案中,所述多肽包括流感病毒M2蛋白的第44-67位的氨基酸序列。所述多肽在M2蛋白第44-67位氨基酸的N末端和/或C末端可以包括另外的氨基酸序列。例如,所述多肽可以包括在M2蛋白第44-67位氨基酸及其两端的天然序列。例如,所述多肽可以包括M2蛋白第44-67位氨基酸的N端延伸的序列,例如M2蛋白第43-67位、第42-67位、第41-67位、第40-67位、第39-67位、第38-67位、第37-67位、第36-67位、第35-67位、第34-67位的氨基酸的序列等。或者,所述多肽可以包括M2蛋白第44-67位氨基酸的C端延伸的序列。例如,所述多肽可以包括M2蛋白的第43-68位、第42-69位、第41-70位、第40-71位、第39-72位、第38-73位、第37-74位、第36-75位、第35-76位、第34-77位的氨基酸的序列等。所述多肽可以包括M2蛋白第44-67位氨基酸N末端和C末端两个方向上延伸的天然序列。
此外,所述多肽也可以在M2蛋白第44-67位氨基酸N末端和/或C末端包括非天然序列,例如异源序列。所述异源序列可以选自各种标签、荧光蛋白、功能性部分和来源于其它蛋白质或多肽的氨基酸序列等,只要该异源序列不影响所述多肽的细胞穿透肽功能即可。
在另一些实施方案中,所述多肽包含上述序列的片段,且该片段具有细胞穿透肽的功能。本发明已经鉴定了流感病毒M2蛋白的第44-67位的氨基酸序列的多个功能性片段。在一些实施方案中,所述片段长度可以为至少8个氨基酸、至少9个氨基酸、至少10个氨基酸、至少11个氨基酸、至少12个氨基酸、至少13个氨基酸、至少14个氨基酸、至少15个氨基酸、至少16个氨基酸、至少17个氨基酸、至少18个氨基酸、至少19个氨基酸、至少20个氨基酸、至少21个氨基酸、至少22个氨基酸或至少23个氨基酸。关于氨基酸片段的选择没有具体限制,只要该片段具有细胞穿透肽的功能。
在一些实施方案中,所述片段包括M2蛋白第44-48位氨基酸或第45-48位氨基酸。具有M2蛋白第44-48位氨基酸或第45-48位氨基酸的多肽片段具有强的细胞穿透肽功能。然而,所述多肽片段也可以不包括具有M2蛋白第44-48位氨基酸或第45-48位氨基酸。
在一些实施方案中,所述片段包括M2蛋白第44-65位氨基酸、第44-61 位氨基酸、第45-62位氨基酸或第44-56位氨基酸,或由这些序列组成。所述片段也可以包括在上述序列的N末端和/或C末端延伸和/或截短了一个或多个氨基酸残基的序列。
在一些实施方案中,所述多肽包括在流感病毒M2蛋白的第44-67位的氨基酸序列或其片段中进行了一个或多个氨基酸残基的修饰的氨基酸序列。所述氨基酸残基的修饰包括氨基酸残基的取代、插入、缺失和/或添加。在一些实施方案中,所述氨基酸修饰是氨基酸取代。
在一些实施方案中,可以基于多肽的长度和/或其氨基酸组成来确定氨基酸残基的数量。例如当多肽的长度为约25个氨基酸时,氨基酸取代、插入、缺失的数量可以是1-12个,例如1、2、3、4、5、6、7、8、9、10、11或12个。当多肽的长度为约20个氨基酸时,氨基酸取代、插入、缺失的数量可以是1-10个,例如1、2、3、4、5、6、7、8、9或10个。当多肽的长度为约15个氨基酸时,氨基酸取代、插入、缺失的数量可以是1-7个,例如1、2、3、4、5、6、7个。
氨基酸取代、插入、缺失的方式没有特别限制。在一些实施方案中,所述氨基酸取代是保守氨基酸取代。“保守氨基酸取代”是指具有相似电荷性质或侧链基团的氨基酸残基之间的取代,其通常不影响蛋白质或多肽的正常功能。在一些实施方案中,插入是疏水性氨基酸或带正电荷的氨基酸的插入。在一些实施方案中,缺失是亲水性氨基酸的缺失。
在另一些实施方案中,所述氨基酸取代的至少一个或多个是取代为疏水性氨基酸或带正电荷的氨基酸。在另一些实施方案中,疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,更优选是I。在另一些实施方案中,带正电荷的氨基酸优选是K、R或H,更优选K或R。在一些实施方案中,所述疏水性氨基酸或带正电荷的氨基酸选自I、F和R残基。在一些实施方案中,亲水性氨基酸优选是D、E、Q、S或T。
所述多肽还可以包括与M2蛋白第44-67位的氨基酸序列或其片段具有至少60%序列一致性的氨基酸序列,只要该多肽具有细胞穿透肽功能。例如,所述多肽可以包括氨基酸序列,其与M2蛋白第44-67位的氨基酸序列或其片段具有至少60%、至少65%、至少70%、至少80%、至少85%、至少90%、或至少95%序列一致性的氨基酸序列,只要该多肽具有细胞穿透肽功能。
可以通过例如使用数学算法测定两种序列间的序列同一性的百分比。通 过使用基于此类数学算法的程序,可以实施用于测定序列同一性的序列比较(即比对)。程序可以由计算机适当执行。此类程序的实例包括但不限于PC/Gene程序的CLUSTAL、ALIGN程序(Version 2.0)、和Wisconsin遗传学软件包的GAP、BESTFIT、BLAST、FASTA、和TFASTA。可以例如通过使用初始参数实施使用这些程序的比对。
在上述多肽的任意实施方案中,其中所述流感病毒可以是任何分型的流感病毒。在一些实施方案中,所述流感病毒可以是H1N1、H5N1、H5N6或H7N9型流感病毒,但不限于此。本领域已知M2蛋白的氨基酸序列在不同分型的流感病毒之间保守。
例如,在一些实施方案中,本发明的M2蛋白可以来源于以下流感病毒株:A/Caledonia/20/1999(H1N1)、A/HongKong/97/98(H5N1)和A/chicken/Jilin/9/2004(H5N1),但不限于此。
在另一个方面,本发明涉及对基于流感病毒M2蛋白的细胞穿透肽的改造方法和获得的变体序列。具体而言,本发明对具有强细胞穿透肽功能的JiLin-2004(H5N1)-M2-44-56、JiLin-2004(H5N1)-M2-45-62和JiLin-2004(H5N1)-M2-44-65多肽进行了改造,并获得了具有相似或甚至更强的细胞穿透肽功能的变体多肽序列。
一方面,本发明涉及多肽,其具有下式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24的氨基酸序列;其中X1是D、R、L、I或不存在;X2是R、I或S;X3是L、I、F、A、R或K;X4是F、R或I;X5是F、R或I;X6是K、R或I;X7是C、I或R;X8是A、I、F、K或R;X9是Y、I、F、K或R;X10是R或S;X11是R、S或不存在;X12是L、I、F、R或K或不存在;X13是K、R、T或不存在;X14是Y、F、R或K,或不存在;X15是G或R或K或不存在;X16是R、L、F或A或不存在;X17是I、K、R或T或不存在;X18是R、I或T或不存在;X19是G、R或K或不存在;X20是P或不存在;X21是S、K或不存在;X22是T、V或不存在;X23是E或不存在;X24是G或不存在;或者
所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或
所述多肽具有所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、 插入或取代的氨基酸序列。
相应的,在一个方面,本发明涉及一种多肽,其具有选自以下的氨基酸序列:
a.包含DRLFFKCIYRRLK的氨基酸序列;
b.包含在DRLFFKCIYRRLK的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,和
c.包含与DRLFFKCIYRRLK具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,
其中所述多肽具有细胞穿透肽的功能。
DRLFFKCIYRRLK对应JiLin-2004(H5N1)流感病毒M2蛋白第44-56位的氨基酸序列(JiLin-2004(H5N1)-M2-44-56),其具有强细胞穿透肽功能。相应的,本发明的细胞穿透肽可以包括该序列或其功能性变体序列。
在一些实施方案中,所述一个或多个氨基酸残基的取代、缺失或插入是1-5个氨基酸残基的取代、缺失或插入,例如1、2、3、4或5个氨基酸取代、缺失或插入。在一些实施方案中,所述取代的至少一个、至少两个、至少三个、至少四个或所有五个可以是取代为疏水性氨基酸或带正电荷的氨基酸,例如选自I、F和R残基。在一些实施方案中,插入是疏水性氨基酸或带正电荷的氨基酸的插入。在一些实施方案中,缺失是亲水性氨基酸的缺失。
在一些实施方案中,多肽具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13的氨基酸序列;其中X1是D或R;X2是R;X3是L、I、或F;X4是F;X5是F;X6是K或R;X7是C或R;X8是I或F;X9是Y、I或F;X10是R;X11是R;X12是L、I或F;且X13是K或R;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
在一些实施方案中,所述多肽具有选自下组的氨基酸序列:RRLFFKCIYRRLK、RRLFFRCIYRRLK、RRLFFRRIYRRLK、RRLFFRRIYRRLR、DRIFFKCIYRRLK、DRIFFKCIIRRLK、DRIFFKCIIRRIK、DRFFFKCIYRRLK、DRFFFKCFYRRLK、DRFFFKCFFRRLK、DRFFFKCFFRRFK和RRFFFRRFFRRFR。
在另一个方面,本发明涉及一种多肽,其具有选自以下的氨基酸序列:
a.包含RLFFKCIYRRLKYGLKRG的氨基酸序列;
b.包含在RLFFKCIYRRLKYGLKRG的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,和
c.包含与RLFFKCIYRRLKYGLKRG具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述多肽具有细胞穿透肽的功能。
RLFFKCIYRRLKYGLKRG对应JiLin-2004(H5N1)流感病毒M2蛋白第45-62位的氨基酸序列(JiLin-2004(H5N1)-M2-45-62),其具有强细胞穿透肽功能。相应的,本发明的细胞穿透肽可以包括该序列或其功能性变体序列。
在一些实施方案中,所述一个或多个氨基酸残基的取代、缺失或插入是1-6个氨基酸残基的取代、缺失或插入,例如1、2、3、4、5或6氨基酸取代、缺失或插入。在一些实施方案中,所述取代的至少一个、至少两个、至少三个、至少四个、至少五个、或全部六个可以是取代为疏水性氨基酸或带正电荷的氨基酸,例如选自I、F和R残基。在一些实施方案中,插入是疏水性氨基酸或带正电荷的氨基酸的插入。在一些实施方案中,缺失是亲水性氨基酸的缺失。
在一些实施方案中,多肽具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18的氨基酸序列;其中X1是R或S;X2是A、L或F;X3是F或I;X4是F或I;X5是R或K;X6是I、C或R;X7是A、I或F;X8是K、Y或F;X9是R或S;X10是R或S;X11是A、L或F;X12是K、R或T;X13是Y、F或K;X14是G、R或K;X15是L、F或A;X16是K、R或T;X17是R或T;且X18是G、R或K或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
在另一些实施方案中,所述多肽具有选自下组的氨基酸序列:RLFFRCIYRRLKYGLKRG、RLFFRRIYRRLKYGLKRG、RLFFRRIYRRLRYGLKRG、RLFFRRIYRRLRYRLKRG、RLFFRRIYRRLRYRLRRG、RLFFRRIYRRLRYRLRRR、RFFFKCIYRRLKYGLKRG、RFFFKCFYRRLKYGLKRG、 RFFFKCFFRRLKYGLKRG、RFFFKCFFRRFKYGLKRG、RFFFKCFFRRFKFGLKRG、RFFFKCFFRRFKFGFKRG和RFFFRRFFRRFRFRFRRR。
在另一些实施方案中,本发明涉及JiLin-2004(H5N1)-M2-45-62多肽的单位点突变多肽序列。例如,在一些实施方案中,所述多肽具有选自下组的氨基酸序列:SLFFKCIYRRLKYGLKRG、RAFFKCIYRRLKYGLKRG、RLIFKCIYRRLKYGLKRG、RLFIKCIYRRLKYGLKRG、RLFFKIIYRRLKYGLKRG、RLFFKCAYRRLKYGLKRG、RLFFKCIKRRLKYGLKRG、RLFFKCIYSRLKYGLKRG、RLFFKCIYRSLKYGLKRG、SLFFKCIYRRLKYGLKRG、RLFFKCIYRRAKYGLKRG、RLFFKCIYRRLTYGLKRG、RLFFKCIYRRLKKGLKRG、RLFFKCIYRRLKYKLKRG、RLFFKCIYRRLKYGAKRG、RLFFKCIYRRLKYGLTRG、RLFFKCIYRRLKYGLKTG和RLFFKCIYRRLKYGLKRK。
在再一个方面,本发明涉及一种多肽,其具有选自以下的氨基酸序列:
a.包含DRLFFKCIYRRLKYGLKRGPST的氨基酸序列;和
b.包含在DRLFFKCIYRRLKYGLKRGPST的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,
c.包含与DRLFFKCIYRRLKYGLKRGPST具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,
其中所述多肽具有细胞穿透肽的功能。
DRLFFKCIYRRLKYGLKRGPST对应JiLin-2004(H5N1)流感病毒M2蛋白第44-65位的氨基酸序列(JiLin-2004(H5N1)-M2-44-65),其具有强细胞穿透肽功能。相应的,本发明的细胞穿透肽可以包括该序列或其功能性变体序列。
在一些实施方案中,所述一个或多个氨基酸残基的取代、缺失或插入是1-10个氨基酸残基的取代、缺失或插入,例如1、2、3、4、5、6、7、8、9或10个氨基酸取代、缺失或插入。在一些实施方案中,所述取代的至少一个、至少两个、至少三个、至少四个、至少五个、至少六个、至少七个、至少八个、至少九个或全部十个可以是取代为疏水性氨基酸或带正电荷的氨基酸,例如选自I、F和R残基。在一些实施方案中,插入是疏水性氨基酸或带正电 荷的氨基酸的插入。在一些实施方案中,缺失是亲水性氨基酸的缺失。
在一些实施方案中,多肽具有X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22的氨基酸序列;其中X1是D或R;X2是R;X3是L或F;X4是F;X5是F;X6是K或R;X7是C或R;X8是I或F;X9是Y或F;X10是R;X11是R;X12是L或F;X13是K或R;X14是Y或F;X15是G或R;X16是L;X17是K或R;X18是R;X19是G、或R或K;X20是P;X21是S或K;且X22是T或V;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
在一些实施方案中,所述多肽具有选自下组的氨基酸序列:DRFFFKCIYRRLKYGLKRGPST、DRFFFKCIYRRLKYGLKRRPST、DRFFFKCIYRRLKFGLKRGPST、DRFFFKCIFRRLKYGLKRGPST、DRFFFKCIFRRLKFGLKRGPST、DRFFFKCFFRRFKFGLKRGPST、RRFFFKCFFRRFKFGLKRGPST、DRFFFKRIYRRLKYRLKRRPST、DRFFFKRIYRRLKYRLKRRPKV、DRFFFKRIFRRLKYRLKRRPST、DRFFFKRIFRRLKFRLKRRPST、DRFFFKRIFRRFKFRLKRRPST、RRFFFKRIFRRFKFRLKRRPST、RRFFFKRIFRRFKFRLKRRPKV、RRLFFKCIYRRLKYGLKRGPST、RRLFFKCIYRRLKYGLKRGPKV、RRFFFKCIYRRLKYGLKRGPST、RRLFFKCIYRRLKYGLKRRPST、RRLFFKCIYRRLKYGLKRKPST、RRLFFRRIYRRLKYGLKRGPST、RRLFFRRIYRRLRYRLRRRPST、DRLFFKRIYRRLKYGLKRGPST、DRLFFRRIYRRLKYGLKRGPST、DRLFFRRIYRRLRYRLRRRPST、DRLFFKCIYRRLKYGLKRRPST、DRLFFKCIYRRLKYRLKRRPST、DRLFFKRIYRRLKYRLKRRPST、RRLFFKRIYRRLKYRLKRRPST、DRLFFKCIYRRLKYGLKRGPKV。
在又一个方面,本发明涉及多肽,其具有选自以下的氨基酸序列:
a.包含DRLFFKCIYRRLKYGLKR的氨基酸序列;和
b.包含在DRLFFKCIYRRLKYGLKR的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,
c.包含与DRLFFKCIYRRLKYGLKR具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,
其中所述多肽具有细胞穿透肽的功能。
在一些实施方案中,所述一个或多个氨基酸残基的取代、缺失或插入是1-10个或1-6个,例如5、4、3或2个氨基酸残基的取代、缺失或插入。
在一些实施方案中,所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸。在一些实施方案中,插入是疏水性氨基酸或带正电荷的氨基酸的插入。在一些实施方案中,缺失是亲水性氨基酸的缺失。
在一些实施方案中,多肽具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18的氨基酸序列;其中X1是D、R、L或I;X2是R或I;X3是L、R或K;X4是F或R;X5是F或R;X6是K或I;X7是C、R或I;X8是I、K或R;X9是Y、K或R;X10是R;X11是R;X12是L、R或K;X13是K;X14是Y或R;X15是G;X16是L或R;X17是K或I;且X18是R或I;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
在一些实施方案中,多肽具有选自下组的氨基酸序列:RRLFFKCIYRRLKYGLKR、LRLFFKCIYRRLKYGLKR、DILFFKCIYRRLKYGLKR、DRRFFKCIYRRLKYGLKR、DRLRRKCIYRRLKYGLKR、DRLFFICIYRRLKYGLKR、DRLFFKRIYRRLKYGLKR、DRLFFKIIYRRLKYGLKR、DRLFFKCKKRRLKYGLKR、DRRRRKCRRRRRKYGRKR、DRLFFKCIYRRRKRGLKR、DRLFFKCIYRRLKYGRKR、DRKRRKCKYRRKKYGRKR、DRLFFKCIYRRLKYGLII、IILFFKCIYRRLKYGLKR。
缀合物和融合蛋白
本发明还涉及缀合物和融合蛋白,其包含本发明的多肽。
在关于缀合物的实施方案中,所述缀合物包含本发明和与所述多肽缀合的部分,所述部分可以没有特别限制,且可以是治疗部分、可检测部分或美 容用部分,选自蛋白质、肽、核酸、抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质和酶。
所述蛋白质、肽、核酸、抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质和酶的选择没有特别限制,只要其不影响本发明的多肽的细胞穿透肽功能。
在一些实施方案中,治疗部分选自:13-顺-视黄酸、2-氨基-6-巯基嘌呤、2-CdA、2-氯脱氧腺苷、5-氟尿嘧啶、6-硫鸟嘌呤、6-巯基嘌呤、异维生素A酸(Accutane)、放线菌素D、阿霉素、Adrucil、安归宁、Ala-Cort、阿地白介素、阿仑单抗、阿里维A酸(Alitretinoin)、Alkaban-AQ、爱克兰、全反式维甲酸、α干扰素、六甲蜜胺、氨甲蝶呤、氨磷汀、鲁米特、阿那格雷、安得乐、阿那曲唑、阿糖胞苷、安然爱斯普、阿可达、瑞宁得、阿诺、三氧化二砷、天冬酰胺酶、ATRA、阿瓦斯汀、BCG、BCNU、贝伐单抗、蓓萨罗丁、比卡鲁胺、BiCNU、Blenoxane、博来霉素、硼替佐米、白消安、Busulfex、C225、亚叶酸钙、Campath、坎普土沙、喜树碱-11、卡培他滨、Carac、卡铂、卡莫司汀、卡莫司汀片、Casodex、CCNU、CDDP、CeeNU、正定霉素、西妥昔单抗、苯丁酸氮芥、顺铂、亚叶酸因子、克拉屈滨、可的松、可美净、CPT-11、环磷酰胺、Cytadren、阿糖胞苷、阿糖胞苷脂质体、Cytosar-U、Cytoxan、达卡巴嗪(Dacarbazine)、放线菌素、达泊霉素α、道诺霉素、柔红霉素、盐酸柔红霉素、柔红霉素脂质体、DaunoXome、Decadron、Delta-Cortef、强的松、地尼白介素-毒素连接物、DepoCyt、地塞米松、醋酸地塞米松、地塞米松磷酸钠、Dexasone、右雷佐生、DHAD、DIC、Diodex、多西他赛、Doxil、阿霉素、多柔比星脂质体、Droxia、DTIC、DTIC-Dome、杜拉隆、Efudex、艾里咖、艾伦斯、乐沙定、爱施巴、Emcyt、表阿霉素、α依伯汀、爱必妥、欧文氏菌L-天门冬酰胺酶、雌莫司汀、Ethyol、凡毕复、依托泊苷、依托泊苷磷酸盐、Eulexin、易维特、依西美坦、法乐通、法洛德、复乳纳、非格司亭、氟尿苷、福达华、氟达拉滨、Fluoroplex、氟尿嘧啶、氟甲睾酮、氟他胺、氟胺酸、FUDR、氟维司群、G-CSF、吉非替尼、吉西他滨、吉妥单抗、Gemzar、格列卫、醋酸亮丙瑞林、储库型醋酸亮丙瑞林、Matulane、Maxidex、氮芥、-盐酸氮芥、美卓龙、甲泼尼龙、Megace、甲地孕酮、醋酸甲地孕酮、美法仑、巯嘌呤、美司那、Mesnex、氨甲喋呤、甲氨蝶呤钠、甲泼尼龙、Mylocel、 来曲唑、Neosar、Neulasta、纽密伽、优保津、Nilandron、尼鲁米特、氮芥、Novaldex、诺肖林、奥曲肽、醋酸奥曲肽、Oncospar、长春新碱、Ontak、Onxal、欧普瑞维尔金、Orapred、Orasone、奥沙利铂、紫杉醇、帕米膦酸、Panretin、伯尔定、Pediapred、PEG干扰素、培门冬酶、培非司亭、PEG-INTRON、PEG-L-天冬酰胺酶、苯丙氨酸氮芥、Platinol、Platinol-AQ、泼尼松龙、泼尼松、Prelone、丙卡巴肼、PROCRIT、普留净、具有卡莫司汀植入物的Prolifeprospan20、Purinethol、雷洛昔芬、氨克生、美罗华、利妥昔单抗、Roveron-A、Rubex、盐酸鲁贝多霉素、善得定、善得定LAR、沙格莫丁、Solu-Cortef、Solu-Medrol、STI-571、链尿霉素、他莫昔芬、塔格雷汀、他克唑、泰索帝、Temodar、替莫唑胺、替尼泊苷、TESPA、沙利度胺、撒利多迈、TheraCys、硫鸟嘌呤、硫鸟嘌呤药片、硫代磷酰胺、Thioplex、塞替派、TICE、Toposar、拓扑替康、托瑞米芬、曲妥珠单抗、维甲酸、Trexall、Trisenox、TSPA、VCR、Velban、万珂、凡毕士、凡善能、Viadur、长春碱、硫酸长春碱、Vincasar Pfs、长春新碱、长春瑞滨、酒石酸长春瑞滨、VLB、VP-16、威猛、希罗达、Zanosar、泽娃灵、Zinecard、诺雷德、唑来膦酸、择泰、格立得晶片、Glivec、GM-CSF、戈舍瑞林、粒细胞集落刺激因子、氟甲睾酮、赫赛汀、Hexadrol、Hexalen、六甲蜜胺、HMM、和美新、Hydrea、乙酸氢化可通、氢化可的松、氢化可的松磷酸钠、氢化可的松琥珀酸钠、磷酸氢化可的松、羟基脲、异贝莫单抗、替坦异贝莫单抗、埃得霉素、伊达比星、Ifex、IFN-化、异环磷酰胺、IL2、IL-11、甲磺酸伊马替尼、咪唑羧酰胺、干扰素α、PEG缀合的干扰素α扰素α、白细胞介素2、白细胞介素-11、甲酰四氢叶酸、留可然、Leukine、亮丙瑞林、闻克斯丁、乐司他丁、脂质体Ara-C、Liquid Pred、洛莫司汀、L-PAM、L-沙可来新、Meticorten、丝裂霉素、丝裂霉素-C、米托蒽醌、M-泼尼松、MTC、MTX、氮芥、密吐霉素、Myleran、Iressa、爱莱诺迪肯、Isotretinoin、Kidrolase、Lanacort、L-门冬酰胺酶和LCR、更昔洛韦、叠氮胸苷(AZT)、拉米夫定(3TC)、阿卡泊隆、乙酰砜钠、阿莱霉素、阿莱西定、氮卓西林、匹美西林、阿米环素、氨氟沙星、甲磺酸氨氟沙星、阿米卡星、硫酸阿米卡星、氨基水杨酸、氨基水杨酸钠、阿莫西林、两性霉素、氨苄青霉素、氨苄青霉素钠、阿帕西林钠、安普霉素、天冬氨酸、硫酸天冬氨酸、阿维霉素、阿伏霉素、阿奇霉素、阿洛西林、阿洛西林钠、盐酸巴卡西林、杆菌肽、杆菌肽亚甲基二水杨酸酯、杆菌肽锌、班贝霉素、苯甲酰钙、 硫酸红霉素、硫酸倍他霉素、比阿培南、比尼霉素、盐酸苯柳胺酯、硫酸镁双巯氧吡啶、布替卡星、硫酸丁酰苷菌素、硫酸卷曲霉素、卡巴多、羧苄青霉素二钠、羧苄青霉素茚基钠、羧苄青霉素苯钠、羧苄青霉素钾、香豆素钠、头孢克洛、头孢羟氨苄、头孢孟多、头孢孟多酯钠、头孢孟多钠、头孢帕罗、头孢曲松、头孢唑啉钠、头孢唑啉、头孢唑啉钠、头孢哌酮、头孢地尼、头孢吡肟、盐酸头孢吡肟、头孢醇、头孢克肟、盐酸头孢甲肟、头孢美唑、头孢美唑钠、头孢尼西单钠、头孢尼西钠、头孢哌酮钠、头孢地尼、头孢噻肟钠、头孢替坦、头孢替坦二钠、盐酸头孢替安、头孢西丁、头孢西丁钠、头孢咪唑、头孢哌齐钠、头孢匹胺、头孢匹胺钠、硫酸头孢匹罗、头孢泊肟丙酯、头孢丙烯、头孢罗定、头孢磺啶钠、头孢他啶、头孢布烯、头孢唑肟钠、头孢曲松钠、头孢呋辛、头孢呋辛酯、头孢乙腈钠、头孢氨苄、盐酸头孢氨苄、头孢菌素、头孢噻啶、头孢噻吩钠、头孢匹林钠、头孢拉啶、盐酸西托环素、乙酰氯霉素、氯霉素、氯霉素棕榈酸酯、氯霉素泛酸盐复合物、氯霉素琥珀酸钠、氨基苯磷酸氯己定、氯二甲苯酚、金霉素硫酸氢盐、盐酸金霉素、西诺沙星、环丙沙星、盐酸环丙沙星、西罗霉素、克拉霉素、盐酸克林沙星、克林霉素、盐酸克林霉素、克林霉素棕榈酸盐酸盐、磷酸克林霉素、氯法齐明、苄星邻氯青霉素、邻氯青霉素钠、氯羟喹、粘菌素甲磺酸钠、香豆霉素、香豆霉素钠、环西林、环丝氨酸、达福普汀、氨苯砜、达托霉素、地美环素、盐酸地美环素、去甲环素、地奴真菌素、敌菌净、双氯西林、双氯西林钠、硫酸二氢链霉素、二吡啶硫酮、地红霉素、多西环素、多西环素钙、多西环素磷酸复合物、盐酸多西环素、屈沙星钠、依诺沙星、依匹西林、盐酸差向四环素、红霉素、醋硬脂酸红霉素、依托红霉素、琥乙红霉素、葡庚糖酸红霉素、乳糖醛酸红霉素、丙酸红霉素、硬脂酸红霉素、乙胺丁醇盐酸盐、乙硫异烟胺、氟罗沙星、氟氯西林、氟氚丙氨酸、氟甲喹、磷霉素、磷霉素氨基丁三醇、呋莫西林、氯化呋喃鎓、酒石酸呋喃鎓、夫西地酸钠、夫西地酸、硫酸庆大霉素、格洛莫南、短杆菌肽、卤丙炔氧苯、海他西林、海他西林钾、海克西定、伊巴沙星、亚胺培南、异康唑、异帕米星、异烟肼、交沙霉素、硫酸卡那霉素、基达霉素、左氧氟沙星、左旋丙基西林钾、来红霉素、林可霉素、盐酸林可霉素、洛美沙星、盐酸洛美沙星、甲磺酸洛美沙星、氯碳头孢、磺胺米隆、甲氯环素、磺基水杨酸甲氯环素、巨霉素磷酸钾、mequidox、美罗培南、美他环素、盐酸美他环素、乌洛托品、马尿酸乌洛托 品、扁桃酸乌洛托品、甲氧西林钠、美替普林、盐酸甲硝哒唑、磷酸甲硝哒唑、美洛西林、美洛西林钠、米诺环素、盐酸米诺环素、盐酸吡霉素、莫能菌素、莫能菌素钠、萘夫西林钠、萘啶酸钠、萘啶酸、纳豆霉素、尼布霉素、新霉素棕榈酸酯、硫酸新霉素、十一碳烯酸新霉素、硫酸奈替米星、中性霉素、硝呋唑烯、硝呋地腙、硝呋太尔、硝呋隆、硝呋达齐、硝呋米特、硝呋吡醇、硝呋喹唑、硝基噻唑、硝基环素、呋喃妥因、硝基米特、诺氟沙星、新生霉素钠、氧氟沙星、昂纳妥普瑞、苯唑西林、苯唑西林钠、肟、肟钠、草酸、土霉素、土霉素钙、盐酸土霉素、帕利霉素、对氯苯酚、保罗霉素、培氟沙星、甲磺酸培氟沙星、青霉素、青霉素G苄星、青霉素G钾、青霉素G普鲁卡因、青霉素G钠、青霉素V、青霉素V苄星、海巴青霉素V、青霉素V钾、戊唑酮钠、苯基氨基水杨酸盐/酯、哌拉西林钠、吡苯青霉素钠、吡西林钠、盐酸普利霉素、盐酸匹氨青霉素、双羟萘酸匹氨青霉素、丙苯酸匹氨青霉素、硫酸多粘菌素B、甲基丝裂霉素、普匹卡星、吡嗪酰胺、锌吡硫、乙酸喹乙胺、醋酸喹地卡明、奎奴普丁、消旋甲砜霉素、雷莫拉宁、雷尼霉素、雷洛霉素、雷帕霉素、利福布汀、利福美坦、利福昔尔、利福酰胺、利福平、利福喷丁、利福昔明、罗利环素、硝酸罗利环素、罗沙米星、丁酸罗沙米星、丙酸罗沙米星、罗沙米星磷酸钠、硬脂酸罗沙米星、罗索沙星、罗沙胂、罗红霉素、三环素、三萜醇钠、萨莫青霉素、沙莫西林、司可芬净、西索米星、硫酸西索米星、司帕沙星、盐酸壮观霉素、螺旋霉素、盐酸偏端菌素、西替霉素、硫酸链霉素、烟肼链霉素、磺胺苯、磺胺苯酰、磺乙酰胺、磺乙酰胺钠、磺胺西汀、磺胺嘧啶、磺胺嘧啶钠、磺胺多辛、磺胺林、磺胺甲基嘧啶、磺胺对甲氧嘧啶、磺胺甲嘧啶、磺胺甲二唑、磺胺甲噁唑、磺胺甲氧嘧啶、磺胺二甲唑、氨苯磺酸锌、磺胺硝苯、柳氮磺胺吡啶、磺胺异噻唑、磺胺噻唑、磺胺吡唑、磺胺异噁唑、乙酰硫代异噁唑、磺胺异噁唑二乙醇胺、磺粘菌素、硫培南、舒他西林、磺氨苄青霉素钠、盐酸酞氨西林、替考拉宁、盐酸替马沙星、替莫西林四环素、盐酸四环素、磷酸四环素络合物、四氧嘧啶、甲砜霉素、噻吩西林钾、替卡西林甲酚钠、替卡西林二钠、替卡西林单钠、替克拉酮、氯化氯苯噻碘、妥布霉素、硫酸妥布霉素、托氟沙星、甲氧苄啶、硫酸甲氧苄啶、三磺嘧啶、醋竹桃霉素、硫酸丙大观霉素、短杆菌素、万古霉素、盐酸万古霉素、维及霉素或拉来霉素,silybin。
在一些实施方案中,可检测部分选自:UV-Vis标记、近红外标记、发光 基团、磷光基团、磁性自旋共振标记、光敏剂、光可裂解部分、螯合中心、重原子、放射性同位素、同位素可检测的自旋共振标记、顺磁性部分、发色团、发光体,例如金属卟啉;苯并卟啉;氮杂苯并卟啉;萘并卟啉、酞菁;多环芳烃,例如苝、苝二亚胺、芘;偶氮染料;呫吨染料;硼二吡咯亚甲基、氮杂-硼二吡咯亚甲基、花青染料、金属-配体络合物例如联吡啶、联吡啶基、菲咯啉、香豆素以及钌和铱的乙酰丙酮化物;吖啶、噁嗪衍生物例如苯并吩噁嗪;氮杂-轮烯、方酸菁;8-羟基喹啉、聚甲炔、发光产生纳米颗粒例如量子点、纳米晶体;喹诺酮、铽络合物;无机荧光体;离子载体例如冠醚附着或衍生染料;Pd(II)八乙基卟啉;Pt(II)-八乙基卟啉;Pd(II)四苯基卟啉;Pt(II)四苯基卟啉;Pd(II)内消旋-四苯基卟啉四苯并吗啡;Pt(II)内消旋-四苯基甲基苯并卟啉;Pd(II)八乙基卟啉酮;Pt(II)八乙基卟啉酮;Pd(II)内消旋-四(五氟苯基)卟啉;Pt(II)内消旋-四(五氟苯基)卟啉;Ru(II)三(4,7-二苯基-1,10-菲咯啉)(Ru(dpp)
3);Ru(II)三(1,10-菲咯啉)(Ru(phen)
3)、三(2,2”-联吡啶)六水合氯化钌(II)(Ru(bpy)
3);赤藓红B;荧光素;异硫氰酸荧光素(FITC);曙红;铱(III)((N-甲基-苯并咪唑-2-基)-7-(二乙基氨基)-香豆素));铟(III)((苯并噻唑-2-基)-7-(二乙基氨基)-香豆素)-2-(乙酰丙酮化物);Lumogen染料;Macroflex荧光红;Macrolex荧光黄;德克萨斯红;罗丹明B;罗丹明6G;硫罗丹明;间甲酚;百里酚蓝;二甲苯酚蓝;甲酚红;氯酚蓝;溴甲酚绿;溴甲酚红;溴百里酚蓝;Cy2;Cy3;Cy5;Cy5.5;Cy7;4-硝基苯酚;茜素;酚酞;邻甲酚酞;氯酚红;钙黄绿素;溴二甲酚;酚红;中性红;硝嗪;3,4,5,6-四溴酚酞;刚果红;荧光素;曙红;2”,7”-二氯荧光素;5(6)-羧基-荧光素;羧基萘并荧光素;8-羟基苯乙烯-1,3,6-三磺酸;半萘并二氟;半萘并荧光素;三(4,7-二苯基-1,10-菲咯啉)二氯化钌(II);(4,7-二苯基-1,10-菲咯啉)钌(II)四苯基硼;铂(II)八乙基卟啉;二烷基碳菁;双十八烷基环二羰花青;芴基甲氧基羰基氯;7-氨基-4-甲基香豆素(Amc);绿色荧光蛋白,例如,GFP、GFP-2、tagGFP、turboGFP、eGFP、Emerald、Azami Green、单体Azami Green、CopGFP、AceGFP、ZsGreenl)、黄色荧光蛋白(例如,YFP、eYFP、Citrine、Venus、YPet、PhiYFP、ZsYellowl)、蓝色荧光蛋白(例如,eBFP、eBFP2、Azurite、mKalamal、GFPuv、Sapphire、T-sapphire)、青色荧光蛋白(例如,eCFP、Cerulean、CyPet、AmCyanl、Midoriishi-Cyan)、红色荧光蛋白(例如,mKate、mKate2、mPlum、DsRed单体、mCherry、mRFP1、DsRed-Express、DsRed2、DsRed- 单体、HcRed-Tandem、HcRedl、AsRed2、eqFP611、mRaspberry、mStrawberry、Jred)、橙色荧光蛋白(例如,mOrange、mKO、Kusabira-Orange、单体Kusabira-Orange、mTangerine、tdTomato)以及任何其他适合的荧光蛋白。
在一些实施方案中,美容用部分可以是美容性多肽,例如棕榈酰五肽4、棕榈酰四肽7、肌肽、乙酰基六肽8、aFGF、bFGF或EGF、肉毒杆菌毒素、弹性蛋白、透明质酸。在一些实施方案中,本发明的多肽与一种所述部分缀合。在另一些实施方案中,本发明的多肽与多种所述部分缀合。在一些实施方案中,本发明的多肽与一种所述部分以非共价形式组合。在另一些实施方案中,本发明的多肽与多种所述部分非共价形式组合。
本发明的多肽与所述部分缀合的方式没有特别限制,可以通过例如物理吸附或化学连接进行缀合。例如,本发明的多肽与所述部分可以通过非共价方式或共价方式缀合。
在关于融合蛋白的实施方案中,所述融合蛋白包含本发明的多肽和与所述多肽融合的部分,所述部分可以选自抗原、抗体或其抗原结合部分、配体、受体、细胞因子、转录调节因子、荧光蛋白和酶。
在一些实施方案中,与多肽融合的部分是治疗部分,例如人生长激素、牛生长激素、猪生长激素、生长激素释放激素、生长激素释放肽、粒细胞-集落刺激因子、粒细胞巨噬细胞-集落刺激因子、巨噬细胞-集落刺激因子、促红细胞生成素、骨形态发生蛋白、干扰素、胰岛素、心房肽激素-III、单克隆抗体、肿瘤坏死因子、巨噬细胞激活因子、白介素、肿瘤降解因子、胰岛素样生长因子、表皮生长因子、组织纤溶酶原激活物和尿激酶。
在一些实施方案中,与多肽融合的部分是可检测部分,例如绿色荧光蛋白,例如,GFP、GFP-2、tagGFP、turboGFP、eGFP、Emerald、Azami Green、单体Azami Green、CopGFP、AceGFP、ZsGreenl)、黄色荧光蛋白(例如,YFP、eYFP、Citrine、Venus、YPet、PhiYFP、ZsYellowl)、蓝色荧光蛋白(例如,eBFP、eBFP2、Azurite、mKalamal、GFPuv、Sapphire、T-sapphire)、青色荧光蛋白(例如,eCFP、Cerulean、CyPet、AmCyanl、Midoriishi-Cyan)、红色荧光蛋白(例如,mKate、mKate2、mPlum、DsRed单体、mCherry、mRFP1、DsRed-Express、DsRed2、DsRed-单体、HcRed-Tandem、HcRedl、AsRed2、eqFP611、mRaspberry、mStrawberry、Jred)、橙色荧光蛋白(例如,mOrange、mKO、Kusabira-Orange、单体Kusabira-Orange、mTangerine、tdTomato)以及 任何其他适合的荧光蛋白。
在一些实施方案中,与多肽融合的部分是美容用部分,包括美容性多肽,例如棕榈酰五肽4、棕榈酰四肽7、肌肽、乙酰基六肽8、aFGF、bFGF或EGF、肉毒杆菌毒素、弹性蛋白、透明质酸。
所述抗原、抗体或其抗原结合部分、配体、受体、细胞因子、转录调节因子、荧光蛋白和酶的选择没有特别限制,只要其不影响本发明的多肽的细胞穿透肽功能。
在一些实施方案中,所述多肽和所述部分直接融合。在另一些实施方案中,所述多肽和所述部分通过接头融合,例如通过柔性接头融合。
在一些实施方案中,所述多肽可以在其N末端与所述部分融合。在另一些实施方案中,所述多肽可以在其C末端与所述部分融合。在再一些实施方案中,所述多肽可以在其N末端和C末端与多个所述部分融合。
方法和用途
在一个方面,本发明涉及一种使多肽穿透细胞的方法,其包括将本发明的多肽、缀合物或融合蛋白与细胞温育的步骤。
在一些实施方案中,所述细胞是细胞系(例如永生化的细胞系),例如动物或植物细胞系,或微生物细胞,例如细菌细胞或真菌细胞,或从受试者分离的原代细胞或培养的植物细胞。
在一些实施方案中,所述细胞是选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞;或者选自分生细胞、石细胞、薄壁细胞、生殖细胞、根毛细胞、导管细胞、筛管细胞、叶肉细胞和保卫细胞、表皮细胞和色素细胞。在一些实施方案中,所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
所述肿瘤细胞的类型没有限制,并且可以来源于各种癌症类型,例如:基底细胞癌、胆道癌;膀胱癌;骨癌;脑和CNS癌;乳腺癌;腹膜癌;宫颈癌;胆管癌;绒毛膜癌;结肠和直肠癌;结缔组织癌;消化系统癌症;子宫内膜癌;食道癌;眼癌;头颈癌;胃癌;胶质母细胞瘤;肝癌;肝癌;上皮内新生物;肾癌;喉癌;白血病;肝癌;肺癌;淋巴瘤,包括霍奇金淋巴瘤和非霍奇金淋巴瘤;黑素瘤;骨髓瘤;神经母细胞瘤;口腔癌;卵巢癌;胰腺癌;前列腺癌;视网膜母细胞瘤;横纹肌肉瘤;直肠癌;呼吸系统癌;唾 液腺癌;肉瘤;皮肤癌;鳞状细胞癌;胃癌;畸胎癌;睾丸癌;甲状腺癌;子宫或子宫内膜癌;泌尿系统癌症;外阴癌;以及其它癌和肉瘤;以及B细胞淋巴瘤;慢性淋巴细胞性白血病(CLL);急性成淋巴细胞性白血病(ALL);毛细胞白血病;慢性成髓细胞性白血病等。
在一些实施方案中,所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞,且不限于此。
在上述使多肽穿透细胞的方法的任意实施方案中,可以将所述多肽、缀合物或融合蛋白与细胞温育5分钟至24小时,例如10分钟至12小时、30分钟至6小时或1小时至3小时。
在上述使多肽穿透细胞的方法的任意实施方案中,所述多肽、缀合物或融合蛋白的浓度可以为0.01μM至100μM,例如0.03μM至30μM,0.1μM至10μM或1μM至3μM。
在另一个方面,本发明涉及一种将分子导入细胞中的方法,所述方法包括将所述分子与本发明的多肽、缀合物或融合蛋白的混合物与细胞温育的步骤。
在一些实施方案中,所述分子选自蛋白质、核酸、肽、脂质、代谢物、药物和小分子化合物。
在一些实施方案中,所述分子选自抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子和酶。
在一些实施方案中,所述分子是小RNA(small RNA),例如选自siRNA和microRNA。
在一些实施方案中,所述细胞是细胞系(例如永生化的细胞系)或从受试者分离的原代细胞。
在一些实施方案中,所述细胞选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞。在一些实施方案中,所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
在一些实施方案中,所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞。
在再一个方面,本发明涉及本发明的多肽、缀合物和融合蛋白在将分子 导入细胞中的用途。
在一些实施方案中,所述分子选自蛋白质、核酸、肽、脂质、代谢物、药物和小分子化合物。
在一些实施方案中,所述分子选自抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子和酶。
在一些实施方案中,所述分子是小RNA,例如选自siRNA和microRNA。
在一些实施方案中,所述细胞是细胞系或从受试者分离的原代细胞。
在一些实施方案中,所述细胞选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞。在一些实施方案中,所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
在一些实施方案中,所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞。
疾病治疗、诊断疾病、示踪,优选胞内示踪或美容用的方法、用途和相关组
合物
在一个方面,本发明涉及一种治疗疾病、诊断疾病、示踪,优选胞内示踪或美容用的方法,所述方法包括向有需要的受试者施用本发明的多肽、缀合物或融合蛋白。
在另一个方面,本发明涉及一种治疗疾病、诊断疾病、示踪,优选胞内示踪或美容用的方法,所述方法包括向有需要的受试者施用本发明的多肽、缀合物或融合蛋白和选自下组的成分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子、酶和核酸,包括小RNA。
在本发明的一个实施方式中,核酸可以是自然的或人工的DNA或RNA分子,其为单链或双链。核酸分子可以是一种或多种同类型的核酸(例如,具有相同的核苷酸序列)或不同类型的核酸。核酸分子包含一种或多种DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒和其它修饰的核酸,但不限于此。
在一些实施方案中,所述小RNA选自siRNA和microRNA。
在本发明的治疗疾病、诊断疾病、示踪,优选胞内示踪或美容用的方法 的任意实施方案中,所述疾病可以选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病。
在一个方面,本发明涉及本发明的多肽、缀合物或融合蛋白在治疗疾病或用于美容中的用途。在一些实施方案中,所述疾病选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病。
在另一个方面,本发明涉及本发明的多肽、缀合物或融合蛋白在制备用于治疗疾病的、诊断疾病、示踪,优选胞内示踪或美容用的药物组合物中的用途。
在一些实施方案中,所述药物组合物还包含选自下组的成分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子、酶和小RNA。
在一些实施方案中,所述小RNA选自siRNA和microRNA。
在上述用途的任意实施方案中,所述疾病可以选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病。
在再一个方面,本发明涉及核酸分子,其包含编码本发明的多肽或融合蛋白的核苷酸序列。
在一个方面,本发明涉及载体,其包含本发明的核酸分子。
在本发明中,美容包括消除延缓皮肤衰老、美白和抗皱。在涉及美容的实施方案中,本领域技术人员可以将美容用的物质,例如美容性多肽,例如棕榈酰五肽4、棕榈酰四肽7、肌肽、乙酰基六肽8、aFGF、bFGF或EGF、肉毒杆菌毒素、弹性蛋白、透明质酸等与本发明的穿透肽以共价或非共价方式连接以递送到细胞内,从而发挥功效。
本文所用“载体”是指可以将多聚核苷酸插入其中的一种核酸运载工具。而当载体能使插入的多核苷酸编码的蛋白获得表达时,该载体称为表达载体。载体可以通过转化、转导或者转染等方法导入宿主细胞,继而使其携带的遗传物质元件在宿主细胞内获得表达。载体是本领域技术人员公认的、包括但不局限于:(1)质粒;(2)噬菌粒;(3)柯斯质粒;(4)人工染色体,如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC);(5)噬菌体如λ噬菌体或M13噬菌体及(6)动物病毒,如逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、孢疹病毒(如单纯孢疹病毒)、 痘病毒、杆状病毒。一种载体可以含有多种控制表达的元件,包括但不局限于,启动子序列、转录起始序列、增强子序列、选择元件及报告基因;此外,载体还可以含有复制起始位点。
在另一个方面,本发明涉及一种组合物,其包含本发明的多肽、缀合物或融合蛋白。
在一些实施方案中,所述组合物还包含选自下组的成分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子、酶、和小RNA。
在一些实施方案中,所述小RNA选自siRNA和microRNA。
在一些实施方案中,所述组合物是药物组合物,且还包含一种或多种药学上可接受的载体。
短语“药学上可接受的载体”是指药学上可接受的材料、组合物或媒介物,如液体或固体填充剂、稀释剂、赋形剂、溶剂、介质、包封材料、制造助剂(例如润滑剂、滑石镁、硬脂酸钙或锌或硬脂酸)或溶剂包封材料,其涉及维持LAP结合剂的稳定性、溶解度或活性。在与配制剂的其它成分相容并且不对患者有害的意义上,每种载体必须是“可接受的”。可充当药学上可接受的载体的材料的一些实例包括:(1)糖,如乳糖、葡萄糖和蔗糖;(2)淀粉,如玉米淀粉和马铃薯淀粉;(3)纤维素及其衍生物,如羧甲基纤维素钠、甲基纤维素、乙基纤维素、微晶纤维素和乙酸纤维素;(4)粉状黄蓍胶;(5)麦芽;(6)明胶;(7)赋形剂,如可可脂和栓剂蜡;(8)油,如花生油、棉籽油、红花油、芝麻油、橄榄油、玉米油和大豆油;(9)二醇,如丙二醇;(10)多元醇,如甘油、山梨糖醇、甘露醇和聚乙二醇(PEG);(11)酯,如油酸乙酯和月桂酸乙酯;(12)琼脂;(13)缓冲剂,如氢氧化镁和氢氧化铝;(14)海藻酸;(15)无热原水;(16)等张盐水;(17)林格氏溶液;(19)pH缓冲溶液;(20)聚酯、聚碳酸酯和/或聚酐;(21)填充剂,如多肽和氨基酸(22)血清组分,如血清白蛋白、HDL和LDL;(23)C2-C12醇,如乙醇;和(24)药物配制剂中使用的其它无毒相容物质。释放剂、包衣剂、防腐剂和抗氧化剂也可以存在于药物配制剂中。
疾病
如本文所用的,术语“癌症”是指恶性赘生物(Stedman’s Medical Dictionary,25th ed.;Hensyl ed.;Williams&Wilkins:Philadelphia,1990)。示例性癌症包括但不限于听神经瘤;腺癌;肾上腺癌;直肠癌;血管肉瘤(例如,淋巴管肉瘤、淋巴管内皮肉瘤、血管肉瘤);盲肠癌;良性单克隆丙球蛋白病;胆癌(例如,胆管癌);膀胱癌;乳腺癌(例如,乳房的腺癌、乳房的乳头状癌、乳房癌症、乳房的髓样癌);脑癌(例如,脑脊膜瘤、成胶质细胞瘤、胶质瘤(例如,星形细胞瘤、少突神经胶质瘤)、髓母细胞瘤);支气管癌;类癌瘤;子宫颈癌(例如,宫颈腺癌);绒毛膜癌;脊索瘤;颅咽管瘤;结肠直肠癌(例如,结肠癌、直肠癌、结肠直肠腺癌);结缔组织癌症;上皮癌;室管膜瘤;内皮肉瘤(例如,卡波西肉瘤、多发性特发性出血性肉瘤);子宫内膜癌(例如,子宫癌、子宫肉瘤);食管癌(例如,食道的腺癌、巴雷特腺癌(Barrett’s adenocarcinoma));尤因肉瘤;眼癌(例如,眼内的黑素瘤、视网膜母细胞瘤);家族性嗜伊红细胞增多症;胆囊癌;胃癌(例如,胃腺癌);胃肠道间质瘤(GIST);生殖细胞癌症;头颈癌(例如,头颈鳞状细胞癌、口腔癌(例如,口腔鳞状细胞癌)、喉部癌(例如,喉癌、咽头癌、鼻咽癌、口咽癌));造血干细胞癌(例如,白血病,例如急性淋巴细胞性白血病(ALL)(例如,B-细胞ALL、T-细胞ALL)、急性髓细胞性白血病(AML)(例如,B-细胞AML、T-细胞AML)、慢性髓细胞性白血病(CML)(例如,B-细胞CML、T-细胞CML),以及慢性淋巴细胞性白血病(CLL)(例如,B-细胞CLL、T-细胞CLL));淋巴瘤,例如霍奇金淋巴瘤(HL)(例如,B-细胞HL、T-细胞HL)和非-霍奇金淋巴瘤(NHL)(例如,B-细胞NHL,例如弥散性大细胞淋巴瘤(DLCL)(例如,弥散性大B-细胞淋巴瘤)、滤泡淋巴瘤、慢性淋巴细胞性白血病/小淋巴细胞淋巴瘤(CLL/SLL)、套细胞淋巴瘤(MCL)、边缘区B-细胞淋巴瘤(例如,粘液相关的淋巴组织(MALT)淋巴瘤、结节边缘区B-细胞淋巴瘤、脾边缘区B-细胞淋巴瘤)、原发性纵隔B-细胞淋巴瘤、伯基特淋巴瘤、淋巴质浆细胞淋巴瘤(即,瓦尔登斯特伦巨球蛋白血症)、毛细胞白血病(HCL)、成免疫细胞性大细胞淋巴瘤、前体B-成淋巴细胞性淋巴瘤和原发性中枢神经系统(CNS)淋巴瘤;和T-细胞NHL,例如前体T-成淋巴细胞性淋巴瘤/白血病、外周T-细胞淋巴瘤(PTCL)(例如,皮肤T-细胞淋巴瘤(CTCL)(例如,蕈样肉芽肿病、塞扎里综合征)、血管免疫母细胞性T-细胞淋巴瘤、结节外自然杀伤T-细胞淋巴瘤、肠病型T-细胞淋巴瘤、皮下脂膜炎样T-细胞淋巴瘤和间变性大细胞淋巴瘤);一种或多种上述白血病/淋巴瘤的混合;以及多发性骨髓瘤(MM))、重链病(例 如,α链病、γ链病、μ链病);血管母细胞瘤;下咽癌;炎性肌纤维母细胞瘤;免疫细胞淀粉样变性;肾癌(例如,肾胚细胞瘤,也称为威尔姆斯瘤、肾细胞癌);肝癌(例如,肝细胞癌(HCC)、恶性肝癌);肺癌(例如,支气管癌、小细胞肺癌(SCLC)、非-小细胞肺癌(NSCLC)、肺腺癌);平滑肌肉瘤(LMS);肥大细胞增多症(例如,系统性肥大细胞增多症);肌肉癌;骨髓增生异常综合征(MDS);间皮瘤;骨髓增生病(MPD)(例如,真性红细胞增多症(PV)、特发性血小板增多症(ET)、原因不明性髓样化生(AMM),也称为骨髓纤维化(MF)、慢性特发性骨髓纤维化、慢性髓细胞性白血病(CML)、慢性中性粒细胞性白血病(CNL)、高嗜酸粒细胞综合征(HES));成神经细胞瘤;神经纤维瘤(例如,1型或2型神经纤维瘤病(NF)、神经鞘瘤);神经内分泌癌(例如,胃肠胰神经内分泌瘤(GEP-NET)、类癌瘤);骨肉瘤(例如,骨癌);卵巢癌(例如,囊腺癌、卵巢胚胎性癌、卵巢腺癌);乳头状腺癌;胰腺癌(例如,胰腺癌、管内乳头状粘蛋白状赘生物(IPMN)、胰岛细胞瘤);阴茎癌(例如,阴茎和阴囊的佩吉特病);松果体瘤;原发性神经外胚层瘤(PNT);浆细胞瘤;类肿瘤综合征;上皮内瘤样病变;前列腺癌(例如,前列腺的腺癌);直肠癌;横纹肌肉瘤;唾液腺癌症;皮肤癌(例如,鳞状细胞癌(SCC)、角化棘皮瘤(KA)、黑素瘤、基底细胞癌(BCC));小肠癌(例如,盲肠癌);软组织肉瘤(例如,恶性纤维组织细胞瘤(MFH)、脂肉瘤、恶性外周神经鞘瘤(MPNST)、软骨肉瘤、纤维肉瘤、粘液肉瘤);皮脂腺癌;小肠癌;汗腺癌;滑膜瘤;睾丸癌(例如,精细胞瘤、睾丸胚胎性癌);甲状腺癌(例如,甲状腺的乳头状癌、乳头状甲状腺癌(PTC)、甲状腺髓样癌);尿道癌;阴道癌;以及外阴癌(例如,外阴的佩吉特病)。
在本公开中,病毒感染包括但不限于痘病毒科病毒性疾病、疱疹病毒科病毒性疾病、腺病毒科病毒性疾病、乳头瘤病毒科与多瘤病毒科病毒性疾病、细小病毒科病毒性疾病、嗜肝DNA病毒科病毒性疾病、逆转录病毒科病毒性疾病、呼肠孤病毒科病毒性疾病、博尔纳病毒科病毒性疾病、弹状病毒科病毒性疾病、丝状病毒科病毒性疾病、副粘病毒科病毒性疾病、正粘病毒科病毒性疾病、布尼亚病毒科病毒性疾病、沙粒病毒科病毒性疾病、小RNA病毒科病毒性疾病、杯状病毒科病毒性疾病、星状病毒科病毒性疾病、冠状病毒科病毒性疾病、披膜病毒科病毒性疾病、黄病毒科病毒性疾病、分类未定病毒性疾病、慢病毒感染。例如,病毒感染是以下病毒引起的感染:甲型、乙 型、丙型肝炎病毒、流感病毒、水痘病毒、Ⅰ型单纯疱疹病毒(HSV-Ⅰ)、Ⅱ型单纯疱疹病毒(HSV-Ⅱ)、牛瘟病毒、呼吸道合胞病毒、巨细胞病毒、海胆病毒、虫媒病毒、汉坦病毒、腮腺炎病毒、麻疹病毒、风疹病毒、Ⅰ型人类免疫缺陷病毒(HIV-1)、Ⅱ型人类免疫缺陷病毒(HIV-2)、任何披盖病毒属病毒(例如登革病毒)、甲病毒属病毒、黄病毒属病毒、冠形病毒属病毒、狂犬病毒、绿猴病毒、伊波拉病毒、副流感病毒、正粘病毒、沙粒病毒、Ⅰ型人T细胞白血病病毒、Ⅱ型人T细胞白血病病毒、猿猴免疫缺陷病毒、慢病毒、埃巴病毒、人疱疹病毒、弥猴疱疹病毒1(B病毒)和痘病毒。
在本公开中,中枢神经系统疾病包括但不限于神经退行性疾病、脑卒中、癫痫、脑外伤、休克、HIV痴呆、青光眼、多发性硬化症等。脑卒中分为出血性和缺血性脑卒中。神经退行性疾病包括阿尔兹海默症、小脑萎缩症、多发性硬化症、原发性侧索硬化、脊髓性肌萎缩症、帕金森病、亨廷顿氏病、克雅二氏病、牛海绵状脑病、共济失调毛细血管扩张症、肌肉萎缩性侧索硬化症。
如本文所用的,“炎性疾病”是指由炎症导致、由炎症产生的疾病或导致炎症的疾病。术语“炎性疾病”还表示失调的炎性反应,其导致巨噬细胞、粒细胞和/或T-淋巴细胞的过度响应,这导致正常组织损伤和/或细胞死亡。炎性疾病可以为急性或慢性炎性病症,并且可以由感染或非-感染原因导致。炎性疾病包括但不限于动脉粥样硬化、动脉硬化、自身免疫性障碍、多发性硬化、系统性红斑狼疮、风湿性多肌痛(PMR)、痛风性关节炎、退行性关节炎、肌腱炎、滑囊炎、牛皮癣、囊性纤维化病、关节骨炎、类风湿性关节炎、炎性关节炎、肖格伦综合征、巨细胞动脉炎、进行性系统性硬化(硬皮病)、强直性脊柱炎、多肌炎、皮肌炎、天疱疮、类天疱疮、糖尿病(例如,I型)、重症肌无力、桥本甲状腺炎、格雷夫斯病、古德帕斯彻病、混合型结缔组织病、硬化性胆管炎、炎性肠病、克罗恩病、溃疡性结肠炎、恶性贫血、炎性皮肤病、常见间质肺炎(UIP)、石棉沉着病、硅肺病、支气管扩张、铍中毒、滑石病、尘肺病、肉瘤样病、脱屑性间质性肺炎、淋巴样间质性肺炎、巨细胞间质性肺炎、细胞性间质性肺炎、外源性变应性肺泡炎、韦格纳肉芽肿病和脉管炎的相关形式(颞动脉炎和结节性多发性动脉炎)、炎性皮肤病、肝炎、迟发型超敏反应(例如,毒葛皮炎)、肺炎、呼吸道炎症、成人呼吸窘迫综合征(ARDS)、脑炎、速发型超敏反应、哮喘、花粉症、变态反应、急性过敏 反应、风湿热、肾小球肾炎、肾盂肾炎、蜂窝织炎、膀胱炎、慢性胆囊炎、缺血(局部缺血损伤)、再灌注损伤、同种异体移植排斥、宿主抗移植物、阑尾炎、动脉炎、眼睑炎、毛细支气管炎、支气管炎、子宫颈炎、胆管炎、绒毛膜羊膜炎、结膜炎、泪腺炎、皮肌炎、心内膜炎、子宫内膜炎、肠炎、小肠结肠炎、上髁炎、附睾炎、筋膜炎、纤维组织炎、胃炎、胃肠炎、牙龈炎、回肠炎、虹膜炎、喉炎、脊髓炎、心肌炎、肾炎、脐炎、卵巢炎、睾丸炎、骨炎、耳炎、胰腺炎、腮腺炎、心包炎、咽炎、胸膜炎、静脉炎、肺炎、直肠炎、前列腺炎、鼻炎、输卵管炎、窦炎、口炎、滑膜炎、睾丸炎、扁桃腺炎、尿道炎、膀胱炎、葡萄膜炎、阴道炎、血管炎、外阴炎、外阴阴道炎、脉管炎、慢性支气管炎、骨髓炎、视神经炎、颞动脉炎、横贯性脊髓炎、坏死性筋膜炎,以及坏死性小肠结肠炎。
如本文所用的,“自身免疫病”是指产生自受试者体内针对体内正常存在的物质和组织的不当免疫应答的疾病。换言之,免疫系统误将身体的一部分当做病原体并攻击自身细胞。这可能限制于某些组织(例如,在自身免疫性甲状腺炎)或包括不同部位的特定组织(例如,古德帕斯彻疾病,其可能影响肺和肾二者的基膜)。治疗自身免疫性疾病通常使用免疫抑制剂,例如,降低免疫应答的药物。示例性自身免疫性疾病包括但不限于肾小球肾炎、古德帕斯彻综合征、坏死性血管炎、淋巴结炎、结节性动脉周围炎、系统性红斑狼疮、类风湿病、关节炎、牛皮癣关节炎、系统性红斑狼疮、牛皮癣、溃疡性结肠炎、系统性硬化症、皮肌炎/多肌炎、抗磷脂抗体综合征、硬皮病、寻常天疱疮、ANCA-相关的血管炎(例如,韦格纳肉芽肿病、显微镜下多血管炎)、葡萄膜炎、肖格伦综合征、克罗恩病、赖特综合征、强直性脊柱炎、莱姆关节炎、古兰-巴雷综合征、桥本甲状腺炎和心肌病。
如本文中所用的,代谢疾病包括但不限于苯丙酮尿症、黄色瘤、淀粉样变性、黄疣病、黄瘤症、脂瘤性纤维瘤、脂肪性纤维瘤、脂肪纤维瘤、黄脂增生病、高血脂症、血脂过多、高脂血、脂肪过多症、脂肪过多、淀粉贮积病、淀粉样变性病、淀粉样变、半乳糖血、肥胖症、高脂血症、骨软化症、佝偻病、骨软化症和佝偻病、骨质疏松症、糖尿病如本文所用的,“线粒体相关疾病”包含亨汀顿氏疾病、肌萎缩性脊髓侧索硬化、线粒体脑肌肉病变合并乳酸血症和类中风症候群(MELAS);肌阵挛癫痫合并红色褴褛肌纤维症,MERRF);神经性肌肉松弛、失调症、色素性视网膜炎/母体遗传莱氏 症状(NARP/MILS);Leber氏视神经病变(LHON);Kearns-Sayre症候群(KSS);皮尔森骨髓胰腺症(PMPS);慢性渐进性眼外肌麻痹(CPEO);瑞氏症候群;阿尔珀斯氏症候群;多个线粒体DNA缺失症候群;线粒体DNA耗乏症候群;复合体Ⅰ缺陷;复合体Ⅱ(琥珀酸脱氢酶(SDH))缺陷;复合体Ⅲ缺陷;细胞色素c氧化酶(COX,复合体Ⅳ)缺陷;复合体Ⅴ缺陷;腺嘌呤核苷酸转运体(ANT)缺陷;丙酮酸脱氢酶(PDH)缺陷;具有乳酸血症的乙基丙二酸酸性尿;具有乳酸血症的3-甲基戊烯二酸酸性尿;体现为在传染期间的衰减的不应性癫痫;体现为在传染期间的衰减的阿斯伯格症候群;体现为在传染期间的衰减的自闭症;注意力不足过动症(ADHD);体现为在传染期间的衰减的脑性麻痹;体现为在传染期间的衰减的失读症;母系遗传血小板减少症;白血病;MNGIE(线粒体肌病变、周围和自主神经病变、胃肠功能异常和癫痫);MARIAHS症候群(线粒体失调症、复发传染、失语症、低尿酸血症/髓磷脂减少症、癫痫发作和二羧酸酸性尿);ND6肌张力不全症;体现为在传染期间的衰减的周期性呕吐症状;具有乳酸血症的3-羟基异丁酸酸性尿;具有乳酸血症的尿崩症;尿苷反应性神经症状(URNS);家族双侧纹状体坏死(FBSN);与胺基糖苷有关的听力损失;松驰心肌病;脾淋巴瘤;钨症状;多个线粒体DNA缺失症状;和肾小管酸血症/尿崩症/失调症症状。
如本文中所用的,线粒体相关疾病包括但不限于亨汀顿氏疾病、肌萎缩性脊髓侧索硬化、线粒体脑肌肉病变合并乳酸血症和类中风症候群MELAS;肌阵挛癫痫合并红色褴褛肌纤维症,MERRF;神经性肌肉松弛、失调症、色素性视网膜炎/母体遗传莱氏症状NARP/MILS;Leber氏视神经病变LHON;Kearns-Sayre症候群KSS;皮尔森骨髓胰腺症PMPS;慢性渐进性眼外肌麻痹CPEO;瑞氏症候群;阿尔珀斯氏症候群;多个线粒体DNA缺失症候群;线粒体DNA耗乏症候群;复合体I缺陷;复合体II琥珀酸脱氢酶SDH缺陷;复合体III缺陷;细胞色素c氧化酶COX,复合体IV缺陷;复合体V缺陷;腺嘌呤核苷酸转运体ANT缺陷;丙酮酸脱氢酶PDH缺陷;具有乳酸血症的乙基丙二酸酸性尿;具有乳酸血症的3-甲基戊烯二酸酸性尿;体现为在传染期间的衰减的不应性癫痫;体现为在传染期间的衰减的阿斯伯格症候群;体现为在传染期间的衰减的自闭症;注意力不足过动症ADHD;体现为在传染期间的衰减的脑性麻痹;体现为在传染期间的衰减的失读症;母系遗传血小板减少症;白血病;MNGIE线粒体肌病变、周围和自主神经病变、胃肠功能异常和癫痫; MARIAHS症候群线粒体失调症、复发传染、失语症、低尿酸血症/髓磷脂减少症、癫痫发作和二羧酸酸性尿;ND6肌张力不全症;体现为在传染期间的衰减的周期性呕吐症状;具有乳酸血症的3-羟基异丁酸酸性尿;具有乳酸血症的尿崩症;尿苷反应性神经症状URNS;家族双侧纹状体坏死FBSN;与胺基糖苷有关的听力损失;松驰心肌病;脾淋巴瘤;钨症状;多个线粒体DNA缺失症状;和肾小管酸血症/尿崩症/失调症症状。
图1:激光共聚焦技术检测罗丹明标记的不同多肽的细胞进入。
图2:流式细胞术检测不同浓度的FITC标记的多肽的细胞进入。
图3:流式细胞术检测FITC标记的多肽的A549细胞进入。多肽浓度:1μM。
图4:流式细胞术检测FITC标记的多肽的A549细胞进入。多肽浓度:3μM。
图5:流式细胞术检测FITC标记的多肽A549细胞的进入。多肽浓度:10μM。
图6:流式细胞术检测不同浓度的FITC标记的多肽的A549细胞进入。
图7:流式细胞术检测FITC标记的多肽的细胞进入。左图,HeLa细胞;多肽浓度:10μM。右图,MRC5细胞,多肽浓度:3μM。
图8:流式细胞术检测FITC标记的不同多肽片段的A549细胞进入。
图9:流式细胞术检测FITC标记的不同多肽片段的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图10:流式细胞术检测FITC标记的不同多肽片段的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图11:流式细胞术检测FITC标记的不同多肽片段的A549细胞进入。多肽浓度:1μM。温育时间:3小时。
图12:流式细胞术检测FITC标记的不同多肽片段的A549细胞进入。多肽浓度:1μM。温育时间:3小时。
图13:流式细胞术检测FITC标记的不同多肽片段的293T细胞进入。多肽浓度:1μM。温育时间:1小时。
图14:流式细胞术检测FITC标记的多肽的293T细胞进入。多肽浓度: 1μM。温育时间:1小时。
图15:流式细胞术检测FITC标记的不同多肽片段的HUVEC细胞进入。多肽浓度:1μM。温育时间:1小时。
图16:流式细胞术检测FITC标记的TAT和M2(44-65)多肽的HUVEC细胞进入。多肽浓度:1μM。温育时间:1小时。
图17:流式细胞术检测FITC标记的不同多肽片段的HCT-116细胞进入。多肽浓度:1μM。温育时间:1小时。
图18:流式细胞术检测FITC标记的TAT、M2(44-65)和M2(45-62)多肽的HCT-116细胞进入。多肽浓度:1μM。温育时间:1小时。
图19:流式细胞术检测FITC标记的不同多肽片段的MNK-45细胞进入。多肽浓度:1μM。温育时间:1小时。
图20:流式细胞术检测FITC标记的TAT、M2(44-65)和M2(45-62)多肽的MKN-45细胞进入。多肽浓度:1μM。温育时间:1小时。
图21:流式细胞术检测FITC标记的不同多肽片段的U937细胞进入。多肽浓度:1μM。温育时间:1小时。
图22:流式细胞术检测FITC标记的TAT、M2(44-65)和M2(45-62)多肽的U937细胞进入。多肽浓度:1μM。温育时间:1小时。
图23:流式细胞术检测FITC标记的TAT、M2(44-65)和M2(44-61)多肽的MRC5细胞进入。多肽浓度:1μM。温育时间:1小时。
图24:流式细胞术检测FITC标记的TAT和M2(44-65)多肽的ESF-1细胞进入。多肽浓度:1μM。温育时间:1小时。
图25:激光共聚焦实验检测FITC标记的不同多肽片段的ESF-1细胞进入。多肽浓度:3μM。温育时间:1小时。
图26:流式细胞术检测不同的温育时间时多肽的A549细胞进入。多肽浓度:1μM。温育时间为左图:5分钟;中间图:10分钟;右图:30分钟。
图27:流式细胞术检测不同的温育时间时多肽的A549细胞进入。多肽浓度:1μM。
图28:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-45-62多肽的A549细胞进入。多肽浓度:1μM。
图29:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-44-61多肽的A549细胞进入。多肽浓度:1μM。
图30:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-44-65多肽的A549细胞进入。多肽浓度:1μM。
图31:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-45-62多肽的A549细胞进入。多肽浓度:3μM。
图32:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-44-61多肽的A549细胞进入。多肽浓度:3μM。
图33:流式细胞术检测比较不同的细胞穿透肽与本发明的Jilin-2004(H5N1)-M2-44-65多肽的A549细胞进入。多肽浓度:3μM。
图34:流式细胞术检测Jilin-2004(H5N1)-M2-44-56多肽的突变序列的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图35:流式细胞术检测Jilin-2004(H5N1)-M2-45-62多肽的突变序列的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图36:激光共聚焦技术检测Jilin-2004(H5N1)-M2-45-62多肽及其突变序列的A549细胞进入。
图37:流式细胞术检测Jilin-2004(H5N1)-M2-45-62多肽的单位点突变序列的A549细胞进入。多肽浓度:1μM。温育时间:3小时。
图38:激光共聚焦技术检测Jilin-2004(H5N1)-M2-45-62多肽及其单位点突变序列的A549细胞进入。
图39:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图40:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的A549细胞进入。多肽浓度:3μM。温育时间:1小时。
图41:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的293T细胞进入。多肽浓度:1μM。温育时间:1小时。
图42:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的MRC5细胞进入。多肽浓度:1μM。温育时间:1小时。
图43:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的U937细胞进入。多肽浓度:1μM。温育时间:1小时。
图44:流式细胞术检测Jilin-2004(H5N1)-M2-44-65多肽的突变序列的HCT-116细胞进入。多肽浓度:1μM。温育时间:1小时。
图45:流式细胞术检测不同的细胞穿透肽携带小RNA的细胞进入。
图46:激光共聚焦技术检测Jilin-2004(H5N1)-M2-45-62多肽携带小RNA的细胞进入。
图47:激光共聚焦技术检测Jilin-2004(H5N1)-M2-44-56多肽携带小RNA的细胞进入。
图48:激光共聚焦技术检测Jilin-2004(H5N1)-M2-44-61、Jilin-2004(H5N1)-M2-44-65和Jilin-2004(H5N1)-M2-44-65mut8多肽携带小RNA的细胞进入。
图49:双荧光报告基因检测不同的细胞穿透肽携带PGY-sRNA-6进入细胞的功能检测。
图50:Jilin-2004(H5N1)-M2-44-56携带β-半乳糖苷酶的细胞进入。
图51:激光共聚焦技术检测EGFP与细胞穿透肽的混合物的A549细胞进入。温育时间:1小时。
图52:流式细胞术检测不同浓度的EGFP-M2(71-85)和EGFP-M2(45-62)融合蛋白的A549细胞进入。温育时间:1小时。
图53:流式细胞术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:10nM。温育时间:1小时。
图54:流式细胞术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:30nM。温育时间:1小时。
图55:流式细胞术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:100nM。温育时间:1小时。
图56:激光共聚焦技术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:30nM。温育时间:1小时。
图57:激光共聚焦技术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:100nM。温育时间:1小时。
图58:激光共聚焦技术检测不同的EGFP融合蛋白的A549细胞进入。蛋白浓度:300nM。温育时间:1小时。
图59:流式细胞术检测Jilin-2004(H5N1)-M2-44-61多肽的突变序列的A549细胞进入。多肽浓度:1μM。温育时间:1小时。
图60:超高分辨显微镜检测Jilin-2004(H5N1)-M2-44-61、Jilin-2004(H5N1)-M2-44-65多肽携带小RNA的细胞进入。
图61:荧光定量PCR检测流感病毒M2不同片段多肽携带小RNA进入细胞。
图62:实时定量qPCR检测Jilin-2004(H5N1)-M2-45-62多肽及其单位点突变序列携带小RNA的A549细胞的进入。
图63:荧光定量PCR检测Jilin-2004(H5N1)-M2-45-62多肽及其突变序列携带小RNA的A549细胞的进入。
图64:荧光定量PCR检测Jilin-2004(H5N1)-M2-44-61多肽及其突变序列携带小RNA的A549细胞的进入。
图65:荧光定量PCR检测Jilin-2004(H5N1)-M2-44-65多肽及其突变序列携带小RNA的A549细胞的进入。
图66:双荧光报告基因检测不同的细胞穿透肽携带HJT-sRNA-m7进入细胞的功能检测。
图67:酶联免疫吸附实验检测不同的细胞穿透肽携带小RNA的LPS刺激细胞后的IL-1β表达。
图68:酶联免疫吸附实验检测不同的细胞穿透肽携带小RNA的LPS刺激细胞后的TNF-α表达。
图69:Western blot检测不同的细胞穿透肽携带HJT-sRNA-m7进入细胞的抗纤维化功能检测。
图70:激光共聚焦检测Jilin-2004(H5N1)-M2-44-61和Jilin-2004(H5N1)-M2-45-62多肽携带GFP质粒进入细胞的表达。
图71:激光共聚焦技术检测EGFP与细胞穿透肽融合蛋白进入小鼠不同器官。
图72:荧光定量PCR检测Jilin-2004(H5N1)-M2-44-61多肽携带PGY-sRNA-23进入小鼠器官。
图73:荧光定量PCR检测Jilin-2004(H5N1)-M2-44-61多肽携带PGY-sRNA-26进入小鼠器官。
图74:酶联免疫吸附实验检测Jilin-2004(H5N1)-M2-44-61多肽携带PGY-sRNA-6的抗炎功能。
图75:荧光定量PCR检测Jilin-2004(H5N1)-M2-44-61携带miR-1246 antagomir进入小鼠肺组织。
图76:酶联免疫吸附实验检测LPS诱导急性肺损伤小鼠中 Jilin-2004(H5N1)-M2-44-61携带miR-1246 antagomir进入后的肺泡灌洗液中TNF-α的表达。
图77:酶联免疫吸附实验检测LPS诱导急性肺损伤小鼠中Jilin-2004(H5N1)-M2-44-61携带小分子silybin的肺泡灌洗液中IL-6的表达。
图78:PET-28a-EGFP载体质粒图谱。
图79:pEAK13载体图谱。
以下将结合实施例进一步说明本发明的内容。应当理解以下实施例仅是说明性的,而不应被认为是对本发明范围的限制。
材料
实施例中使用的所有小RNA和NS1-GFP质粒。
小RNA 序列
PGY-sRNA-23 CCCUCCGCGGCCAGCUUCU
PGY-sRNA-26 UCCGGAAUGAUUGGGCGUAAAGCGU
PGY-sRNA-6 GUUCAGAGUUCUACAGUCCGA
NS1-GFP质粒是本实验室构建的(pEAK13载体),NS1是流感病毒A/HongKong/97/98(H5N1)的NS1蛋白(表达在细胞核中。NS1-GFP是N端NS1,直接融合GFP蛋白)。
EGFP融合蛋白:GFP在N端且多肽在C端直接融合表达(PET-28a-EGFP载体)。
EGFP的编码序列:
NS1蛋白序列(225aa)
实施例1:一般实验方法
1、多肽溶液的配置
1)配置1mM的多肽储存液
根据合成的不同多肽(未标记的多肽、罗丹明标记的多肽和FITC标记的多肽)的质量与相对分子质量计算加入的超纯水的量(0.22μm的滤膜过滤),溶解后将储存液分装并于-80度避光保存。
2)配置不同浓度的多肽工作液
根据不同多肽的使用浓度,对于不同类型的细胞选择对应的培养基作为稀释液,配置多肽工作液。
2、流式细胞术检测多肽的进入
2.1流式细胞术检测罗丹明或者FITC标记的多肽的进入
1).将细胞用0.05%的胰蛋白酶消化后,分至12孔板的孔内。控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).待细胞生长24小时后,观察细胞密度。将细胞培养基换成用培养基配置好的多肽工作液。将细胞放置在37℃,5%CO
2培养箱中避光温育相应时间。
3).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
4).使用0.05%胰蛋白酶消化细胞,随后弃去胰酶。将细胞重悬于1mL无菌PBS并置于1.5mL离心管中。4℃,300g离心10分钟。
5).弃去上清液,将细胞重悬于200μL无菌PBS。
6).使用流式细胞仪C6检测多肽的细胞进入。
2.2流式细胞术检测多肽运载FAM标记的小RNA的细胞进入
1).将A549细胞用0.05%的胰蛋白酶消化后,分至12孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).待细胞生长24小时后,观察细胞密度。将30μM的多肽与300nM的FAM标记的小RNA混合,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育相应时间。
3).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
4).使用0.05%胰蛋白酶消化细胞,随后弃去胰酶。将细胞重悬于1mL无菌PBS并置于1.5mL离心管中。4℃,300g离心10分钟。
5).弃去上清液,将细胞重悬于200μL无菌PBS。
6).使用流式细胞仪C6检测小RNA的细胞进入。
2.3流式细胞术检测多肽-EGFP融合蛋白的细胞进入
1).将A549细胞用0.05%的胰蛋白酶消化后,分至12孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).待细胞生长24小时后,观察细胞密度。用培养基配置好不同浓度的融合蛋白工作液,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育相应时间。
3).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
4).使用0.05%胰蛋白酶消化细胞,随后弃去胰酶。将细胞重悬于1mL无菌PBS并置于1.5mL离心管中。4℃,300g离心10分钟。
5).弃去上清液,将细胞重悬于200μL无菌PBS。
6).使用流式细胞仪C6检测融合蛋白的进入。
3、激光共聚焦技术检测多肽的进入
3.1激光共聚焦技术检测罗丹明或者FITC标记的多肽的细胞进入
1).将多聚赖氨酸包被的细胞载玻片置于48孔板的孔内,使用相应培养基清洗两次。
2).将A549细胞用0.05%的胰蛋白酶消化后,分至48孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
3).待细胞生长24小时后,观察细胞密度。将细胞培养基换成用培养基配置好的不同浓度的多肽工作液,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育相应时间。
4).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
5).弃去PBS,以200μL/孔加入4%的多聚甲醛室温固定15-20分钟。
6).弃去多聚甲醛,用含有0.1%triton的无菌PBS清洗三遍,每次放置在100转/分钟的水平摇床上摇晃5分钟。
7).弃去PBS后,以200μL/孔加入用含有0.1%triton的无菌PBS配置的含有细胞骨架F-actin抗体(体积比为1:200)和DAPI(体积比为1:1000)的溶液,室温避光放置30分钟。
8).弃去上清液,用含有0.1%triton的无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
9).封片,晾干后使用Zeiss共聚焦显微镜观察多肽的细胞进入。
3.2激光共聚焦技术检测未标记的多肽运载Cy3标记的小RNA的细胞进
入
1).将多聚赖氨酸包被的细胞载玻片置于48孔板的孔内,使用相应培养基清洗两次。
2).将A549细胞用0.05%的胰蛋白酶消化后,分至48孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
3).待细胞生长24小时后,将细胞培养基换成用培养基配置好的未标记的多肽(30μM)与Cy3标记的PGY-6-dsRNA(100nM)的混合液,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育1小时。
4).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
5).弃去PBS,以200μL/孔加入4%的多聚甲醛室温固定15-20分钟。
6).弃去多聚甲醛,用含有0.1%triton的无菌PBS清洗三遍,每次放置在 100转/分钟的水平摇床上摇晃5分钟。
7).去PBS后,以200μL/孔加入用含有0.1%triton的无菌PBS配置的含有细胞骨架F-actin抗体(体积比为1:200)和DAPI(体积比为1:1000)的溶液,室温避光放置30分钟。
8).弃去上清液,用含有0.1%triton的无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
9).封片,晾干后使用Zeiss共聚焦显微镜观察Cy3标记的小RNA的细胞进入。
3.3激光共聚焦实验检测FITC标记的多肽运载Cy3标记的小RNA的细胞
进入
1).将多聚赖氨酸包被的细胞载玻片置于48孔板的孔内,使用相应培养基清洗两次。
2).将A549细胞用0.05%的胰蛋白酶消化后,分至48孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
3).待细胞生长24小时后,将细胞培养基换成用培养基配置好的FITC标记的多肽(10μM)与Cy3标记的PGY-6-dsRNA(400nM)的混合液,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育1小时。
4).弃去培养基,将细胞用无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
5).弃去PBS,以200μL/孔加入4%的多聚甲醛室温固定15-20分钟。
6).弃去多聚甲醛,用含有0.1%triton的无菌PBS清洗三遍,每次放置在100转/分钟的水平摇床上摇晃5分钟。
7).弃去PBS后,以200μL/孔加入用含有0.1%triton的无菌PBS配置的含有DAPI(体积比为1:1000)的溶液,室温避光放置30分钟。
8).弃去上清液,用含有0.1%triton的无菌PBS清洗三次,每次清洗放置在100转/分钟的水平摇床上摇晃5分钟。
9).封片,晾干后使用Zeiss共聚焦显微镜观察FITC标记的多肽和Cy3标记的小RNA的细胞进入。
4.显微镜下观察多肽运载β-半乳糖苷酶的细胞进入
1).将A549细胞用0.05%的胰蛋白酶消化后,分至12孔板的孔内,控制 铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).待细胞生长24小时后,配置多肽(50μM)与β-半乳糖苷酶(50nM)的混合液,于37℃放置30分钟。将细胞培养基换成用培养基配置好的混合液,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育1小时。
3).按照BioVision的β-半乳糖苷酶染色试剂盒的使用说明(Catalog#K802-250)进行染色实验。
4).弃去培养基,将细胞用无菌PBS清洗一次。加入500μL固定液于室温放置10-15分钟。
5).弃去固定液,将细胞用无菌PBS清洗两次。
6).加入500μL染色溶液(470μL染色液,5μL染色补充液,25μL溶于DMSO的20mg/ml X-gal),37℃过夜染色。
7).在倒置显微镜下观察多肽运载β-半乳糖苷酶的细胞进入。
5.实时定量qPCR检测多肽携带小RNA的进入。
5.1多肽携带小RNA进行A549细胞的样本制备
1).将A549细胞用0.05%的胰蛋白酶消化后,分至12孔板的孔内,控制铺板密度使得细胞在24小时后长至约80%~85%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).待细胞生长24小时后,配置多肽(10μM)与小RNA(100nM)的混合液于50μL DEPC处理的H
2O中。加入12孔板细胞每孔后将细胞放置在37℃,5%CO
2培养箱中避光温育1小时。
3).弃去培养基,将细胞用无菌PBS清洗三次,每次摇床100rpm/min摇晃清洗。
4).12孔板细胞每孔加入1mL TRizol,室温裂解10-15min,用于RNA提取。
5.2多肽携带小RNA进行小鼠器官的样本制备
1).C57 BL/6雄性小鼠周龄6~8周,体重20克左右,每组4只,并做好标记。
2).根据合成的多肽的质量与相对分子质量计算加入的超纯水的量(0.22μm的滤膜过滤),溶解多肽。同时根据小RNA的摩尔数计算溶解小RNA所需的超纯水的量。静置、混匀,待多肽和小RNA溶解后进行下一步实验。
3).将小RNA按照1:1的比例进行混合,混匀后,分装到无菌1.5ml EP管中,再将多肽溶液加入到EP管中,使得小RNA与多肽的P:N比为1:10。按照每只小鼠3nmol小RNA的量,在混合物中加入超纯水,使得每只小鼠的注射体积为300μL。混匀,室温放置5分钟。
4).腹腔注射1小时后,牺牲小鼠,取器官,包括脑心脏、肝脏、脾脏、肺、肾脏、胃、小肠、胸腺在内的8种器官或组织。并立即置于液氮保存。
5).在小鼠血液样品中,按照1:3的比例加入TRIzol LS,混匀,置于冰上裂解。取2ml平底离心管,在管中加入1mL TRizol,然后将适量组织块放入离心管中(心脏纵切取一半,肝脏取肝门处约0.2g,脾脏横切取一半,肺取右侧肺叶,肾取一侧肾脏,脑纵切取一半,睾丸取一侧,胸腺的全部,全部胆囊,胃取一半并洗净,小肠约取1厘米长度的肠管)。在冰上研磨组织至可以被TRIzol充分裂解,用于RNA的提取。
5.3细胞或者小鼠组织样本的总RNA提取
1).按照200μL氯仿/mL TRIzol的体积比在样品中加入氯仿,盖紧EP管盖后,用力振荡混匀样品,室温静置15min,期间再震荡摇晃一次。
2).4℃13200g·min
-1离心20min。期间标记一批新的1.5mL EP管。
3).缓慢吸取上层水相至备好的相应离心管中。1mL TRIzol裂解样品吸取540μL左右的上层水相。
4).在上层水相中加入0.8倍水相体积的预冷异丙醇,充分混匀,-40℃冰箱放置30min。
5).13200g·min
-1 4℃离心25min,此时可见到RNA沉淀贴在管壁上,小心弃上清,开盖倒置在吸水纸上。
6).加入1mL 75%乙醇(用DEPC处理过的水配制),震荡悬浮沉淀。
7).13200g·min
-1 4℃离心10min,尽量弃上清,并开盖倒置于吸水纸上。
8).重复步骤6-7
9).小心将管底多余液体吸走,室温晾干。
10).观察RNA沉淀的大小,根据沉淀大小用不同体积的DEPC处理的H
2O溶解RNA沉淀,完全溶解后充分混匀。
11).取1μL RNA样品用NanoDrop 2000测定吸光度值,对RNA的纯度和浓度进行测定,以利于后期逆转实验的进行。
5.4 RNA逆转录成cDNA
1).按照RNA样品数量及名称标记PCR管子。
2).按如下配制逆转体系
3).small RNA(sRNA)逆转录专用引物中,应包含所有目的sRNA和内参U6的逆转录引物。在每个PCR小管中加入10μL配好的逆转录体系,再加入2μg相应的RNA(加入RNA的体积为10μL,不足10μL的部分,用Nuclease-free H2O补齐,使其终体积为20μL)。
4).按照如下程序进行逆转
25℃ 10min
37℃ 120min
85℃ 5min
4℃ pause
逆转录产物cDNA按照需要加入无菌H
2O进行稀释后,用于荧光实时定量PCR实验。5.5实时定量qPCR检测小RNA的表达
1).配实时荧光定量PCR反应体系,每个反应体系中应含如下组分:
2).根据样品数计算总需体积数,配成混合液后,在384孔板中每孔加入9μL体系,然后加入1μL cDNA。
3).将384孔板加好反应体系后,用封口膜将板子封好,瞬离,使反应体系位于孔底。
4).将384孔板放入仪器的反应托架上,选择程序模板为:
a:95℃ 5min
b:95℃ 10s
c:55℃ 15s
d:72℃ 20s 荧光信号采集 b-d循环40次
e:熔点曲线反应程序
f:冷却反应
5).在反应进行时,设置样品名称和检测基因等信息,待反应结束后,选择相对定量,使用Advanced relative compare analysis分析方式,计算出内参基因和目的基因的相对Ct值。
6).根据公式:基因相对表达量值=2
(-(Ct目的基因-Ct内参)进行目的基因相对表达量的计算。
6.双荧光报告基因系统检测多肽携带小RNA进入的功能研究
1).将HEK293T细胞用0.05%的胰蛋白酶消化后,分至48孔板的孔内,控制铺板密度使得细胞在12小时后长至约50%~60%。将细胞放置在37℃,5%CO
2培养箱中培养。
2).配置多肽(30μM)分别与两种小RNA(300nM)(HJT-sRNA-m7,PGY-sRNA-6)的混合液于50μL完全培养基中。加入48孔板每孔后将细胞放置在37℃,5%CO
2培养箱中温育9小时。
3).用Lipo2000转染试剂转染野生型和突变型带有COLLAGEN3A1基因3’UTR区和RELA基因3’UTR区的双荧光素酶报告基因质粒,0.25μg/孔。
4).转染48小时后,利用Promega的双荧光报告基因检测试剂盒检测luciferase的荧光强度。
7.酶联免疫吸附实验检测多肽携带小RNA进入的功能研究。
7.1多肽携带小RNA进入细胞的功能研究
1).THP-1细胞分至12孔板中,细胞放置在37℃,5%CO
2培养箱中培养。
2).配置多肽(30μM)分别与PGY-sRNA-6(200nM)的混合液于50μL完全培养基中。加入12孔板细胞每孔后将细胞放置在37℃,5%CO
2培养箱中温育24小时。
3).给予1μg/mL脂多糖LPS刺激细胞,作用24h后,将细胞转移至1.5mL EP管中,4℃,1,000rpm,离心5min,转移细胞上清至新1.5mL EP管中,加入100Xcock tail,利用ELISA检测炎症细胞因子(TNF-α和IL-1β)的表达水平。
4).包被:采用R&D公司的自包被ELISA板(IL-1β DY201-05,TNF-α DY210-05),用PBS稀释Capture Antibody(IL-1,TNF-α)(根据说明书上的稀释比例),室温包被过夜,约16-18h;
5).洗板:取出包被好的ELISA板,将CaptureAntibody液倒掉并在滤纸上将残余液体拍干,而后加入已配置好的洗液(PBS+0.1%tween 20)300μL进行清洗,每次停留1min(用ELISA板振荡器),每次也须将液体倒掉并在滤纸上将残余液体拍干(下同),清洗4次;
6).封闭:清洗完毕后,加入300μL封闭液(PBS+1%BSA),室温下温育1h;
7).准备:在1h间须准备相应标准品(IL-1,TNF-α),根据说明书配好最高浓度后按照1/2的浓度梯度进行稀释,稀释7次,最后第八管加入稀释液作为0管;
8).洗板:温育1h后使用洗液清洗4次;
9).加样:将准备好的标准品加入ELISA板的左右两排,其他孔中加入样品,室温孵育2h;
10).加一抗:洗液清洗4次,加入100μL Detection Antibody,封好后室温孵育2h;
11).加二抗:洗液清洗4次,加入100μLAvidin-HRP,封好后室温孵育20min;
12).加底物:洗液清洗4次,加入100μL TMB Substrate Solution,尽量在暗中操作,而后马上置于抽屉中暗置10~20min左右,颜色变蓝后,加入100μL终止液终止反应,颜色由蓝变黄;
13).在30min内进行吸光度测定,450nm检测波长,570nm参考波长。
7.2多肽携带小RNA进入小鼠器官的功能研究
1).C57 BL/6雄性小鼠周龄6~8周,体重20克左右,每组4只,并做好标记。根据合成的多肽的质量与相对分子质量计算加入的超纯水的量(0.22μm的滤膜过滤),溶解多肽。同时根据小RNA的摩尔数计算溶解小RNA所需的 超纯水的量。静置、混匀,待多肽和小RNA溶解后进行下一步实验。
2).将PGY-sRNA-6与多肽溶液加入到EP管中,。按照每只小鼠10nmol小RNA的量,在混合物中加入超纯水,使得每只小鼠的注射体积为300μL。混匀,室温放置5分钟。
3).提前24小时和提前1小时两次腹腔注射后,在无菌条件下,将poly(I:C)溶于PBS中配制贮存液浓度为10mg/mL。按每只小鼠给药500ug poly(I:C)的剂量,每管50uL分装。气管滴注法造急性肺损伤模型,6h后牺牲小鼠,收取肺泡灌洗液待检测。
4).包被:采用R&D公司的自包被ELISA板(IL-6 DY406,TNF-α DY410),用PBS稀释Capture Antibody(IL-6,TNF-α)(根据说明书上的稀释比例),室温包被过夜,约16-18h;
5).洗板:取出包被好的ELISA板,将CaptureAntibody液倒掉并在滤纸上将残余液体拍干,而后加入已配置好的洗液(PBS+0.1%tween 20)300μL进行清洗,每次停留1min(用ELISA板振荡器),每次也须将液体倒掉并在滤纸上将残余液体拍干(下同),清洗4次;
6).封闭:清洗完毕后,加入300μL封闭液(PBS+1%BSA),室温下温育1h;
7).准备:在1h间须准备相应标准品(IL-6,TNF-α),根据说明书配好最高浓度后按照1/2的浓度梯度进行稀释,稀释7次,最后第八管加入稀释液作为0管;
8).洗板:温育1h后使用洗液清洗4次;
9).加样:将准备好的标准品加入ELISA板的左右两排,其他孔中加入样品,室温孵育2h;
10).加一抗:洗液清洗4次,加入100μL Detection Antibody,封好后室温孵育2h;
11).加二抗:洗液清洗4次,加入100μLAvidin-HRP,封好后室温孵育20min;
12).加底物:洗液清洗4次,加入100μL TMB Substrate Solution,尽量在暗中操作,而后马上置于抽屉中暗置10~20min左右,带颜色变蓝后,加入100μL终止液终止反应,颜色由蓝变黄;
13).在30min内进行吸光度测定,450nm检测波长,570nm参考波长。
8.蛋白免疫印迹实验检测多肽携带小RNA进入细胞的功能研究。
8.1多肽携带小RNA进入MCR-5细胞样品收取
1).MRC-5细胞分至12孔板中,细胞放置在37℃,5%CO
2培养箱中培养。
2).配置多肽(10μM)分别与HJT-sRNA-m7(300nM)的混合液于50μL完全培养基中。加入12孔板细胞每孔后将细胞放置在37℃,5%CO
2培养箱中温育24小时。
3).给予刺激物3ng/mL转化生长因子TGFβ1)刺激MRC-5细胞,作用72小时后,用强RIPA裂解液收取细胞,用于检测相关基因的蛋白表达水平。
8.2蛋白免疫印迹法检测(Western blot)
A.制胶:采用10%浓度分离胶(下层胶)和5%浓度的浓缩胶(上层胶),15孔梳子所做泳道,每个泳道样品蛋白上样量相等;
B.蛋白电泳:加入电泳缓冲液,电泳起始电压80V;当溴酚兰染料到分离胶后,提高电压至120V继续电泳,直至溴酚兰染料达到分离胶底部或全部泳出凝胶;
C.湿法转膜:按照转膜夹板(负极)-海绵-滤纸-凝胶-PVDF膜-滤纸-海绵-转膜夹板(正极)的顺序进行组装;安装后并将整个转膜装置置于4℃冷室;恒定电流300mA,转膜120min;
D.封闭:转膜结束后置于3%BSA封闭液中,室温封闭1h;
E.一抗孵育:将封闭后的PVDF膜转移至杂交袋中,加入含有对应一抗(一抗的信息如下)的3%BSA封闭液,赶出袋中气泡,密封后4℃过夜孵育;
纤连蛋白抗体(sigma F7387)
Actin抗体(sigma A5441)
F.洗膜:将PVDF膜取出,用TBST洗膜3次,每次10min;
G.二抗孵育:弃去TBST,加入含有带有辣根过氧化物酶(HRP)的山羊抗兔或山羊抗小鼠的二抗(购自杭州联科生物技术有限公司)的3%BSA封闭液(二抗稀释比例1:5000),室温孵育1小时;
H.洗膜:用TBST洗膜3次,每次10min;
I.显影:配制Western显色液(1:1,V/V,Merck Millipore,ECL化学发光显色液购自Millipore公司),并将配制好的显色液均匀滴加于膜结合蛋白的一侧;用保鲜膜小心的将膜包好,显色后观察;
J.分析:用Image J软件进行分析。
9.激光共聚焦实验检测多肽携带GFP质粒进入细胞并表达。
1).将多聚赖氨酸包被的细胞载玻片置于48孔板的孔内,使用相应培养基清洗两次。
2).将HEK293T细胞用0.05%的胰蛋白酶消化后,分至48孔板的孔内,控制铺板密度使得细胞在12小时后长至约50%~60%。将细胞放置在37℃,5%CO
2培养箱中培养。
3).待细胞生长12小时后,用完全培养基配置好的多肽与质粒(0.25μg/孔)的混合液,N/P为400:1,加入后将细胞放置在37℃,5%CO
2培养箱中避光温育48小时。
4).弃去培养基,将细胞用无菌PBS清洗三次。
5).弃去PBS,以200μL/孔加入4%的多聚甲醛室温固定15-20分钟。
6).弃去多聚甲醛,用无菌PBS清洗三遍。
7).弃去PBS后,封片,晾干后使用Zeiss共聚焦显微镜观察GFP绿色荧光蛋白的表达。
10.免疫组化检测多肽与EGFP融合蛋白进入小鼠器官的功能研究。
1).C57 BL/6雄性小鼠周龄6~8周,体重20克左右,每组4只,并做好标记。
2).根据融合蛋白的储存浓度和相对分子质量,计算蛋白稀释比例,使得每360μL蛋白溶液中含EGFP融合蛋白1mg。
3).每只小鼠腹腔注射360μL PBS或含1mg融合蛋白的PBS。
4).1小时后,牺牲小鼠,取小鼠器官(肝脏、脾脏、肾脏和脑),石蜡包埋,并进行石蜡切片。
5).脱蜡
a.将切片置于架子上,依据下列方法依次冲洗:
二甲苯:2X3分钟
二甲苯与无水乙醇1:1混匀:3分钟
无水乙醇:2X3分钟
95%乙醇:3分钟
70%乙醇:3分钟
50%乙醇:3分钟
冷水流洗
b.抗原修复前确保切片一直浸没在水中,切勿变干,变干后会导致非特异性抗体结合产生高背景。
6).抗原修复
a.按上所述将切片脱蜡至水。
b.依据用户说明书设置蒸煮锅并预热。
c.在烧瓶中预热合适的修复缓冲液并煮沸(用微波炉加热会更方便)。
d.将盛放玻片架的容器放置蒸煮锅中。
e.将热修复缓冲液小心加到容器中,然后放入玻片架。也可以采用更简捷的操作,先向容器中加热修复缓冲液再一同放入蒸煮锅中。
f.加盖。盛放缓冲液的容器也须配备盖子。起始时玻片架可能会使修复溶液温度降低,但几分钟内会回升到95-100℃之间。
g.达到温度后维持20分钟。
h.20分钟后,取出容器放置水中冷却10分钟。
7).封闭
(1)在含0.025%Triton X-100的TBS中漂洗玻片2×5分钟,轻轻震荡。
(2)用含10%正常血清、1%BSA的TBS室温封闭2小时。控干封闭液(不是漂洗),并用纸巾将玻片周围擦干。
8).孵育一抗
a.一抗用含1%BSA的TBS稀释后加到玻片上。
b.4℃孵育过夜。
9).孵育二抗
a.用含0.025%Triton X-100的TBS漂洗2×5分钟,并轻轻震荡。
b.用含0.025%Triton X-100的TBS漂洗2×5分钟,并轻轻震荡。
c.在TBS中漂洗3X 5分钟。
d.封固剂和盖玻片进行封固。
10).使用Zeiss共聚焦显微镜观察EGFP荧光强度,并用ImagJ软件进行统计。
11.酶联免疫吸附实验检测多肽携带小分子药物silybin和小RNA antagomir进入小鼠器官的功能研究。
11.1多肽携带小分子进入小鼠器官的功能研究
1).C57 BL/6雄性小鼠周龄6~8周,体重20克左右,每组4只,并做好标记。根据合成的多肽的质量与相对分子质量计算加入的超纯水的量(0.22μm的滤膜过滤),溶解多肽,DMSO溶解小分子药物。静置、混匀,待多肽和小RNA溶解后进行下一步实验。
2).将10mg/kg的多肽溶液与小分子药物silybin(100mg/kg)加入到EP管中,最后在混合物中加入超纯水,使得每只小鼠的灌胃体积为200μL。混匀,室温放置5分钟。
3).提前48小时、提前24小时和提前1小时三次灌胃后,在无菌条件下,将LPS溶于PBS中配制贮存液浓度为1mg/mL。按每只小鼠给药50μL的剂量,气管滴注法造急性肺损伤模型,9h后牺牲小鼠,收取肺泡灌洗液待检测。
11.2多肽携带小RNA antagomir进入小鼠器官的功能研究
1).C57 BL/6雄性小鼠周龄6~8周,体重20克左右,每组4只,并做好标记。根据合成的多肽的质量与相对分子质量计算加入的超纯水的量(0.22μm的滤膜过滤),溶解多肽,DMSO溶解小分子药物。静置、混匀,待多肽和小RNA溶解后进行下一步实验。
2).将10mg/kg的多肽溶液与miR-1246 antagomir(20μg/只)加入到EP管中,最后在混合物中加入超纯水,使得每只小鼠的注射体积为100μL。混匀,室温放置5分钟。
3).提前提前24小时和提前1小时两次腹腔注射后,在无菌条件下,将LPS溶于PBS中配制贮存液浓度为1mg/mL。按每只小鼠给药50μL的剂量,气管滴注法造急性肺损伤模型,9h后牺牲小鼠,收取肺泡灌洗液待检测。
实施例2:来源于流感病毒M2蛋白的多肽序列的细胞进入
基于Caledonia/20/1999(H1N1)和A/HongKong/97/98(H5N1)两株流感病毒的M2蛋白的序列,合成了如表1中列出的多肽序列,其中TAT HIV作为阳性对照细胞穿透肽。为了便于检测多肽的细胞进入,使用罗丹明标签在N端标记了多肽。
表1.罗丹明标记的多肽序列
多肽的细胞进入的激光共聚焦实验结果如图1所示。罗丹明标记的Caledonia/20/1999(H1N1)-M2-N-M-AH(45-62)和A/HongKong/97/98(H5N1)-M2-N-M-AH(45-62)多肽以及阳性对照TAT多肽在浓度为30μM时都可进入A549细胞。而罗丹明标记的Caledonia/20/1999(H1N1)-M2-N-M-AH(60-82)和A/HongKong/97/98(H5N1)-M2-N-M-AH(60-82)多肽在浓度为30μM时没有在A549细胞内检测到信号,即没有进入细胞。上述结果表明,流感病毒M2蛋白具有细胞穿透肽的功能,且其细胞穿透肽功能与氨基酸45-62这段片段相关。
实施例3:M2蛋白的细胞穿透肽功能片段的鉴定
为了确定M2蛋白的细胞穿透肽特性的优选作用肽段范围,基于A/chicken/Jilin/9/2004(H5N1)的M2蛋白序列(其与实施例2中使用的A/HongKong/97/98(H5N1)-M2高度保守)合成了表2中所示的多肽序列。根据M2蛋白的结构,对其由97个氨基酸组成的序列进行了分段合成。为了便于检测多肽的细胞进入,使用FITC在N端标记了多肽。
表2.FITC标记的基于M2蛋白的多肽序列
首先检测了FITC标记的Jilin-2004(H5N1)-M2-45-62多肽在不同浓度(100μM、30μM、10μM、3μM和1μM)下的细胞进入功能,其结果如图2所示。从该结果可见,Jilin-2004(H5N1)-M2-45-62多肽在测试的所有浓度下均能实现明显的A549细胞进入,且其进入效果远强于FITC标记的TAT多肽(阳性对照)。值得注意的是,TAT多肽在浓度为3μM时已经观察不到细胞进入,而FITC标记的Jilin-2004(H5N1)-M2-45-62多肽在低至1μM的浓度下细胞进入效果仍然十分明显。上述结果表明,基于流感病毒M2蛋白的Jilin-2004(H5N1)-M2-45-62多肽具有远强于阳性对照TAT的细胞穿透功能,使得其在低浓度在也能实现细胞进入。
检测了表2中的所有合成的FITC标记的多肽的细胞进入功能。使用的多 肽浓度为1μM、3μM和10μM,其流式细胞术结果分别如图3、图4和图5所示。其中,当使用浓度为1μM的多肽时,结果如图3所示,Jilin-2004(H5N1)-M2-45-62、Jilin-2004(H5N1)-M2-44-61和Jilin-2004(H5N1)-M2-47-64在温育1小时后进入A549细胞。当使用的多肽浓度为3μM或10μM时,结果分别如图4和图5所示,Jilin-2004(H5N1)-M2-45-62、Jilin-2004(H5N1)-M2-44-61、Jilin-2004(H5N1)-M2-47-64和Jilin-2004(H5N1)-M2-50-67在温育1小时后进入A549细胞。此外,还观察到除了Jilin-2004(H5N1)-M2-50-67外,其它三种多肽的细胞进入效果均强于作为阳性对照的TAT多肽。上述结果表明M2蛋白的细胞穿透肽功能与氨基酸44-67相关。
进一步检测了上述具有细胞穿透功能的四种多肽(Jilin-2004(H5N1)-M2-45-62、Jilin-2004(H5N1)-M2-44-61、Jilin-2004(H5N1)-M2-47-64和Jilin-2004(H5N1)-M2-50-67)在更低浓度下的细胞进入效果。使用0.03μM、0.1μM、0.3μM、1μM、3μM和10μM的浓度进行了检测,其结果如图6所示。该结果表明,当多肽在浓度降低至0.1μM和0.03μM时,多肽依然能够进入A549细胞,其中Jilin-2004(H5N1)-M2-44-61多肽是细胞进入效果甚至更优的多肽。
此外,当使用N端多肽Jilin-2004(H5N1)-M2-1-24,跨末端多肽Jilin-2004(H5N1)-M2-25-43时均没有检测到细胞进入信号。另外,M2蛋白的胞内肽段FITC-Jilin-2004(H5N1)-M2-53-70、FITC-Jilin-2004(H5N1)-M2-56-73、FITC-Jilin-2004(H5N1)-M2-59-76、FITC-Jilin-2004(H5N1)-M2-62-79和FITC-Jilin-2004(H5N1)-M2-65-82都没有显示出细胞进入性质。
为了验证M2相关多肽在其他细胞类型中是否也具有细胞穿透特性,使用HeLa细胞和MRC5细胞检测了Jilin-2004(H5N1)-M2-45-62、Jilin-2004(H5N1)-M2-44-61、Jilin-2004(H5N1)-M2-47-64和Jilin-2004(H5N1)-M2-50-67多肽的细胞穿透特性。其结果如图7所示。上述结果与使用A549细胞所得的结果一致,表明M2相关多肽的细胞穿透肽功能不限于特定的细胞,而具有一定的普遍性。
实施例4:优选多肽片段的鉴定
根据实施例2和实施例3中的结果可知,M2蛋白的细胞穿透肽特性主要集中于片段44-67。因此,进一步合成了上述片段的N端和C端的依次截短片段(表3)。通过检测表3中所示的多肽片段的细胞进入功能鉴定优选多肽片段。
表3:M2蛋白44-67序列的截短片段
使用流式细胞术检测了上述多肽的细胞进入特性。图8显示了从N端依次截短的多肽的数据。该结果表明,随着N端第44位氨基酸到第48位氨基酸的依次去除,多肽的细胞进入效果逐步减弱,其中当存在第44位氨基酸时细胞 进入效果更好。
图9和图10显示了从C端(第67位氨基酸)依次截短的多肽的流式细胞术检测结果,其中使用的多肽浓度为1μM,温育时间为1小时。该结果表明,Jilin-2004(H5N1)-M2-44-65和Jilin-2004(H5N1)-M2-44-61多肽相比于其它多肽具有甚至更好的进入效果。图11和图12显示了温育3小时的细胞进入结果,其与图9和图10中的结果一致,表明Jilin-2004(H5N1)-M2-44-65和Jilin-2004(H5N1)-M2-44-61多肽具有甚至更好的进入效果。还显示了JiLin-2004(H5N1)-M2-45-62多肽也有很好的细胞穿透肽效果。
为了证明M2相关多肽的细胞进入功能具有普遍性而不受到特定细胞类型的限制,在293T细胞、HUVEC细胞、HCT-116细胞、MKN-45细胞、MRC5细胞、U397细胞和ESF-1细胞这些类型各异的细胞中检测了M2蛋白第44-67位氨基酸的多肽及其截短片段的细胞穿透特性,其结果如图13至图25所示。其中,图13和图14显示了使用293T细胞的结果;图15和图16显示了使用HUVEC细胞的结果;图17和图18显示了使用HCT-116细胞的结果;图19和20显示了使用MKN-45细胞的结果;图21和图22显示了使用U937细胞的结果;图23显示了使用MRC5细胞的结果;并且图24和图25显示了使用ESF-1细胞的结果。在上述不同细胞中观察到了与A549细胞中一致的结果,即基于M2蛋白第44-67位氨基酸的多肽及其截短片段在不同细胞系中均具有细胞穿透肽的特性,且Jilin-2004(H5N1)-M2-44-65、Jilin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-45-62多肽具有甚至更好的进入效果。
实施例5:温育时间对多肽的细胞进入的影响
选择Jilin-2004(H5N1)-M2-44-61多肽,使用A549细胞研究了多肽与细胞的温育时间对多肽的细胞进入的影响。空白A549细胞,NC和TAT分别作为空白对照、阴性对照和阳性对照。首先检测了5min,10min,30min这三个时间点的细胞进入,其结果如图26所示。该结果表明,当使用1μM的Jilin-2004(H5N1)-M2-44-61多肽时,与A549细胞温育5分钟就能检测到其细胞进入,且随着温育时间的增加其细胞进入量也增加。
进一步将温育时间扩展至5分钟、10分钟、30分钟、1小时、2小时、3小时和6小时,并检测多肽的细胞进入效果。如图27中的结果所示,当使用1μM的NC阴性对照多肽时,在所有时间点均没有多肽进入。当使用1μM的阳性 对照TAT多肽,其在5分钟时开始进入细胞,且在1小时的时间点进入效果明显。对于1μM的Jilin-2004(H5N1)-M2-44-61多肽,其在5分钟时开始进入细胞,且在30分钟时已经有很强的进入效果,且在1小时、3小时和6小时三个时间点进入效果相差不大。值得注意的是,在相同的时间点,Jilin-2004(H5N1)-M2-44-61多肽的细胞进入效果远强于阳性对照TAT多肽。基于上述结果,选择多肽进入效果明显的最短时间,即1小时作为后续研究的温育时间。
实施例6:基于M2蛋白的细胞穿透肽与现有细胞穿透肽的细胞进入效果比较
合成了FITC标记已报道的17种细胞穿透肽(见表4)。使用A549细胞,在1μM的多肽浓度和1小时的温育时间的条件下比较了基于流感病毒M2蛋白的JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-65多肽与上述17种细胞穿透肽的细胞进入效果,如图28、图29和图30所示,JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-65多肽的细胞进入效果明显好于现有的细胞穿透肽。相似的,使用A549细胞,在3μM的多肽浓度和1小时的温育时间的条件下进行了比较。如图31、图32、图33中的结果所示,JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-65多肽的细胞进入效果明显好于现有的细胞穿透肽。
表4.现有细胞穿透肽序列
多肽 | 序列 |
HIV-1TAT48-60 | FITC-Ahx-GRKKRRQRRRPPQ |
HIV-1TAT49-57 | FITC-Ahx-RKKRRQRRR |
Penetratin,pAntp(43-58) | FITC-Ahx-RQIKIWFQNRRMKWKK |
DPV1047 | FITC-Ahx-VKRGLKLRHVRPRVTRMDV |
MPG | FITC-Ahx-GALFLGFLGAAGSTMGAWSQPKKKRKV |
Pep-1 | FITC-Ahx-KETWWETWWTEWSQPKKKRKV |
pVEC | FITC-Ahx-LLIILRRRIRKQAHAHSK |
ARF(1-22) | FITC-Ahx-MVRRFLVTLRIRRACGPPRVRV |
BPrPr(1-28) | FITC-Ahx-MVKSKIGSWILVLFVAMWSDVGLCKKRP |
MAP | FITC-Ahx-KLALKLALKALKAALKLA |
Transportan | FITC-Ahx-GWTLNSAGYLLGKINLKALAALAKKIL |
p28 | FITC-Ahx-LSTAADMQGVVTDGMASGLDKDYLKPDD |
VT5 | FITC-Ahx-DPKGDPKGVTVTVTVTVTGKGDPKPD |
Bac 7(Bac 1-24) | FITC-Ahx-RRIRPRPPRLPRPRPRPLPFPRPG |
C105Y | FITC-Ahx-CSIPPEVKFNKPFVYLI |
PFVYLI | FITC-Ahx-PFVYLI |
Pep-7 | FITC-Ahx-SDLWEMMMVSLACQY |
实施例7:对JiLin-2004(H5N1)-M2-44-56多肽的改造
进一步,对细胞进入效果明显的JiLin-2004(H5N1)-M2-44-56、JiLin-2004(H5N1)-M2-45-62和JiLin-2004(H5N1)-M2-44-65多肽进行改造。在多肽序列中突变一个或多个氨基酸残基,并检测氨基酸突变对其细胞穿透肽功能的影响。表5显示了JiLin-2004(H5N1)-M2-44-56及其突变的多肽序列。
表5.JiLin-2004(H5N1)-M2-44-56及其突变多肽序列
多肽 | 序列 |
FITC-JL-2004(H5N1)-M2-44-56 | FITC-Ahx-DRLFFKCIYRRLK(Seq ID No.35) |
FITC-JL-M2-44-56-mut1 | FITC-Ahx-RRLFFKCIYRRLK(Seq ID No.39) |
FITC-JL-M2-44-56-mut2 | FITC-Ahx-RRLFFRCIYRRLK(Seq ID No.40) |
FITC-JL-M2-44-56-mut3 | FITC-Ahx-RRLFFRRIYRRLK(Seq ID No.41) |
FITC-JL-M2-44-56-mut4 | FITC-Ahx-RRLFFRRIYRRLR(Seq ID No.42) |
FITC-JL-M2-44-56-mut5 | FITC-Ahx-DRIFFKCIYRRLK(Seq ID No.43) |
FITC-JL-M2-44-56-mut6 | FITC-Ahx-DRIFFKCIIRRLK(Seq ID No.44) |
FITC-JL-M2-44-56-mut7 | FITC-Ahx-DRIFFKCIIRRIK(Seq ID No.45) |
FITC-JL-M2-44-56-mut8 | FITC-Ahx-DRFFFKCIYRRLK(Seq ID No.46) |
FITC-JL-M2-44-56-mut9 | FITC-Ahx-DRFFFKCFYRRLK(Seq ID No.47) |
FITC-JL-M2-44-56-mut10 | FITC-Ahx-DRFFFKCFFRRLK(Seq ID No.48) |
FITC-JL-M2-44-56-mut11 | FITC-Ahx-DRFFFKCFFRRFK(Seq ID No.49) |
FITC-JL-M2-44-56-mut12 | FITC-Ahx-RRFFFRRFFRRFR(Seq ID No.50) |
通过流式细胞术检测12种JiLin-2004(H5N1)-M2-44-56突变体多肽序列与阳性对照TAT多肽和亲本JiLin-2004(H5N1)-M2-44-56之间的细胞穿透肽功能的比较。根据图34的结果所示,JiLin-2004(H5N1)-M2-44-56和其12条突变 体多肽序列均有细胞穿透肽的功能,且都强于阳性对照TAT。其中mut9突变体的细胞穿透肽功能相比于亲本多肽增强。
实施例8-1:对JiLin-2004(H5N1)-M2-45-62多肽的改造
合成了如表6中所示的基于JiLin-2004(H5N1)-M2-45-62多肽的突变多肽序列。
表6.JiLin-2004(H5N1)-M2-45-62及其突变多肽序列
通过流式细胞术检测13种JiLin-2004(H5N1)-M2-45-62突变体多肽序列与阳性对照TAT多肽和亲本JiLin-2004(H5N1)-M2-45-62之间的细胞穿透肽功能的比较。根据图35的结果所示,JiLin-2004(H5N1)-M2-45-62和其13条突变体多肽序列均有细胞穿透肽的功能,且都强于阳性对照TAT。值得注意的是,13种JiLin-2004(H5N1)-M2-45-62突变体多肽的细胞穿透肽功能均强于亲本 JiLin-2004(H5N1)-M2-45-62多肽。
通过激光共聚焦技术从影像学上检测JiLin-2004(H5N1)-M2-45-62与其突变体的细胞穿透肽功能。结果如图36所示,JiLin-2004(H5N1)-M2-45-62和其13条突变体多肽序列均有细胞穿透肽的功能。且突变体mut2、mut3、mut4、mut5、mut6和mut13的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-45-62多肽。
此外,合成了表7中所示的基于JiLin-2004(H5N1)-M2-45-62多肽的单位点突变多肽序列,并检测了其细胞穿透肽功能。
表7.JiLin-2004(H5N1)-M2-45-62及其单位点突变多肽序列
通过流式细胞术检测18种JiLin-2004(H5N1)-M2-45-62单位点突变体多肽序列与阳性对照TAT多肽和亲本JiLin-2004(H5N1)-M2-45-62之间的细胞穿透肽功能的比较。根据图37的结果所示,JiLin-2004(H5N1)-M2-45-62和其18条突变体多肽序列均有细胞穿透肽的功能,且都强于阳性对照TAT。值得注意的是,单位点突变序列mut46、mut51、mut52、mut53、mut54、mut58、mut59、mut60和mut62的细胞穿透肽功能均强于亲本JiLin-2004(H5N1)-M2-45-62多肽。
通过激光共聚焦技术从影像学上检测JiLin-2004(H5N1)-M2-45-62与其单位点突变体的细胞穿透肽功能。结果如图38所示,JiLin-2004(H5N1)-M2-45-62和其18条单位点突变体多肽序列均有细胞穿透肽的功能。且突变体mut45、mut48、mut50、mut51和mut61的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-45-62多肽。
实施例8-2:对JiLin-2004(H5N1)-M2-44-61多肽的改造
合成了如表8中所示的基于JiLin-2004(H5N1)-M2-44-61多肽的突变多肽序列。
表8.JiLin-2004(H5N1)-M2-44-61及其突变多肽序列
通过流式细胞术检测15种JiLin-2004(H5N1)-M2-44-61突变体多肽序列与阳性对照TAT多肽和亲本JiLin-2004(H5N1)-M2-44-61在A549细胞中的细胞穿透肽功能的比较。
如图59所示,当使用A549细胞和1μM的多肽浓度时,JiLin-2004(H5N1)-M2-44-61多肽及其15种突变体均有细胞穿透肽的功能,且都强于阳性对照TAT。其中,突变体mut13和mut14的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-44-61多肽。
实施例9:对JiLin-2004(H5N1)-M2-44-65多肽的改造
合成了如表9中所示的基于JiLin-2004(H5N1)-M2-45-65多肽的突变多肽序列。
表9.JiLin-2004(H5N1)-M2-44-65及其突变多肽序列
通过流式细胞术检测29种JiLin-2004(H5N1)-M2-44-65突变体多肽序列与阳性对照TAT多肽和亲本JiLin-2004(H5N1)-M2-44-65在A549细胞、293T细胞、MRC5细胞、U937细胞和HCT-116细胞中的细胞穿透肽功能的比较。
如图39所示,当使用A549细胞和1μM的多肽浓度时,JiLin-2004(H5N1)-M2-44-65多肽及其28种突变体均有细胞穿透肽的功能,且都强于阳性对照TAT。其中,突变体mut8、mut25和mut26的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-44-65多肽。此外,如图40所示,当使用3μM的多肽浓度时也获得了类似的结果,其中JiLin-2004(H5N1)-M2-44-65多肽及其28种突变体的细胞穿透肽功能均强于阳性对照TAT。其中突变体mut8、mut9、mut10、mut12、mut24、mut25和mut26的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-44-65多肽。
图41显示了使用293T细胞的检测结果。其中,JiLin-2004(H5N1)-M2-44-65多肽及其28种突变体均有细胞穿透肽的功能,且都强于阳性对照TAT。突变体mut8、mut9、mut12、mut17、mut25、mut26和mut27的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-44-65多肽。
图42显示了使用MRC5细胞的检测结果。其中,JiLin-2004(H5N1)-M2-44-65多肽及其28种突变体均有细胞穿透肽的功能,且都强于阳性对照TAT。突变体mut8、mut9、mut12和mut25的细胞穿透肽功能强于亲本JiLin-2004(H5N1)-M2-44-65多肽。
此外,对于在A549细胞、293T细胞和MRC5细胞中部分突变体多肽,在U937细胞和HCT-116细胞中验证了其细胞穿透肽效果,结果分别如图43和图44所示,其中图43显示了使用U937细胞的结果,图44显示了使用HCT-116细胞的结果。当使用1μM的多肽浓度时,上述突变体多肽均具有细胞穿透肽功能,且都强于阳性对照TAT。
实施例10:细胞穿透肽携带小RNA进入细胞
先前的研究表明,大多数细胞穿透肽可以携带生物活性分子例如小RNA进入细胞。为了验证本发明的细胞穿透肽的上述特性,使用本发明 JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-56多肽研究其携带小RNA进入细胞中的效果。使用FAM标记的小RNA在A549细胞中进行了实验。如图45所示,当使用30μM的多肽和300nM的小RNA时,上述三种多肽在1小时均能够携带小RNA进入细胞,且相比于相同浓度的阳性对照TAT,其携带小RNA的能力显著更强。值得注意的是,JiLin-2004(H5N1)-M2-44-61携带FAM标记的小RNA的能力强于转染试剂RNAiMax。
随后对上述每一种多肽进行了进一步验证。对于JiLin-2004(H5N1)-M2-45-62,使用FITC标记的多肽和Cy3标记的小RNA在A549细胞中进行实验。结果如图46中所示,当使用10μM的多肽和200nM的小RNA时,JiLin-2004(H5N1)-M2-45-62在1小时就能够携带小RNA进入细胞,且相比于相同浓度的阳性对照TAT,其携带小RNA的能力显著更强。
对于JiLin-2004(H5N1)-M2-44-56多肽,当将30μM的多肽和100nM的Cy3标记的小RNA混合并与A549细胞温育时,如图47中的结果所示,在1小时多肽就能够携带小RNA进入细胞,且其效果强于转染试剂RNAiMax。
此外,检测了JiLin-2004(H5N1)-M2-44-61、JiLin-2004(H5N1)-M2-44-65多肽及其突变体mut8(JiLin-2004(H5N1)-M2-44-65mut8)携带小RNA的能力。当将10μM的多肽和200nM的Cy3标记的小RNA混合并与A549细胞温育时,如图48中的结果所示,在1小时多肽就能够携带小RNA进入细胞,且其效果强于转染试剂RNAiMax。其中,JiLin-2004(H5N1)-M2-44-65mut8突变体多肽携带小RNA进入细胞的能力甚至更强。10μM的多肽和200nM的Cy3标记的小RNA混合并与A549细胞温育时,如图60所示,超高分辨显微镜下观察JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-65多肽可以携带Cy3标记的小RNA进入A549细胞,并且效果明显强于转染试剂RNAiMax,也强于TAT。
上述实验均通过激光共聚焦实验检测多肽携带小RNA的进入,我们又通过实时定量qPCR的方法,通过检测多肽携带的小RNA在细胞内的相对表达丰度确定多肽对小RNA的携带能力。如图61所示,根据流感病毒M2的不同肽段的细胞穿透功能,分别检测对照组空白细胞,多肽溶剂与100nM的PGY-sRNA-26的混合物以及10μM的多肽JiLin-2004(H5N1)-M2-1-24、JiLin-2004(H5N1)-M2-25-43、JiLin-2004(H5N1)-M2-45-62、 JiLin-2004(H5N1)-M2-60-82以及对照细胞穿透肽TAT分别和100nM的PGY-sRNA-26混合并与A549细胞温育1小时后,只有多肽JiLin-2004(H5N1)-M2-45-62有携带小RNA进入细胞的能力。在此实验条件下,对照细胞穿透肽TAT携带小RNA的能力很弱。
图62显示,JiLin-2004(H5N1)-M2-45-62及其单位点突变多肽序列全部有携带小RNA进入细胞的能力,且野生型JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-45-62 mut45、JiLin-2004(H5N1)-M2-45-62 mut46、JiLin-2004(H5N1)-M2-45-62 mut47、JiLin-2004(H5N1)-M2-45-62 mut48、JiLin-2004(H5N1)-M2-45-62 mut49、JiLin-2004(H5N1)-M2-45-62 mut51、JiLin-2004(H5N1)-M2-45-62 mut52、JiLin-2004(H5N1)-M2-45-62 mut53、JiLin-2004(H5N1)-M2-45-62 mut55、JiLin-2004(H5N1)-M2-45-62 mut56、JiLin-2004(H5N1)-M2-45-62 mut59和JiLin-2004(H5N1)-M2-45-62 mut61携带小RNA进入细胞的能力均强于转染试剂RNAiMax组。
图63显示,JiLin-2004(H5N1)-M2-45-62及其突变多肽序列全部有携带小RNA进入细胞的能力,且野生型JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-45-62 mut1、JiLin-2004(H5N1)-M2-45-62 mut5、JiLin-2004(H5N1)-M2-45-62 mut8和JiLin-2004(H5N1)-M2-45-62 mut23携带小RNA进入细胞的能力均强于转染试剂RNAiMax组。
图64显示,JiLin-2004(H5N1)-M2-44-61及其突变多肽序列全部有携带小RNA进入细胞的能力,且野生型JiLin-2004(H5N1)-M2-44-61、JiLin-2004(H5N1)-M2-44-61 mut1、JiLin-2004(H5N1)-M2-44-61 mut4、JiLin-2004(H5N1)-M2-44-61 mut6、JiLin-2004(H5N1)-M2-44-61 mut8、JiLin-2004(H5N1)-M2-44-61 mut10、JiLin-2004(H5N1)-M2-44-61 mut12、JiLin-2004(H5N1)-M2-44-61 mut14、JiLin-2004(H5N1)-M2-44-61 mut16和JiLin-2004(H5N1)-M2-44-61 mut17携带小RNA进入细胞的能力均强于转染试剂RNAiMax组。
图65显示,JiLin-2004(H5N1)-M2-44-65及其突变多肽序列全部有携带小RNA进入细胞的能力,且野生型JiLin-2004(H5N1)-M2-44-65、JiLin-2004(H5N1)-M2-44-65 mut1、JiLin-2004(H5N1)-M2-44-65 mut2、JiLin-2004(H5N1)-M2-44-65 mut5、JiLin-2004(H5N1)-M2-44-65 mut6、JiLin-2004(H5N1)-M2-44-65 mut7、JiLin-2004(H5N1)-M2-44-65 mut11、 JiLin-2004(H5N1)-M2-44-65 mut15、JiLin-2004(H5N1)-M2-44-65 mut17、JiLin-2004(H5N1)-M2-44-65 mut23、JiLin-2004(H5N1)-M2-44-65 mut26和JiLin-2004(H5N1)-M2-44-65 mut27携带小RNA进入细胞的能力均强于转染试剂RNAiMax组。
如上所有实验结果总结出,流感病毒来源的有细胞穿透肽功能的多肽均能够携带小RNA进入细胞,并且携带能力均强于对照细胞穿透肽TAT。多数细胞穿透肽携带小RNA进入细胞的能力明显强于目前公认的转染试剂RNAimax。
实施例11-1:细胞穿透肽携带小RNA进入并发挥其功能
在实施例9的基础上进一步验证了本发明的细胞穿透肽携带小RNA进入细胞后是否能实现小RNA的正常功能。先前的实验已经证明PGY-dsRNA-6能够靶向结合RELA基因的3‘-UTR区域并实现抑制其表达的功能。使用JiLin-2004(H5N1)-M2-45-62,JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-56和293T细胞进行了实验。将浓度为30μM的细胞穿透肽与300nM的PGY-dsRNA-6混合后与细胞温育,并检测细胞中的荧光素酶报告基因。从图49所示的结果可见,JiLin-2004(H5N1)-M2-45-62、JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-44-56均可将PGY-dsRNA-6带入细胞并实现其功能,并且携带PGY-dsRNA-6的能力强于阳性对照TAT。其中,JiLin-2004(H5N1)-M2-44-61的细胞穿透肽效果接近转染试剂RNAiMax。
同样,HJT-sRNA-m7能够靶向结合COLLAGEN3A1基因的3‘-UTR区域并实现抑制其表达的功能。使用JiLin-2004(H5N1)-M2-44-61在HEK293T细胞中进行了实验。将浓度为30μM的细胞穿透肽与300nM的HJT-sRNA-m7混合后与细胞温育,并检测细胞中的荧光素酶报告基因。从图66所示的结果可见,JiLin-2004(H5N1)-M2-44-61可将HJT-sRNA-m7带入细胞并实现其功能,并且携带HJT-sRNA-m7的能力强于阳性对照TAT。其中,JiLin-2004(H5N1)-M2-44-61的细胞穿透肽效果接近转染试剂RNAiMax。
PGY-dsRNA-6可以靶向结合RELA基因的3‘-UTR区发挥其抗炎功能,图67和图68显示,LPS诱导的THP-1的炎症模型中,JiLin-2004(H5N1)-M2-44-61携带的PGY-sRNA-6有效的降低THP-1细胞上清液中IL-1β和TNF-α的表达。 故JiLin-2004(H5N1)-M2-44-61可携带小RNA进入细胞并发挥其小RNA的功能。
HJT-sRNA-m7可以靶向结合COLLAGEN3A1基因的3‘-UTR区发挥其纤维化的功能,图69显示,TGF-beta1诱导的MRC-5细胞纤维化模型中,JiLin-2004(H5N1)-M2-44-61携带的HJT-sRNA-m7有效的降低MRC-5细胞中Fibronectin的表达。再次证明JiLin-2004(H5N1)-M2-44-61可携带小RNA进入细胞并发挥其小RNA的功能。
实施例11-2:细胞穿透肽携带质粒进入并发挥其表达功能
本发明证实了流感病毒M2来源的细胞穿透肽JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-45-62可携带小RNA进入细胞,并发挥其小RNA本身的功能。我们尝试用携带可以在细胞核内表达GFP蛋白的质粒,图70显示,JiLin-2004(H5N1)-M2-44-61和JiLin-2004(H5N1)-M2-45-62均可将NS1-GFP质粒携带至HEK293细胞中,并在细胞核内表达GFP蛋白。而对照TAT组几乎没有GFP荧光蛋白的表达。
实施例12:细胞穿透肽携带蛋白质进入细胞
先前的研究表明,一些细胞穿透肽可以携带蛋白质进入细胞。为了验证本发明的细胞穿透肽的上述特性,使用JiLin-2004(H5N1)-M2-44-56验证其携带β-半乳糖苷酶蛋白进入A549细胞的能力。将50μM的JiLin-2004(H5N1)-M2-44-56多肽与50nM的β-半乳糖苷酶混合30分钟,随后将该混合物与A549细胞温育1小时,并通过β-半乳糖苷酶显色实验检测β-半乳糖苷酶蛋白的细胞进入,其结果如图50所示。该结果表明,本发明的细胞穿透肽能够携带β-半乳糖苷酶蛋白进入细胞,且与相同浓度的阳性对照TAT相比,其携带蛋白质进入细胞的能力显著更强。
此外,使用EGFP蛋白进行了进一步验证。如图51所示,当将3μM的JiLin-2004(H5N1)-M2-44-56多肽与1μM的GFP蛋白混合并与A549细胞温育1小时,观察到JiLin-2004(H5N1)-M2-44-56多肽携带GFP蛋白进入细胞,且其效果强于阳性对照TAT。
实施例13:细胞穿透肽与EGFP的融合蛋白具有细胞穿透肽的功能
进一步使用本发明的细胞穿透肽研究了当其与蛋白质进行融合时该融合蛋白是否仍然具有细胞穿透肽的功能。图52显示了使用不同浓度(10nM、30nM、100nM和300nM)的EGFP-JiLin-2004(H5N1)-M2-45-62融合蛋白以及EGFP-TAT和EGFP-JiLin-2004(H5N1)-M2-71-85作为对照的实验,其中将融合蛋白与A549细胞温育1小时。图53、图54和图55分别显示了使用10nM、30nM以及100nM的EGFP-JiLin-2004(H5N1)-M2-45-62和EGFP-JiLin-2004(H5N1)-M2-44-61融合蛋白的实验结果,其中将融合蛋白与A549细胞温育1小时。
从这些图中的结果可见,EGFP-JiLin-2004(H5N1)-M2-45-62和EGFP-JiLin-2004(H5N1)-M2-44-61融合蛋白在上述浓度下均能进入A549细胞,而EGFP-TAT融合蛋白仅在高浓度(100nM)时才观察到细胞进入。图56、图57和图58显示了相关的激光共聚焦实验结果,其中,图56显示了使用10nM细胞穿透肽的结果,图57显示了使用30nM细胞穿透肽的结果,而图57显示了使用100nM的结果,其与图53至图55的流式细胞术结果一致。上述结果表明,本发明的细胞穿透肽当与其它蛋白质进行融合时,能够保持其细胞穿透肽能力,并使得融合蛋白以高效率进入细胞。
实施例14:细胞穿透肽与EGFP的融合蛋白可直接进入小鼠器官
实施例13证明了EGFP-JiLin-2004(H5N1)-M2-45-62和EGFP-JiLin-2004(H5N1)-M2-44-61融合蛋白仍具有穿透肽功能,并可以高效的进入细胞。图71显示了EGFP-JiLin-2004(H5N1)-M2-44-61在小鼠腹腔注射1小时后均可以进入小鼠脑、肾脏、肝脏和脾脏组织,其进入效果强于同等实验条件下的细胞穿透肽对照TAT。
实施例15:细胞穿透肽可携带小RNA进入小鼠器官
实施例10中,通过激光共聚焦检测和实时定量qPCR方法检测了流感病毒M2蛋白来源的细胞穿透肽和对照细胞穿透肽携带小RNA进入细胞的功能,挑选在细胞实验中携带小RNA能力最强的JiLin-2004(H5N1)-M2-44-61进行小鼠实验验证。图72和图73显示,JiLin-2004(H5N1)-M2-44-61可有效的将小RNA(PGY-sRNA-23和PGY-sRNA-26)递送到小鼠器官中,其中小鼠的心 脏、肝脏、脾脏、肺、肾脏、胃、小肠、胸腺在内的8种器官或组织均检测到小RNA的表达。JiLin-2004(H5N1)-M2-44-61在小鼠上递送小RNA的能力明显强于TAT。
实施例16:细胞穿透肽可携带小RNA进入小鼠器官并发挥功能
PGY-dsRNA-6可以靶向结合RELA基因的3‘-UTR区发挥其抗炎功能,在poly(I:C)诱导的小鼠急性肺损伤模型中,如图74显示JiLin-2004(H5N1)-M2-44-61携带的PGY-sRNA-6可以有效的降低小鼠肺泡灌洗液中的IL-6和TNF-α的表达,减轻小鼠急性肺损伤。而细胞穿透肽对照TAT携带的PGY-sRNA-6只可以轻微降低小鼠肺泡灌洗液中IL-6的表达,对TNF-α的表达无降低效果。JiLin-2004(H5N1)-M2-44-61在小鼠器官中携带小RNA的能力强于TAT,且小RNA可以更好的发挥其功能。
实施例17:细胞穿透肽可携带小RNAantagomir进入小鼠器官并发挥功能
已有文献报道,miR1246 antagomir可以有效降低LPS引起的小鼠急性肺损伤,我们通过实验验证JiLin-2004(H5N1)-M2-44-61是否可以携带miR1246 antagomir进入小鼠器官,更好的发挥其抗急性肺损伤的功能。图75显示,JiLin-2004(H5N1)-M2-44-61可以使得miR1246 antagomir更好的进入小鼠肺组织,而对照组TAT几乎对miR1246 antagomir进入肺组织无促进作用。图76所示,LPS刺激小鼠的急性肺损伤模型中,JiLin-2004(H5N1)-M2-44-61携带miR1246 antagomir有最好的防止肺损伤的作用。故JiLin-2004(H5N1)-M2-44-61可帮助小RNA antagomir更好的进入小鼠体内,并发挥其作用。
实施例18:细胞穿透肽可携带小分子药物进入小鼠器官并发挥功能
已有文献报道,小分子药物silybin可以有效降低LPS引起的小鼠急性肺损伤,我们通过实验验证JiLin-2004(H5N1)-M2-44-61是否可以携带小分子药物silybin进入小鼠器官并更好的发挥其抗急性肺损伤的功能。图77所示,LPS刺激小鼠的急性肺损伤模型中,JiLin-2004(H5N1)-M2-44-61本身无防止肺损伤的作用,小分子化合物silybin在此剂量下有防止肺损伤的趋势,而JiLin-2004(H5N1)-M2-44-61携带小分子药物silybin有最好的防止肺损伤的作用。故JiLin-2004(H5N1)-M2-44-61可帮助小分子化合物更好的进入小鼠体 内,并发挥其作用。
Claims (86)
- 一种多肽,其具有选自以下的氨基酸序列:a.包含流感病毒M2蛋白第44-67位氨基酸的序列或其片段的氨基酸序列;b.包含在流感病毒M2蛋白第44-67位氨基酸的序列或其片段中进行了一个或多个氨基酸残基的修饰的氨基酸序列;和c.包含与流感病毒M2蛋白第44-67位氨基酸的序列或其片段具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述片段长度为至少8个氨基酸,且其中所述多肽具有细胞穿透肽的功能。
- 权利要求1所述的多肽,其中所述片段长度为至少10个氨基酸。
- 权利要求2所述的多肽,其中所述片段长度为至少13个氨基酸。
- 权利要求1-3任一项所述的多肽,其中所述片段包含M2蛋白第44-48氨基酸或45-48位氨基酸。
- 权利要求4所述的多肽,其中所述片段包含流感病毒M2蛋白第44-65位氨基酸、第44-61位氨基酸、第45-62位氨基酸或第44-56位氨基酸。
- 权利要求1-5中任一项中所述的多肽,其中所述一个或多个氨基酸残基的修饰是一个或多个氨基酸残基的取代、缺失或插入。
- 权利要求6所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-10个氨基酸残基的取代、缺失或插入。
- 权利要求6所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-5,例如4、3或2个氨基酸残基的取代、缺失或插入。
- 权利要求6-8中任一项所述的多肽,其中所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸,所述插入是疏水性氨基酸或带正电荷的氨基酸的插入,且所述缺失是亲水性氨基酸的缺失;其中疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,更优选是I;带正电荷的氨基酸优选是K、R或H,更优选K或R;亲水性氨基酸优选是D、E、Q、S或T。
- 权利要求9所述的多肽,其中所述疏水性氨基酸或带正电荷的氨基酸 选自异亮氨酸(I)、苯丙氨酸(F)和精氨酸(R)残基。
- 权利要求1-10中任一项所述的多肽,其中所述流感病毒是H1N1、H5N1、H5N6或H7N9型流感病毒。
- 权利要求1-10中任一项所述的多肽,其具有下式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24的氨基酸序列;其中X1是D、R、L、I或不存在;X2是R、I或S;X3是L、I、F、A、R或K;X4是F、R或I;X5是F、R或I;X6是K、R或I;X7是C、I或R;X8是A、I、F、K或R;X9是Y、I、F、K或R;X10是R或S;X11是R、S或不存在;X12是L、I、F、R或K或不存在;X13是K、R、T或不存在;X14是Y、F、R或K,或不存在;X15是G、R、K或不存在;X16是R、L、F或A或不存在;X17是I、K、R或T或不存在;X18是R、I、T或不存在;X19是G、R、K或不存在;X20是P或不存在;X21是S、K或不存在;X22是T、V或不存在;X23是E或不存在;X24是G或不存在;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、 至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述多肽具有所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
- 一种多肽,其具有选自以下的氨基酸序列:a.包含DRLFFKCIYRRLK的氨基酸序列;b.包含在DRLFFKCIYRRLK的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,和c.包含与DRLFFKCIYRRLK具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述多肽具有细胞穿透肽的功能。
- 权利要求13所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-5个,例如4、3或2个氨基酸的取代、缺失或插入。
- 权利要求13或14所述的多肽,其中所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸,所述插入是疏水性氨基酸或带正电荷的氨基酸的插入,且所述缺失是亲水性氨基酸的缺失;其中疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,优选是I;带正电荷的氨基酸优选是K、R或H,更优选K或R;亲水性氨基酸优选是D、E、Q、S或T。
- 权利要求15所述的多肽,其中所述疏水性氨基酸或带正电荷的氨基酸选自I、F和R残基。
- 权利要求13-16中任一项的多肽,其具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13的氨基酸序列;其中X1是D或R;X2是R;X3是L、I、或F;X4是F;X5是F;X6是K或R;X7是C或R;X8是I或F;X9是Y、I或F;X10是R;X11是R;X12是L、I或F;且X13是K或R;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
- 权利要求13所述的多肽,其中所述多肽具有选自下组的氨基酸序列:RRLFFKCIYRRLK、RRLFFRCIYRRLK、RRLFFRRIYRRLK、RRLFFRRIYRRLR、DRIFFKCIYRRLK、DRIFFKCIIRRLK、DRIFFKCIIRRIK、DRFFFKCIYRRLK、DRFFFKCFYRRLK、DRFFFKCFFRRLK、DRFFFKCFFRRFK和RRFFFRRFFRRFR。
- 一种多肽,其具有选自以下的氨基酸序列:a.包含RLFFKCIYRRLKYGLKRG的氨基酸序列;b.包含在RLFFKCIYRRLKYGLKRG的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,和c.包含与RLFFKCIYRRLKYGLKRG具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述多肽具有细胞穿透肽的功能。
- 权利要求19所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-6个,例如5、4、3或2个氨基酸残基的取代、缺失或插入。
- 权利要求19或20所述的多肽,其中所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸,所述插入是疏水性氨基酸或带正电荷的氨基酸的插入,且所述缺失是亲水性氨基酸的缺失;其中疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,优选是I;亲水性氨基酸优选是D、E、Q、S或T;带正电荷的氨基酸优选是K、R或H,更优选K或R;亲水性氨基酸优选是D、E、Q、S或T。
- 权利要求21所述的多肽,其中所述疏水性氨基酸或带正电荷的氨基 酸选自I、F和R残基。
- 权利要求19-22中任一项所述的多肽,其具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18的氨基酸序列;其中X1是R或S;X2是A、L或F;X3是F或I;X4是F或I;X5是R或K;X6是I、C或R;X7是A、I或F;X8是K、Y或F;X9是R或S;X10是R或S;X11是A、L或F;X12是K、R或T;X13是Y、F或K;X14是G、R或K;X15是L、F或A;X16是K、R或T;X17是R或T;且X18是G、R或K;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
- 权利要求19所述的多肽,其中所述多肽具有选自下组的氨基酸序列:RLFFRCIYRRLKYGLKRG、RLFFRRIYRRLKYGLKRG、RLFFRRIYRRLRYGLKRG、RLFFRRIYRRLRYRLKRG、RLFFRRIYRRLRYRLRRG、RLFFRRIYRRLRYRLRRR、RFFFKCIYRRLKYGLKRG、RFFFKCFYRRLKYGLKRG、 RFFFKCFFRRLKYGLKRG、RFFFKCFFRRFKYGLKRG、RFFFKCFFRRFKFGLKRG、RFFFKCFFRRFKFGFKRG和RFFFRRFFRRFRFRFRRR。
- 权利要求19所述的多肽,其中所述多肽具有选自下组的氨基酸序列:SLFFKCIYRRLKYGLKRG、RAFFKCIYRRLKYGLKRG、RLIFKCIYRRLKYGLKRG、RLFIKCIYRRLKYGLKRG、RLFFKIIYRRLKYGLKRG、RLFFKCAYRRLKYGLKRG、RLFFKCIKRRLKYGLKRG、RLFFKCIYSRLKYGLKRG、RLFFKCIYRSLKYGLKRG、SLFFKCIYRRLKYGLKRG、RLFFKCIYRRAKYGLKRG、RLFFKCIYRRLTYGLKRG、RLFFKCIYRRLKKGLKRG、RLFFKCIYRRLKYKLKRG、RLFFKCIYRRLKYGAKRG、RLFFKCIYRRLKYGLTRG、RLFFKCIYRRLKYGLKTG和RLFFKCIYRRLKYGLKRK。
- 一种多肽,其具有选自以下的氨基酸序列:a.包含DRLFFKCIYRRLKYGLKRGPST的氨基酸序列;和b.包含在DRLFFKCIYRRLKYGLKRGPST的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,c.包含与DRLFFKCIYRRLKYGLKRGPST具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述多肽具有细胞穿透肽的功能。
- 权利要求26所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-10个或1-6个,例如5、4、3或2个氨基酸残基的取代、缺失或插入。
- 权利要求26或27所述的多肽,其中所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸,所述插入是疏水性氨基酸或带正电荷的氨基酸的插入,且所述缺失是亲水性氨基酸的缺失;其中疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,优选是I;带正电荷的氨基酸优选是K、R或H,更优选K或R;亲水性氨基酸优选是D、E、Q、S或T。
- 权利要求28所述的多肽,其中所述疏水性氨基酸或带正电荷的氨基 酸选自I、F和R残基。
- 权利要求26-29中任一项所述的多肽,其具有X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22的氨基酸序列;其中X1是D或R;X2是R;X3是L或F;X4是F;X5是F;X6是K或R;X7是C或R;X8是I或F;X9是Y或F;X10是R;X11是R;X12是L或F;X13是K或R;X14是Y或F;X15是G或R;X16是L;X17是K或R;X18是R;X19是G、或R或K;X20是P;X21是S或K;且X22是T或V;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
- 权利要求26所述的多肽,其中所述多肽具有选自下组的氨基酸序列: DRFFFKCIYRRLKYGLKRGPST、DRFFFKCIYRRLKYGLKRRPST、DRFFFKCIYRRLKFGLKRGPST、DRFFFKCIFRRLKYGLKRGPST、DRFFFKCIFRRLKFGLKRGPST、DRFFFKCFFRRFKFGLKRGPST、RRFFFKCFFRRFKFGLKRGPST、DRFFFKRIYRRLKYRLKRRPST、DRFFFKRIYRRLKYRLKRRPKV、DRFFFKRIFRRLKYRLKRRPST、DRFFFKRIFRRLKFRLKRRPST、DRFFFKRIFRRFKFRLKRRPST、RRFFFKRIFRRFKFRLKRRPST、RRFFFKRIFRRFKFRLKRRPKV、RRLFFKCIYRRLKYGLKRGPST、RRLFFKCIYRRLKYGLKRGPKV、RRFFFKCIYRRLKYGLKRGPST、RRLFFKCIYRRLKYGLKRRPST、RRLFFKCIYRRLKYGLKRKPST、RRLFFRRIYRRLKYGLKRGPST、RRLFFRRIYRRLRYRLRRRPST、DRLFFKRIYRRLKYGLKRGPST、DRLFFRRIYRRLKYGLKRGPST、DRLFFRRIYRRLRYRLRRRPST、DRLFFKCIYRRLKYGLKRRPST、DRLFFKCIYRRLKYRLKRRPST、DRLFFKRIYRRLKYRLKRRPST、RRLFFKRIYRRLKYRLKRRPST、DRLFFKCIYRRLKYGLKRGPKV。
- 一种多肽,其具有选自以下的氨基酸序列:a.包含DRLFFKCIYRRLKYGLKR的氨基酸序列;和b.包含在DRLFFKCIYRRLKYGLKR的氨基酸序列中进行了一个或多个氨基酸残基的取代、缺失或插入的氨基酸序列,c.包含与DRLFFKCIYRRLKYGLKR具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列,其中所述多肽具有细胞穿透肽的功能。
- 权利要求32所述的多肽,其中所述一个或多个氨基酸残基的取代、缺失或插入是1-10个或1-6个,例如5、4、3或2个氨基酸残基的取代、缺失或插入。
- 权利要求32或33所述的多肽,其中所述取代的至少一个是取代为疏水性氨基酸或带正电荷的氨基酸,所述插入是疏水性氨基酸或带正电荷的氨基酸的插入,且所述缺失是亲水性氨基酸的缺失;其中疏水性氨基酸优选是C、A、F、I、L、M、P、V、W、M或Y,优选是I;带正电荷的氨基酸优选是K、R或H,更优选K或R;亲水性氨基酸优选是D、E、Q、S或T。
- 权利要求32-34中任一项的多肽,其具有式X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18的氨基酸序列;其中X1是D、R、L或I;X2是R或I;X3是L、R或K;X4是F或R;X5是F或R;X6是K或I;X7是C、R或I;X8是I、K或R;X9是Y、K或R;X10是R;X11是R;X12是L、R或K;X13是K;X14是Y或R;X15是G;X16是L或R;X17是K或I;且X18是R或I;或者所述多肽具有与所述氨基酸序列具有至少60%、至少70%、至少80%、至少85%、至少90%、至少95%或100%序列同一性的氨基酸序列;或所述氨基酸序列中进行了一个或多个氨基酸残基的缺失、插入或取代的氨基酸序列。
- 权利要求32所述的多肽,其中所述多肽具有选自下组的氨基酸序列:RRLFFKCIYRRLKYGLKR、LRLFFKCIYRRLKYGLKR、DILFFKCIYRRLKYGLKR、DRRFFKCIYRRLKYGLKR、DRLRRKCIYRRLKYGLKR、DRLFFICIYRRLKYGLKR、DRLFFKRIYRRLKYGLKR、DRLFFKIIYRRLKYGLKR、 DRLFFKCKKRRLKYGLKR、DRRRRKCRRRRRKYGRKR、DRLFFKCIYRRRKRGLKR、DRLFFKCIYRRLKYGRKR、DRKRRKCKYRRKKYGRKR、DRLFFKCIYRRLKYGLII、IILFFKCIYRRLKYGLKR。
- 一种缀合物或组合物,其中所述缀合物包含权利要求1-36中任一项所述的多肽和与所述多肽缀合的部分,所述组合物包含权利要求1-36中任一项所述的多肽和与所述多肽非共价连接的部分;其中所述部分是治疗部分、可检测部分或美容用部分,选自蛋白质、肽、核酸、抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质和酶;优选地,所述治疗部分选自:13-顺-视黄酸、2-氨基-6-巯基嘌呤、2-CdA、2-氯脱氧腺苷、5-氟尿嘧啶、6-硫鸟嘌呤、6-巯基嘌呤、异维生素A酸(Accutane)、放线菌素D、阿霉素、Adrucil、安归宁、Ala-Cort、阿地白介素、阿仑单抗、阿里维A酸(Alitretinoin)、Alkaban-AQ、爱克兰、全反式维甲酸、α干扰素、六甲蜜胺、氨甲蝶呤、氨磷汀、鲁米特、阿那格雷、安得乐、阿那曲唑、阿糖胞苷、安然爱斯普、阿可达、瑞宁得、阿诺、三氧化二砷、天冬酰胺酶、ATRA、阿瓦斯汀、BCG、BCNU、贝伐单抗、蓓萨罗丁、比卡鲁胺、BiCNU、Blenoxane、博来霉素、硼替佐米、白消安、Busulfex、C225、亚叶酸钙、Campath、坎普土沙、喜树碱-11、卡培他滨、Carac、卡铂、卡莫司汀、卡莫司汀片、Casodex、CCNU、CDDP、CeeNU、正定霉素、西妥昔单抗、苯丁酸氮芥、顺铂、亚叶酸因子、克拉屈滨、可的松、可美净、CPT-11、环磷酰胺、Cytadren、阿糖胞苷、阿糖胞苷脂质体、Cytosar-U、Cytoxan、达卡巴嗪(Dacarbazine)、放线菌素、达泊霉素α、道诺霉素、柔红霉素、盐酸柔红霉素、柔红霉素脂质体、DaunoXome、Decadron、Delta-Cortef、强的松、地尼白介素-毒素连接物、DepoCyt、地塞米松、醋酸地塞米松、地塞米松磷酸钠、Dexasone、右雷佐生、DHAD、DIC、Diodex、多西他赛、Doxil、阿霉素、多柔比星脂质体、Droxia、DTIC、DTIC-Dome、杜拉隆、Efudex、艾里咖、艾伦斯、乐沙定、爱施巴、Emcyt、表阿霉素、α依伯汀、爱必妥、欧文氏菌L-天门冬酰胺酶、雌莫司汀、Ethyol、凡毕复、依托泊苷、依托泊苷磷酸盐、Eulexin、易维特、依西美坦、法乐通、法洛德、复乳纳、非格司亭、氟尿苷、福达华、氟达拉滨、Fluoroplex、氟尿嘧啶、氟甲睾酮、氟他胺、 氟胺酸、FUDR、氟维司群、G-CSF、吉非替尼、吉西他滨、吉妥单抗、Gemzar、格列卫、醋酸亮丙瑞林、储库型醋酸亮丙瑞林、Matulane、Maxidex、氮芥、-盐酸氮芥、美卓龙、甲泼尼龙、Megace、甲地孕酮、醋酸甲地孕酮、美法仑、巯嘌呤、美司那、Mesnex、氨甲喋呤、甲氨蝶呤钠、甲泼尼龙、Mylocel、来曲唑、Neosar、Neulasta、纽密伽、优保津、Nilandron、尼鲁米特、氮芥、Novaldex、诺肖林、奥曲肽、醋酸奥曲肽、Oncospar、长春新碱、Ontak、Onxal、欧普瑞维尔金、Orapred、Orasone、奥沙利铂、紫杉醇、帕米膦酸、Panretin、伯尔定、Pediapred、PEG干扰素、培门冬酶、培非司亭、PEG-INTRON、PEG-L-天冬酰胺酶、苯丙氨酸氮芥、Platinol、Platinol-AQ、泼尼松龙、泼尼松、Prelone、丙卡巴肼、PROCRIT、普留净、具有卡莫司汀植入物的Prolifeprospan20、Purinethol、雷洛昔芬、氨克生、美罗华、利妥昔单抗、Roveron-A、Rubex、盐酸鲁贝多霉素、善得定、善得定LAR、沙格莫丁、Solu-Cortef、Solu-Medrol、STI-571、链尿霉素、他莫昔芬、塔格雷汀、他克唑、泰索帝、Temodar、替莫唑胺、替尼泊苷、TESPA、沙利度胺、撒利多迈、TheraCys、硫鸟嘌呤、硫鸟嘌呤药片、硫代磷酰胺、Thioplex、塞替派、TICE、Toposar、拓扑替康、托瑞米芬、曲妥珠单抗、维甲酸、Trexall、Trisenox、TSPA、VCR、Velban、万珂、凡毕士、凡善能、Viadur、长春碱、硫酸长春碱、Vincasar Pfs、长春新碱、长春瑞滨、酒石酸长春瑞滨、VLB、VP-16、威猛、希罗达、Zanosar、泽娃灵、Zinecard、诺雷德、唑来膦酸、择泰、格立得晶片、Glivec、GM-CSF、戈舍瑞林、粒细胞集落刺激因子、氟甲睾酮、赫赛汀、Hexadrol、Hexalen、六甲蜜胺、HMM、和美新、Hydrea、乙酸氢化可通、氢化可的松、氢化可的松磷酸钠、氢化可的松琥珀酸钠、磷酸氢化可的松、羟基脲、异贝莫单抗、替坦异贝莫单抗、埃得霉素、伊达比星、Ifex、IFN-化、异环磷酰胺、IL2、IL-11、甲磺酸伊马替尼、咪唑羧酰胺、干扰素α、PEG缀合的干扰素α扰素α、白细胞介素2、白细胞介素-11、甲酰四氢叶酸、留可然、Leukine、亮丙瑞林、闻克斯丁、乐司他丁、脂质体Ara-C、Liquid Pred、洛莫司汀、L-PAM、L-沙可来新、Meticorten、丝裂霉素、丝裂霉素-C、米托蒽醌、M-泼尼松、MTC、MTX、氮芥、密吐霉素、Myleran、Iressa、爱莱诺迪肯、Isotretinoin、Kidrolase、Lanacort、L-门冬酰胺酶和LCR、更昔洛韦、叠氮胸苷(AZT)、拉米夫定(3TC)、阿卡泊隆、乙酰砜钠、阿莱霉素、阿莱西定、氮卓西林、匹美西林、阿米环素、氨氟沙星、甲磺酸氨氟沙星、阿 米卡星、硫酸阿米卡星、氨基水杨酸、氨基水杨酸钠、阿莫西林、两性霉素、氨苄青霉素、氨苄青霉素钠、阿帕西林钠、安普霉素、天冬氨酸、硫酸天冬氨酸、阿维霉素、阿伏霉素、阿奇霉素、阿洛西林、阿洛西林钠、盐酸巴卡西林、杆菌肽、杆菌肽亚甲基二水杨酸酯、杆菌肽锌、班贝霉素、苯甲酰钙、硫酸红霉素、硫酸倍他霉素、比阿培南、比尼霉素、盐酸苯柳胺酯、硫酸镁双巯氧吡啶、布替卡星、硫酸丁酰苷菌素、硫酸卷曲霉素、卡巴多、羧苄青霉素二钠、羧苄青霉素茚基钠、羧苄青霉素苯钠、羧苄青霉素钾、香豆素钠、头孢克洛、头孢羟氨苄、头孢孟多、头孢孟多酯钠、头孢孟多钠、头孢帕罗、头孢曲松、头孢唑啉钠、头孢唑啉、头孢唑啉钠、头孢哌酮、头孢地尼、头孢吡肟、盐酸头孢吡肟、头孢醇、头孢克肟、盐酸头孢甲肟、头孢美唑、头孢美唑钠、头孢尼西单钠、头孢尼西钠、头孢哌酮钠、头孢地尼、头孢噻肟钠、头孢替坦、头孢替坦二钠、盐酸头孢替安、头孢西丁、头孢西丁钠、头孢咪唑、头孢哌齐钠、头孢匹胺、头孢匹胺钠、硫酸头孢匹罗、头孢泊肟丙酯、头孢丙烯、头孢罗定、头孢磺啶钠、头孢他啶、头孢布烯、头孢唑肟钠、头孢曲松钠、头孢呋辛、头孢呋辛酯、头孢乙腈钠、头孢氨苄、盐酸头孢氨苄、头孢菌素、头孢噻啶、头孢噻吩钠、头孢匹林钠、头孢拉啶、盐酸西托环素、乙酰氯霉素、氯霉素、氯霉素棕榈酸酯、氯霉素泛酸盐复合物、氯霉素琥珀酸钠、氨基苯磷酸氯己定、氯二甲苯酚、金霉素硫酸氢盐、盐酸金霉素、西诺沙星、环丙沙星、盐酸环丙沙星、西罗霉素、克拉霉素、盐酸克林沙星、克林霉素、盐酸克林霉素、克林霉素棕榈酸盐酸盐、磷酸克林霉素、氯法齐明、苄星邻氯青霉素、邻氯青霉素钠、氯羟喹、粘菌素甲磺酸钠、香豆霉素、香豆霉素钠、环西林、环丝氨酸、达福普汀、氨苯砜、达托霉素、地美环素、盐酸地美环素、去甲环素、地奴真菌素、敌菌净、双氯西林、双氯西林钠、硫酸二氢链霉素、二吡啶硫酮、地红霉素、多西环素、多西环素钙、多西环素磷酸复合物、盐酸多西环素、屈沙星钠、依诺沙星、依匹西林、盐酸差向四环素、红霉素、醋硬脂酸红霉素、依托红霉素、琥乙红霉素、葡庚糖酸红霉素、乳糖醛酸红霉素、丙酸红霉素、硬脂酸红霉素、乙胺丁醇盐酸盐、乙硫异烟胺、氟罗沙星、氟氯西林、氟氚丙氨酸、氟甲喹、磷霉素、磷霉素氨基丁三醇、呋莫西林、氯化呋喃鎓、酒石酸呋喃鎓、夫西地酸钠、夫西地酸、硫酸庆大霉素、格洛莫南、短杆菌肽、卤丙炔氧苯、海他西林、海他西林钾、海克西定、伊巴沙星、亚胺培南、异康唑、异帕米星、异烟肼、 交沙霉素、硫酸卡那霉素、基达霉素、左氧氟沙星、左旋丙基西林钾、来红霉素、林可霉素、盐酸林可霉素、洛美沙星、盐酸洛美沙星、甲磺酸洛美沙星、氯碳头孢、磺胺米隆、甲氯环素、磺基水杨酸甲氯环素、巨霉素磷酸钾、mequidox、美罗培南、美他环素、盐酸美他环素、乌洛托品、马尿酸乌洛托品、扁桃酸乌洛托品、甲氧西林钠、美替普林、盐酸甲硝哒唑、磷酸甲硝哒唑、美洛西林、美洛西林钠、米诺环素、盐酸米诺环素、盐酸吡霉素、莫能菌素、莫能菌素钠、萘夫西林钠、萘啶酸钠、萘啶酸、纳豆霉素、尼布霉素、新霉素棕榈酸酯、硫酸新霉素、十一碳烯酸新霉素、硫酸奈替米星、中性霉素、硝呋唑烯、硝呋地腙、硝呋太尔、硝呋隆、硝呋达齐、硝呋米特、硝呋吡醇、硝呋喹唑、硝基噻唑、硝基环素、呋喃妥因、硝基米特、诺氟沙星、新生霉素钠、氧氟沙星、昂纳妥普瑞、苯唑西林、苯唑西林钠、肟、肟钠、草酸、土霉素、土霉素钙、盐酸土霉素、帕利霉素、对氯苯酚、保罗霉素、培氟沙星、甲磺酸培氟沙星、青霉素、青霉素G苄星、青霉素G钾、青霉素G普鲁卡因、青霉素G钠、青霉素V、青霉素V苄星、海巴青霉素V、青霉素V钾、戊唑酮钠、苯基氨基水杨酸盐/酯、哌拉西林钠、吡苯青霉素钠、吡西林钠、盐酸普利霉素、盐酸匹氨青霉素、双羟萘酸匹氨青霉素、丙苯酸匹氨青霉素、硫酸多粘菌素B、甲基丝裂霉素、普匹卡星、吡嗪酰胺、锌吡硫、乙酸喹乙胺、醋酸喹地卡明、奎奴普丁、消旋甲砜霉素、雷莫拉宁、雷尼霉素、雷洛霉素、雷帕霉素、利福布汀、利福美坦、利福昔尔、利福酰胺、利福平、利福喷丁、利福昔明、罗利环素、硝酸罗利环素、罗沙米星、丁酸罗沙米星、丙酸罗沙米星、罗沙米星磷酸钠、硬脂酸罗沙米星、罗索沙星、罗沙胂、罗红霉素、三环素、三萜醇钠、萨莫青霉素、沙莫西林、司可芬净、西索米星、硫酸西索米星、司帕沙星、盐酸壮观霉素、螺旋霉素、盐酸偏端菌素、西替霉素、硫酸链霉素、烟肼链霉素、磺胺苯、磺胺苯酰、磺乙酰胺、磺乙酰胺钠、磺胺西汀、磺胺嘧啶、磺胺嘧啶钠、磺胺多辛、磺胺林、磺胺甲基嘧啶、磺胺对甲氧嘧啶、磺胺甲嘧啶、磺胺甲二唑、磺胺甲噁唑、磺胺甲氧嘧啶、磺胺二甲唑、氨苯磺酸锌、磺胺硝苯、柳氮磺胺吡啶、磺胺异噻唑、磺胺噻唑、磺胺吡唑、磺胺异噁唑、乙酰硫代异噁唑、磺胺异噁唑二乙醇胺、磺粘菌素、硫培南、舒他西林、磺氨苄青霉素钠、盐酸酞氨西林、替考拉宁、盐酸替马沙星、替莫西林四环素、盐酸四环素、磷酸四环素络合物、四氧嘧啶、甲砜霉素、噻吩西林钾、替卡西林甲酚钠、替卡西林二钠、替卡西林单钠、 替克拉酮、氯化氯苯噻碘、妥布霉素、硫酸妥布霉素、托氟沙星、甲氧苄啶、硫酸甲氧苄啶、三磺嘧啶、醋竹桃霉素、硫酸丙大观霉素、短杆菌素、万古霉素、盐酸万古霉素、维及霉素或拉来霉素,silybin;优选地,所述可检测部分选自:UV-Vis标记、近红外标记、发光基团、磷光基团、磁性自旋共振标记、光敏剂、光可裂解部分、螯合中心、重原子、放射性同位素、同位素可检测的自旋共振标记、顺磁性部分、发色团、发光体,例如金属卟啉;苯并卟啉;氮杂苯并卟啉;萘并卟啉、酞菁;多环芳烃,例如苝、苝二亚胺、芘;偶氮染料;呫吨染料;硼二吡咯亚甲基、氮杂-硼二吡咯亚甲基、花青染料、金属-配体络合物例如联吡啶、联吡啶基、菲咯啉、香豆素以及钌和铱的乙酰丙酮化物;吖啶、噁嗪衍生物例如苯并吩噁嗪;氮杂-轮烯、方酸菁;8-羟基喹啉、聚甲炔、发光产生纳米颗粒例如量子点、纳米晶体;喹诺酮、铽络合物;无机荧光体;离子载体例如冠醚附着或衍生染料;Pd(II)八乙基卟啉;Pt(II)-八乙基卟啉;Pd(II)四苯基卟啉;Pt(II)四苯基卟啉;Pd(II)内消旋-四苯基卟啉四苯并吗啡;Pt(II)内消旋-四苯基甲基苯并卟啉;Pd(II)八乙基卟啉酮;Pt(II)八乙基卟啉酮;Pd(II)内消旋-四(五氟苯基)卟啉;Pt(II)内消旋-四(五氟苯基)卟啉;Ru(II)三(4,7-二苯基-1,10-菲咯啉)(Ru(dpp) 3);Ru(II)三(1,10-菲咯啉)(Ru(phen) 3)、三(2,2”-联吡啶)六水合氯化钌(II)(Ru(bpy) 3);赤藓红B;荧光素;异硫氰酸荧光素(FITC);曙红;铱(III)((N-甲基-苯并咪唑-2-基)-7-(二乙基氨基)-香豆素));铟(III)((苯并噻唑-2-基)-7-(二乙基氨基)-香豆素)-2-(乙酰丙酮化物);Lumogen染料;Macroflex荧光红;Macrolex荧光黄;德克萨斯红;罗丹明B;罗丹明6G;硫罗丹明;间甲酚;百里酚蓝;二甲苯酚蓝;甲酚红;氯酚蓝;溴甲酚绿;溴甲酚红;溴百里酚蓝;Cy2;Cy3;Cy5;Cy5.5;Cy7;4-硝基苯酚;茜素;酚酞;邻甲酚酞;氯酚红;钙黄绿素;溴二甲酚;酚红;中性红;硝嗪;3,4,5,6-四溴酚酞;刚果红;荧光素;曙红;2”,7”-二氯荧光素;5(6)-羧基-荧光素;羧基萘并荧光素;8-羟基苯乙烯-1,3,6-三磺酸;半萘并二氟;半萘并荧光素;三(4,7-二苯基-1,10-菲咯啉)二氯化钌(II);(4,7-二苯基-1,10-菲咯啉)钌(II)四苯基硼;铂(II)八乙基卟啉;二烷基碳菁;双十八烷基环二羰花青;芴基甲氧基羰基氯;7-氨基-4-甲基香豆素(Amc);绿色荧光蛋白,例如,GFP、GFP-2、tagGFP、turboGFP、eGFP、Emerald、Azami Green、单体Azami Green、CopGFP、AceGFP、ZsGreenl)、黄色荧光蛋白(例如,YFP、eYFP、Citrine、Venus、 YPet、PhiYFP、ZsYellowl)、蓝色荧光蛋白(例如,eBFP、eBFP2、Azurite、mKalamal、GFPuv、Sapphire、T-sapphire)、青色荧光蛋白(例如,eCFP、Cerulean、CyPet、AmCyanl、Midoriishi-Cyan)、红色荧光蛋白(例如,mKate、mKate2、mPlum、DsRed单体、mCherry、mRFP1、DsRed-Express、DsRed2、DsRed-单体、HcRed-Tandem、HcRedl、AsRed2、eqFP611、mRaspberry、mStrawberry、Jred)、橙色荧光蛋白(例如,mOrange、mKO、Kusabira-Orange、单体Kusabira-Orange、mTangerine、tdTomato)以及任何其他适合的荧光蛋白;优选地,所述美容用部分选自美容性多肽,例如棕榈酰五肽4、棕榈酰四肽7、肌肽、乙酰基六肽8、aFGF、bFGF或EGF、肉毒杆菌毒素;优选地,所述核酸是自然的或人工的单链或双链DNA或RNA分子,其包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 一种融合蛋白,所述融合蛋白包含权利要求1-36中任一项所述的多肽和与所述多肽融合的部分,所述部分选自抗原、抗体或其抗原结合部分、配体、受体、细胞因子、转录调节因子、荧光蛋白和酶;优选地,所述部分是治疗部分,例如人生长激素、牛生长激素、猪生长激素、生长激素释放激素、生长激素释放肽、粒细胞-集落刺激因子、粒细胞巨噬细胞-集落刺激因子、巨噬细胞-集落刺激因子、促红细胞生成素、骨形态发生蛋白、干扰素、胰岛素、心房肽激素-III、单克隆抗体、肿瘤坏死因子、巨噬细胞激活因子、白介素、肿瘤降解因子、胰岛素样生长因子、表皮生长因子、组织纤溶酶原激活物和尿激酶;或者优选地,所述部分是可检测部分,例如绿色荧光蛋白,例如,GFP、GFP-2、tagGFP、turboGFP、eGFP、Emerald、Azami Green、单体Azami Green、CopGFP、AceGFP、ZsGreenl)、黄色荧光蛋白(例如,YFP、eYFP、Citrine、Venus、YPet、PhiYFP、ZsYellowl)、蓝色荧光蛋白(例如,eBFP、eBFP2、Azurite、mKalamal、GFPuv、Sapphire、T-sapphire)、青色荧光蛋白(例如,eCFP、Cerulean、CyPet、AmCyanl、Midoriishi-Cyan)、红色荧光蛋白(例如,mKate、mKate2、mPlum、DsRed单体、mCherry、mRFP1、DsRed-Express、DsRed2、DsRed-单体、HcRed-Tandem、HcRedl、AsRed2、eqFP611、mRaspberry、mStrawberry、Jred)、橙色荧光蛋白(例如,mOrange、mKO、Kusabira-Orange、 单体Kusabira-Orange、mTangerine、tdTomato)以及任何其他适合的荧光蛋白;优选地,所述部分是美容用部分,选自美容性多肽,例如棕榈酰五肽4、棕榈酰四肽7、肌肽、乙酰基六肽8、aFGF、bFGF或EGF、肉毒杆菌毒素、弹性蛋白、透明质酸。
- 权利要求38所述的融合蛋白,其中所述多肽和所述部分通过接头连接。
- 使多肽穿透细胞的方法,包括将权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白与细胞温育的步骤。
- 权利要求40所述的方法,其中所述细胞是细胞系,例如动物或植物细胞系,或微生物细胞,例如细菌细胞或真菌细胞,或从受试者分离的原代细胞或培养的植物细胞。
- 权利要求40的方法,其中所述细胞选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞;或者选自分生细胞、石细胞、薄壁细胞、生殖细胞、根毛细胞、导管细胞、筛管细胞、叶肉细胞和保卫细胞、表皮细胞和色素细胞。
- 权利要求42所述的方法,其中所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
- 权利要求40所述的方法,其中所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞。
- 权利要求40-44中任一项所述的方法,其中将所述多肽、缀合物或组合物或融合蛋白与细胞温育5分钟至24小时。
- 权利要求45所述的方法,其中将所述多肽、缀合物或组合物或融合蛋白与细胞温育30分钟至6小时。
- 权利要求40-46中任一项所述的方法,其中所述多肽、缀合物或组合物或融合蛋白的浓度为0.01μM至100μM。
- 权利要求47所述的方法,其中所述多肽、缀合物或组合物或融合蛋白的浓度为0.03μM至30μM。
- 一种将分子导入细胞中的方法,所述方法包括将所述分子与权利要求1-36中任一项所述的多肽一起与细胞温育的步骤,或者将权利要求37所述 的缀合物,或权利要求38或39所述的融合蛋白与细胞温育的步骤。
- 权利要求49所述的方法,其中所述分子是治疗部分、可检测部分或美容用部分,例如选自蛋白质、核酸、肽、脂质、代谢物、药物和小分子化合物;优选地,所述治疗部分是权利要求37中所述的治疗部分;优选地,所述可检测部分是权利要求37中所述的可检测部分;优选地,所述美容用部分是权利要求37中所述的美容用部分;优选地,所述核酸是自然的或人工的单链或双链DNA或RNA分子,包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 权利要求49所述的方法,其中所述分子选自抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子和酶。
- 权利要求49所述的方法,其中所述分子是小RNA(small RNA)。
- 权利要求52所述的方法,其中所述小RNA选自siRNA和microRNA,例如小RNA antagomir;siRNA优选是PGY-dsRNA-6、PGY-sRNA-23和PGY-sRNA-26。
- 权利要求49-53中任一项所述的方法,其中所述细胞是细胞系,例如动物或植物细胞系,或微生物细胞,例如细菌细胞或真菌细胞,或从受试者分离的原代细胞或培养的植物细胞。
- 权利要求49-53中任一项的方法,其中所述细胞选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞;或者选自分生细胞、石细胞、薄壁细胞、生殖细胞、根毛细胞、导管细胞、筛管细胞、叶肉细胞和保卫细胞、表皮细胞和色素细胞。
- 权利要求55所述的方法,其中所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
- 权利要求49-53中任一项所述的方法,其中所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞。
- 权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组 合物,或权利要求38或39所述的融合蛋白在将分子导入细胞中的用途。
- 权利要求58所述的用途,其中所述分子是治疗部分、可检测部分或美容用部分,选自蛋白质、核酸、肽、脂质、代谢物、药物和小分子化合物;优选地,所述治疗部分是权利要求37中所述的治疗部分;优选地,所述可检测部分是权利要求37中所述的可检测部分;优选地,所述美容用部分是权利要求37中所述的美容用部分;优选地,所述核酸是自然的或人工的DNA或RNA分子,其为单链或双链,包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 权利要求58所述的用途,其中所述分子选自抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子和酶。
- 权利要求58所述的用途,其中所述分子是小RNA或质粒。
- 权利要求61所述的用途,其中所述小RNA选自siRNA和microRNA,例如小RNA antagomir;siRNA优选是PGY-dsRNA-6、PGY-sRNA-23和PGY-sRNA-26。
- 权利要求58-62中任一项所述的用途,其中所述细胞是细胞系,例如动物或植物细胞系,或微生物细胞,例如细菌细胞或真菌细胞,或从受试者分离的原代细胞或培养的植物细胞。
- 权利要求58-62中任一项所述的用途,其中所述细胞选自肿瘤细胞、成纤维细胞、上皮细胞、内皮细胞、免疫细胞、皮肤细胞和神经细胞;或者选自分生细胞、石细胞、薄壁细胞、生殖细胞、根毛细胞、导管细胞、筛管细胞、叶肉细胞和保卫细胞、表皮细胞和色素细胞。
- 权利要求64所述的用途,其中所述上皮细胞选自消化道上皮细胞和呼吸道上皮细胞。
- 权利要求58-62中任一项所述的用途,其中所述细胞选自A549细胞、HCT-116细胞、MKN-45细胞、293T细胞、HUVEC细胞、ESF-1细胞、HeLa细胞和MRC-5细胞。
- 一种治疗疾病、诊断疾病、示踪,优选胞内示踪或用于美容的方法,所述方法包括向有需要的受试者或细胞施用权利要求1-36中任一项所述的 多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白。
- 权利要求67所述的方法,所述方法包括向有需要的受试者或细胞施用权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白和选自下组的治疗部分、可检测部分或美容用部分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子、酶、核酸,例如质粒,和小RNA;优选地,所述治疗部分是权利要求37中所述的治疗部分;优选地,所述可检测部分是权利要求37中所述的可检测部分;优选地,所述美容用部分是权利要求37中所述的美容用部分;其中优选地所述核酸是自然的或人工的单链或双链DNA或RNA分子,包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 权利要求68所述的方法,其中所述小RNA选自siRNA和microRNA,例如小RNA antagomir;siRNA优选是PGY-dsRNA-6、PGY-sRNA-23和PGY-sRNA-26。
- 权利要求67-69中任一项所述的方法,所述疾病选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病;或者所述美容包括消除延缓皮肤衰老、美白和抗皱;优选地,其中所述癌症选自听神经瘤;腺癌;肾上腺癌;直肠癌;血管肉瘤,例如淋巴管肉瘤、淋巴管内皮肉瘤、血管肉瘤;盲肠癌;良性单克隆丙球蛋白病;胆癌,例如胆管癌;膀胱癌;乳腺癌,例如乳房的腺癌、乳房的乳头状癌、乳房癌症、乳房的髓样癌;脑癌,例如脑脊膜瘤、成胶质细胞瘤、胶质瘤,例如星形细胞瘤、少突神经胶质瘤、髓母细胞瘤;支气管癌;类癌瘤;子宫颈癌,例如宫颈腺癌;绒毛膜癌;脊索瘤;颅咽管瘤;结肠直肠癌,例如结肠癌、直肠癌、结肠直肠腺癌;结缔组织癌症;上皮癌;室管膜瘤;内皮肉瘤,例如卡波西肉瘤、多发性特发性出血性肉瘤;子宫内膜癌,例如子宫癌、子宫肉瘤;食管癌,例如食道腺癌、巴雷特腺癌;尤因肉瘤;眼癌,例如眼内的黑素瘤、视网膜母细胞瘤;家族性嗜伊红细胞增多症;胆 囊癌;胃癌,例如胃腺癌;胃肠道间质瘤;生殖细胞癌症;头颈癌,例如头颈鳞状细胞癌、口腔癌,例如口腔鳞状细胞癌、喉部癌,例如喉癌、咽头癌、鼻咽癌、口咽癌;造血干细胞癌,例如白血病,例如急性淋巴细胞性白血病,例如B-细胞ALL、T-细胞ALL,急性髓细胞性白血病AML,例如B-细胞AML、T-细胞AML、慢性髓细胞性白血病CML,例如B-细胞CML、T-细胞CML,以及慢性淋巴细胞性白血病CLL,例如B-细胞CLL、T-细胞CLL;淋巴瘤,例如霍奇金淋巴瘤HL,例如B-细胞HL、T-细胞HL和非-霍奇金淋巴瘤NHL,例如B-细胞NHL,例如弥散性大细胞淋巴瘤DLCL,例如弥散性大B-细胞淋巴瘤、滤泡淋巴瘤、慢性淋巴细胞性白血病/小淋巴细胞淋巴瘤CLL/SLL、套细胞淋巴瘤MCL、边缘区B-细胞淋巴瘤,例如粘液相关的淋巴组织MALT淋巴瘤、结节边缘区B-细胞淋巴瘤、脾边缘区B-细胞淋巴瘤原发性纵隔B-细胞淋巴瘤、伯基特淋巴瘤、淋巴质浆细胞淋巴瘤、毛细胞白血病HCL、成免疫细胞性大细胞淋巴瘤、前体B-成淋巴细胞性淋巴瘤和原发性中枢神经系统CNS淋巴瘤;和T-细胞NHL,例如前体T-成淋巴细胞性淋巴瘤/白血病、外周T-细胞淋巴瘤PTCL,例如皮肤T-细胞淋巴瘤CTCL,例如蕈样肉芽肿病、塞扎里综合征、血管免疫母细胞性T-细胞淋巴瘤、结节外自然杀伤T-细胞淋巴瘤、肠病型T-细胞淋巴瘤、皮下脂膜炎样T-细胞淋巴瘤和间变性大细胞淋巴瘤;一种或多种上述白血病/淋巴瘤的混合;以及多发性骨髓瘤MM、重链病,例如α链病、γ链病、μ链病;血管母细胞瘤;下咽癌;炎性肌纤维母细胞瘤;免疫细胞淀粉样变性;肾癌,例如肾胚细胞瘤;肝癌,例如肝细胞癌HCC、恶性肝癌;肺癌,例如支气管癌、小细胞肺癌SCLC、非-小细胞肺癌NSCLC、肺腺癌;平滑肌肉瘤LMS;肥大细胞增多症,例如系统性肥大细胞增多症;肌肉癌;骨髓增生异常综合征MDS;间皮瘤;骨髓增生病MPD,例如真性红细胞增多症PV、特发性血小板增多症ET、原因不明性髓样化生AMM,也称为骨髓纤维化MF、慢性特发性骨髓纤维化、慢性髓细胞性白血病CML、慢性中性粒细胞性白血病CNL、高嗜酸粒细胞综合征HES;成神经细胞瘤;神经纤维瘤,例如1型或2型神经纤维瘤病NF、神经鞘瘤;神经内分泌癌,例如胃肠胰神经内分泌瘤GEP-NET、类癌瘤;骨肉瘤,例如骨癌;卵巢癌,例如囊腺癌、卵巢胚胎性癌、卵巢腺癌;乳头状腺癌;胰腺癌,例如胰腺癌、管内乳头状粘蛋白状赘生物IPMN、胰岛细胞瘤;阴茎癌,例如阴茎和阴囊的佩吉特病;松果体瘤;原发性神经外胚层瘤PNT;浆细胞瘤;类肿瘤综合 征;上皮内瘤样病变;前列腺癌,例如前列腺的腺癌;直肠癌;横纹肌肉瘤;唾液腺癌症;皮肤癌,例如鳞状细胞癌SCC、角化棘皮瘤KA、黑素瘤、基底细胞癌BCC;小肠癌,例如盲肠癌;软组织肉瘤,例如恶性纤维组织细胞瘤MFH、脂肉瘤、恶性外周神经鞘瘤MPNST、软骨肉瘤、纤维肉瘤、粘液肉瘤;皮脂腺癌;小肠癌;汗腺癌;滑膜瘤;睾丸癌,例如精细胞瘤、睾丸胚胎性癌;甲状腺癌,例如甲状腺的乳头状癌、乳头状甲状腺癌PTC、甲状腺髓样癌;尿道癌;阴道癌;以及外阴癌,例如外阴的佩吉特病;优选地,其中所述病毒感染选自痘病毒科病毒性疾病、疱疹病毒科病毒性疾病、腺病毒科病毒性疾病、乳头瘤病毒科与多瘤病毒科病毒性疾病、细小病毒科病毒性疾病、嗜肝DNA病毒科病毒性疾病、逆转录病毒科病毒性疾病、呼肠孤病毒科病毒性疾病、博尔纳病毒科病毒性疾病、弹状病毒科病毒性疾病、丝状病毒科病毒性疾病、副粘病毒科病毒性疾病、正粘病毒科病毒性疾病、布尼亚病毒科病毒性疾病、沙粒病毒科病毒性疾病、小RNA病毒科病毒性疾病、杯状病毒科病毒性疾病、星状病毒科病毒性疾病、冠状病毒科病毒性疾病、披膜病毒科病毒性疾病、黄病毒科病毒性疾病、分类未定病毒性疾病、慢病毒感染;例如病毒感染是以下病毒引起的感染:甲型、乙型、丙型肝炎病毒、流感病毒、水痘病毒、I型单纯疱疹病毒HSV-I、II型单纯疱疹病毒HSV-II、牛瘟病毒、呼吸道合胞病毒、巨细胞病毒、海胆病毒、虫媒病毒、汉坦病毒、腮腺炎病毒、麻疹病毒、风疹病毒、I型人类免疫缺陷病毒HIV-I、II型人类免疫缺陷病毒HIV-2、任何披盖病毒属病毒例如登革病毒、甲病毒属病毒、黄病毒属病毒、冠形病毒属病毒、狂犬病毒、绿猴病毒、伊波拉病毒、副流感病毒、正粘病毒、沙粒病毒、I型人T细胞白血病病毒、II型人T细胞白血病病毒、猿猴免疫缺陷病毒、慢病毒、埃巴病毒、人疱疹病毒、弥猴疱疹病毒1B病毒和痘病毒;优选地,其中所述中枢神经系统疾病选自:神经退行性疾病、脑卒中、癫痫、脑外伤、休克、HIV痴呆、青光眼、多发性硬化症等;脑卒中分为出血性和缺血性脑卒中;神经退行性疾病包括阿尔兹海默症、小脑萎缩症、多发性硬化症、原发性侧索硬化、脊髓性肌萎缩症、帕金森病、亨廷顿氏病、克雅二氏病、牛海绵状脑病、共济失调毛细血管扩张症、肌肉萎缩性侧索硬化症;优选地,其中所述炎性疾病选自动脉粥样硬化、动脉硬化、自身免疫性 障碍、多发性硬化、系统性红斑狼疮、风湿性多肌痛PMR、痛风性关节炎、退行性关节炎、肌腱炎、滑囊炎、牛皮癣、囊性纤维化病、关节骨炎、类风湿性关节炎、炎性关节炎、肖格伦综合征、巨细胞动脉炎、进行性系统性硬化硬皮病、强直性脊柱炎、多肌炎、皮肌炎、天疱疮、类天疱疮、糖尿病,例如I型、重症肌无力、桥本甲状腺炎、格雷夫斯病、古德帕斯彻病、混合型结缔组织病、硬化性胆管炎、炎性肠病、克罗恩病、溃疡性结肠炎、恶性贫血、炎性皮肤病、常见间质肺炎UIP、石棉沉着病、硅肺病、支气管扩张、铍中毒、滑石病、尘肺病、肉瘤样病、脱屑性间质性肺炎、淋巴样间质性肺炎、巨细胞间质性肺炎、细胞性间质性肺炎、外源性变应性肺泡炎、韦格纳肉芽肿病和脉管炎的相关形式颞动脉炎和结节性多发性动脉炎、炎性皮肤病、肝炎、迟发型超敏反应,例如毒葛皮炎、肺炎、呼吸道炎症、成人呼吸窘迫综合征ARDS、脑炎、速发型超敏反应、哮喘、花粉症、变态反应、急性过敏反应、风湿热、肾小球肾炎、肾盂肾炎、蜂窝织炎、膀胱炎、慢性胆囊炎、缺血局部缺血损伤、再灌注损伤、同种异体移植排斥、宿主抗移植物、阑尾炎、动脉炎、眼睑炎、毛细支气管炎、支气管炎、子宫颈炎、胆管炎、绒毛膜羊膜炎、结膜炎、泪腺炎、皮肌炎、心内膜炎、子宫内膜炎、肠炎、小肠结肠炎、上髁炎、附睾炎、筋膜炎、纤维组织炎、胃炎、胃肠炎、牙龈炎、回肠炎、虹膜炎、喉炎、脊髓炎、心肌炎、肾炎、脐炎、卵巢炎、睾丸炎、骨炎、耳炎、胰腺炎、腮腺炎、心包炎、咽炎、胸膜炎、静脉炎、肺炎、直肠炎、前列腺炎、鼻炎、输卵管炎、窦炎、口炎、滑膜炎、睾丸炎、扁桃腺炎、尿道炎、膀胱炎、葡萄膜炎、阴道炎、血管炎、外阴炎、外阴阴道炎、脉管炎、慢性支气管炎、骨髓炎、视神经炎、颞动脉炎、横贯性脊髓炎、坏死性筋膜炎,以及坏死性小肠结肠炎;优选地,其中所述自身免疫性疾病选自:肾小球肾炎、古德帕斯彻综合征、坏死性血管炎、淋巴结炎、结节性动脉周围炎、系统性红斑狼疮、类风湿病、关节炎、牛皮癣关节炎、系统性红斑狼疮、牛皮癣、溃疡性结肠炎、系统性硬化症、皮肌炎/多肌炎、抗磷脂抗体综合征、硬皮病、寻常天疱疮、ANCA-相关的血管炎,例如韦格纳肉芽肿病、显微镜下多血管炎、葡萄膜炎、肖格伦综合征、克罗恩病、赖特综合征、强直性脊柱炎、莱姆关节炎、古兰-巴雷综合征、桥本甲状腺炎和心肌病;优选地,其中所述代谢性疾病选自:苯丙酮尿症、黄色瘤、淀粉样变性、 黄疣病、黄瘤症、脂瘤性纤维瘤、脂肪性纤维瘤、脂肪纤维瘤、黄脂增生病、高血脂症、血脂过多、高脂血、脂肪过多症、脂肪过多、淀粉贮积病、淀粉样变性病、淀粉样变、半乳糖血、肥胖症、高脂血症、骨软化症、佝偻病、骨软化症和佝偻病、骨质疏松症、糖尿病;优选地,其中所述线粒体相关疾病选自:亨汀顿氏疾病、肌萎缩性脊髓侧索硬化、线粒体脑肌肉病变合并乳酸血症和类中风症候群MELAS;肌阵挛癫痫合并红色褴褛肌纤维症,MERRF;神经性肌肉松弛、失调症、色素性视网膜炎/母体遗传莱氏症状NARP/MILS;Leber氏视神经病变LHON;Kearns-Sayre症候群KSS;皮尔森骨髓胰腺症PMPS;慢性渐进性眼外肌麻痹CPEO;瑞氏症候群;阿尔珀斯氏症候群;多个线粒体DNA缺失症候群;线粒体DNA耗乏症候群;复合体I缺陷;复合体II琥珀酸脱氢酶SDH缺陷;复合体III缺陷;细胞色素c氧化酶COX,复合体IV缺陷;复合体V缺陷;腺嘌呤核苷酸转运体ANT缺陷;丙酮酸脱氢酶PDH缺陷;具有乳酸血症的乙基丙二酸酸性尿;具有乳酸血症的3-甲基戊烯二酸酸性尿;体现为在传染期间的衰减的不应性癫痫;体现为在传染期间的衰减的阿斯伯格症候群;体现为在传染期间的衰减的自闭症;注意力不足过动症ADHD;体现为在传染期间的衰减的脑性麻痹;体现为在传染期间的衰减的失读症;母系遗传血小板减少症;白血病;MNGIE线粒体肌病变、周围和自主神经病变、胃肠功能异常和癫痫;MARIAHS症候群线粒体失调症、复发传染、失语症、低尿酸血症/髓磷脂减少症、癫痫发作和二羧酸酸性尿;ND6肌张力不全症;体现为在传染期间的衰减的周期性呕吐症状;具有乳酸血症的3-羟基异丁酸酸性尿;具有乳酸血症的尿崩症;尿苷反应性神经症状URNS;家族双侧纹状体坏死FBSN;与胺基糖苷有关的听力损失;松驰心肌病;脾淋巴瘤;钨症状;多个线粒体DNA缺失症状;和肾小管酸血症/尿崩症/失调症症状。
- 权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白在治疗疾病、诊断疾病、示踪,优选胞内示踪或在美容中的用途。
- 权利要求71所述的用途,其中所述疾病选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病,优选地,所述疾病是权利要求70中所述的疾病;优选地,所述美容包括消除延缓皮肤衰老、美白和抗皱。
- 权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白在制备用于治疗疾病、诊断疾病、示踪,优选胞内示踪或用于美容的药物组合物中的用途。
- 权利要求73所述的用途,其中所述药物组合物还包含治疗部分、可检测部分或美容用部分,选自下组的成分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显色物质、抗原、细胞因子、转录调节因子、酶、和核酸;优选地,所述治疗部分是权利要求37中所述的治疗部分;优选地,所述可检测部分是权利要求37中所述的可检测部分;优选地,所述美容用部分是权利要求37中所述的美容用部分;其中优选地所述核酸是自然的或人工的DNA或RNA分子,其为单链或双链,包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 权利要求74所述的用途,其中所述小RNA选自siRNA和microRNA,例如小RNA antagomir;siRNA优选是PGY-dsRNA-6、PGY-sRNA-23和PGY-sRNA-26。
- 权利要求73-75中任一项所述的用途,其中所述疾病选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病,优选地,所述疾病是权利要求70中所述的疾病优选地,所述美容包括消除延缓皮肤衰老、美白和抗皱。
- 核酸分子,所述核酸分子包含编码权利要求1-36中任一项的多肽,或权利要求38或39所述的融合蛋白的核苷酸序列。
- 载体,所述载体包含权利要求77所述的核酸分子。
- 组合物,所述组合物包含一种或多种权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白。
- 权利要求79的所述组合物,其中所述组合物还包含治疗部分、可检测部分或美容用部分,选自下组的成分:抗生素、抗炎症药物、抗肿瘤药物、神经保护剂、化疗剂、细胞毒素、放射性同位素、荧光标记物、发光物、显 色物质、抗原、细胞因子、转录调节因子、酶、和核酸;优选地,所述治疗部分是权利要求37中所述的治疗部分;优选地,所述可检测部分是权利要求37中所述的可检测部分;优选地,所述美容用部分是权利要求37中所述的美容用部分;优选地,所述核酸是自然的或人工的DNA或RNA分子,其为单链或双链,包含一种或多种小RNA、DNA、cDNA、诱饵DNA、RNA、siRNA、miRNA、shRNA、stRNA、snoRNA、snRNA、PNA、反义寡聚体、质粒、粘粒、噬菌体、人工染色体和其它修饰的核酸。
- 权利要求80所述的组合物,其中所述小RNA选自siRNA和microRNA,例如小RNA antagomir;siRNA优选是PGY-dsRNA-6、PGY-sRNA-23和PGY-sRNA-26。
- 权利要求79-81中任一项所述的组合物,其中所述组合物是药物组合物,且还包含一种或多种药学上可接受的载体。
- 宿主细胞,其包含根据权利要求78的载体。
- 生成权利要求1-36中任一项所述的多肽的方法,其包括在合适的培养基中培养权利要求83的宿主细胞,并且收集权利要求1-36中任一项所述的多肽。
- 权利要求1-36中任一项所述的多肽,权利要求37所述的缀合物或组合物,或权利要求38或39所述的融合蛋白、权利要求77的核酸、权利要求78的载体或权利要求79-82中任一项的组合物,用于治疗疾病、诊断疾病、示踪,优选胞内示踪或用于美容。
- 权利要求85所述的多肽、缀合物或组合物、融合蛋白、核酸、载体或组合物,其中所述疾病选自癌症、病毒感染、中枢神经系统疾病、炎性疾病、自身免疫病、线粒体相关疾病和代谢疾病,优选地,所述疾病是权利要求70中所述的疾病;优选地,所述美容包括消除延缓皮肤衰老、美白和抗皱。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3118412A CA3118412A1 (en) | 2018-11-02 | 2019-11-01 | Cell-penetrating peptide based on influenza virus m2 protein |
US17/289,848 US20220169680A1 (en) | 2018-11-02 | 2019-11-01 | Cell-penetrating peptide based on influenza virus m2 protein |
CN201980068883.0A CN112912386B (zh) | 2018-11-02 | 2019-11-01 | 基于流感病毒m2蛋白的细胞穿透肽 |
EP19877803.7A EP3912989A4 (en) | 2018-11-02 | 2019-11-01 | PENETRATING PEPTIDE BASED ON THE M2 PROTEIN OF THE INFLUENZA VIRUS |
CN202311329341.9A CN117384259A (zh) | 2018-11-02 | 2019-11-01 | 基于流感病毒m2蛋白的细胞穿透肽 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018113755 | 2018-11-02 | ||
CNPCT/CN2018/113755 | 2018-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020088667A1 true WO2020088667A1 (zh) | 2020-05-07 |
Family
ID=70464631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/115107 WO2020088667A1 (zh) | 2018-11-02 | 2019-11-01 | 基于流感病毒m2蛋白的细胞穿透肽 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220169680A1 (zh) |
EP (1) | EP3912989A4 (zh) |
CN (2) | CN112912386B (zh) |
CA (1) | CA3118412A1 (zh) |
WO (1) | WO2020088667A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022855A (zh) * | 2020-06-08 | 2020-12-04 | 北京大学深圳研究生院 | PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用 |
US11155802B2 (en) * | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
WO2024048890A1 (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 레메디 | 피부 미백 활성을 가지는 펩타이드를 포함하는 조성물 |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
US11969461B2 (en) | 2016-03-02 | 2024-04-30 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101412747A (zh) * | 2008-10-21 | 2009-04-22 | 中国药科大学 | 新型穿膜肽及其用途 |
CN102311500A (zh) * | 2010-07-02 | 2012-01-11 | 杭州师范大学 | 一种抗病毒融合蛋白及其应用 |
CN103282375A (zh) * | 2010-12-02 | 2013-09-04 | 比奥诺尔免疫有限公司 | 肽支架设计 |
CN104140457A (zh) * | 2013-05-08 | 2014-11-12 | 浙江日升昌药业有限公司 | 一种肿瘤细胞靶向性穿膜肽 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113429A2 (en) * | 2005-04-13 | 2006-10-26 | Xc Research, Inc. | Viral inhibitors |
NZ704191A (en) * | 2010-06-14 | 2016-05-27 | Hoffmann La Roche | Cell-penetrating peptides and uses therof |
US10378016B2 (en) * | 2010-12-06 | 2019-08-13 | Children's Medical Center Corporation | Composition and method for oligonucleotide delivery |
WO2016056681A1 (ko) * | 2014-10-06 | 2016-04-14 | 주식회사 바이오리더스 | 인플루엔자 바이러스 항원의 세포표면 발현벡터 및 이에 의해 형질전환된 미생물 |
US20180161425A1 (en) * | 2014-12-10 | 2018-06-14 | Vaxsia Biomedical Inc. | Novel protein structure used for efficient antibody production in immunization |
CN111526886A (zh) * | 2017-10-27 | 2020-08-11 | 国家血清研究所 | 多基因流感疫苗 |
-
2019
- 2019-11-01 CN CN201980068883.0A patent/CN112912386B/zh active Active
- 2019-11-01 US US17/289,848 patent/US20220169680A1/en active Pending
- 2019-11-01 EP EP19877803.7A patent/EP3912989A4/en active Pending
- 2019-11-01 CA CA3118412A patent/CA3118412A1/en active Pending
- 2019-11-01 CN CN202311329341.9A patent/CN117384259A/zh active Pending
- 2019-11-01 WO PCT/CN2019/115107 patent/WO2020088667A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101412747A (zh) * | 2008-10-21 | 2009-04-22 | 中国药科大学 | 新型穿膜肽及其用途 |
CN102311500A (zh) * | 2010-07-02 | 2012-01-11 | 杭州师范大学 | 一种抗病毒融合蛋白及其应用 |
CN103282375A (zh) * | 2010-12-02 | 2013-09-04 | 比奥诺尔免疫有限公司 | 肽支架设计 |
CN104140457A (zh) * | 2013-05-08 | 2014-11-12 | 浙江日升昌药业有限公司 | 一种肿瘤细胞靶向性穿膜肽 |
Non-Patent Citations (1)
Title |
---|
"Stedman's Medical Dictionary", 1990, WILLIAMS & WILKINS |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11969461B2 (en) | 2016-03-02 | 2024-04-30 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
US11155802B2 (en) * | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
CN112022855A (zh) * | 2020-06-08 | 2020-12-04 | 北京大学深圳研究生院 | PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用 |
WO2024048890A1 (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 레메디 | 피부 미백 활성을 가지는 펩타이드를 포함하는 조성물 |
Also Published As
Publication number | Publication date |
---|---|
EP3912989A4 (en) | 2022-05-18 |
CN112912386B (zh) | 2023-10-20 |
CN112912386A (zh) | 2021-06-04 |
EP3912989A1 (en) | 2021-11-24 |
CA3118412A1 (en) | 2020-05-07 |
US20220169680A1 (en) | 2022-06-02 |
CN117384259A (zh) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020088667A1 (zh) | 基于流感病毒m2蛋白的细胞穿透肽 | |
ES2705068T3 (es) | Síntesis química y cribado de bibliotecas de péptidos bicíclicos | |
US9272043B2 (en) | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery | |
US11078235B2 (en) | Cyclic peptide conjugates and methods of use | |
JP5697123B2 (ja) | 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法 | |
CN111511405A (zh) | 用于细胞内递送mRNA的肽和纳米颗粒 | |
JP2020502051A (ja) | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 | |
BR112020009592A2 (pt) | derivados de ácido oxoacridinil acético e métodos de uso | |
US20240150404A1 (en) | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | |
CA3145425A1 (en) | Cationic lipids and uses thereof | |
JP2019534317A (ja) | リジン特異的ヒストンデメチラーゼ−1阻害剤及びその使用 | |
JP2023524747A (ja) | 脳送達のための合成脂質様材料 | |
TW202220674A (zh) | 用於聚陰離子貨物化合物遞送的多組分遞送系統 | |
Bang et al. | Amphiphilic small peptides for delivery of plasmid DNAs and siRNAs | |
EP4358989A2 (en) | Bicyclic peptidyl pan-ras inhibitors | |
Bang et al. | Targeted delivery of self-assembled nanocomplex between fusion peptides and siRNAs for breast cancer treatment | |
US20220251079A1 (en) | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use | |
WO2023093780A1 (zh) | 工程化迁移体及其制备方法和用途 | |
US20230241092A1 (en) | Lipid nanoparticles for delivery of sting-dependent adjuvants | |
WO2023178327A1 (en) | Membrane translocation domains and uses thereof | |
EP4359544A1 (en) | Sting dependent adjuvants | |
WO2019164450A1 (en) | Complex, hydrogel and method | |
WO2024026141A2 (en) | Cyclic cell-penetrating peptides and uses thereof | |
WO2014187313A1 (zh) | 一种化合物的细胞透膜的方法 | |
de Jong et al. | Delivery of genetic material with virus-like particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19877803 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3118412 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019877803 Country of ref document: EP Effective date: 20210602 |